CN106039409B

CN106039409B - Method for preparing construct using bio-brick comprising endothelial cells

Info

Publication number: CN106039409B
Application number: CN201610211795.XA
Authority: CN
Inventors: 康裕建; 左潇
Original assignee: Revotek Co ltd
Current assignee: Revotek Co ltd
Priority date: 2015-04-07
Filing date: 2016-04-07
Publication date: 2021-04-06
Anticipated expiration: 2036-04-07
Also published as: CN106039421A; CN106039421B; CN108079384A; CN106039413A; CN106039409A; CN106039413B; CN108079384B

Abstract

The present invention relates to the technical fields of biology, regenerative medicine, bioprinting (e.g. 3D bioprinting), tissue engineering, etc. The present invention relates to a method for making a construct using a bio-brick comprising endothelial cells. In particular, the present invention relates to a bio-brick useful for bioprinting (e.g. 3D bioprinting) and tissue engineering, a composition (e.g. bio-ink) comprising the bio-brick, a method of making the bio-brick and uses thereof, and a construct (e.g. three-dimensional construct) comprising or constructed using the bio-brick/bio-ink, wherein the bio-brick comprises: a cell, a nuclear layer that encapsulates the cell (e.g., endothelial cells), and, a shell layer that encapsulates the nuclear layer.

Description

Method for preparing construct using bio-brick comprising endothelial cells

Technical Field

The present invention relates to the technical fields of biology, regenerative medicine, bioprinting (e.g. 3D bioprinting), tissue engineering, etc. In particular, the present invention relates to a bio-brick comprising endothelial cells useful for bioprinting (e.g. 3D bioprinting) and tissue engineering, a composition (e.g. bio-ink) comprising the bio-brick, a method of making the bio-brick and its use, and a construct (e.g. a three-dimensional construct) comprising the bio-brick or constructed using the bio-brick/bio-ink comprising microvessels.

Background

In human tissues, cells are arranged and distributed according to a certain rule and order. Tissues with different functions have different cell arrangements. For example, epithelial cells constituting epithelial tissues are closely arranged in a monolayer to ensure their protective function; the muscle cells are arranged in a cord shape to ensure the contraction function; the nerve cells are arranged in parallel or are interwoven into a net to enhance the information transmission function and the like. Abnormalities in cell arrangement are manifested by abnormalities in cell morphology, intercellular junctions, and overall function of cell populations. Abnormal cell arrangement exists in pathological changes of various tissues and organs, which causes abnormal cell function and damages the overall structure and function of the tissues and organs. For example, the hepatic cell cord arrangement in liver tumor tissue is disordered and has no normal hepatic lobular structure; the cell barrier function is damaged due to the disorder of the arrangement of the epithelial cells of the small intestine, the absorption of endotoxin in the intestinal tract is increased, and endotoxemia is formed; the disorder of the arrangement of blood vessel smooth muscle cells causes the reduction of blood vessel compliance, the reduction of elasticity, the reduction of pressure resistance and the like. Therefore, the realization of precise arrangement of cells is the key of artificial construction of tissues and organs.

3D bioprinting is a technique that has emerged in recent years that has been attempted to build complex tissues and organs. Several 3D bioprinting techniques have been reported so far, and the most interesting of them is the 3D bioprinting technique proposed by CYFUSE BIOMEDICAL KK corporation (hereinafter referred to as CYFUSE technique for short, see, for example, US patent application US 14/126,681, and the 3D bioprinting technique proposed by Organovo corporation (hereinafter referred to as Organovo technique for short, see, for example, chinese patent application CN 103946374A).

The Cyfuse technology mainly involves the following steps: constructing cell balls to form micro tissue blocks; different pieces of micro-tissue are stacked together in a specific spatial arrangement by means of the "xipho" and further the stacked pieces of micro-tissue are connected together to form a tissue of a desired structure by means of the property of spontaneous fusion of cells.

The basic principle of the Organovo technology is as follows: first preparing a bio-ink (i.e., cells) and a bio-paper (usually a gel) required for bio-printing; then, 3D printing is performed using bio-ink and bio-paper according to the 3D model of the tissue or organ to be printed by: (1) printing a layer of bio-ink, i.e., placing one layer of cells on top of another layer of cells or gel; (2) printing a sheet of bio-paper, i.e., placing a layer of gel on the cells; (3) and (3) continuously repeating the steps (1) and (2) until the new tissue or organ is printed.

However, these known bioprinting techniques also suffer from significant drawbacks. In particular, none of the currently known bioprinting methods allow to achieve a precise arrangement of cells and therefore to produce micro-tissue masses with a fine structure. At the same time, in the bioprinting methods known to date, the cells used are all devoid of mechanical protection. Therefore, when the cells are used for 3D bioprinting, the cells are easily damaged or killed by damage of external pressure or shear force. This greatly limits the application of bioprinting techniques. Furthermore, some known bioprinting techniques require the use of large numbers of cells when constructing the micro tissue mass, which further severely limits the application of bioprinting techniques.

Therefore, none of the currently known 3D bioprinting techniques can achieve the construction of complex tissues or organs with three-dimensional structures in a manner that the number of cells is controllable, the cells are arranged precisely, and the cell survival rate of the prepared three-dimensional constructs is low and the size is severely limited.

Microvessels are the only channels for cells inside the tissue to access nutrients and to discharge metabolites. Artificial constructs (e.g., artificial tissues) constructed using biobricks need to be able to form microvessels so that the cells inside can survive. Therefore, the internal presence of microvessels is an important requirement for the tissue mass to have biological functions.

Summary of The Invention

In order to solve the above technical problems, the present inventors have developed a basic unit, bio-brick, which can be used for printing tissues or organs. The cell type and the cell number of the biological brick are controllable, and the size of the biological brick is controllable, so that the biological ink can be used for preparing standardized and controllable biological ink, and the prepared biological ink can realize accurate arrangement of cells in a biological printing process and accurate biological printing of tissues or organs. In addition, the biological brick also provides effective mechanical protection for cells, thereby ensuring the survival rate of the cells in the printing process (reaching more than 90 percent). The bio-brick of the present invention can be used as a base unit for bio-printing and also as a research tool. The bio-brick of the present invention may also form an artificial construct (e.g., an artificial tissue) comprising microvessels.

Accordingly, in one aspect, the present invention provides a bio-brick comprising: a cell, a nuclear layer encapsulating the cell, and a shell layer encapsulating the cell and the nuclear layer, wherein the cell encapsulated by the nuclear layer comprises endothelial cells and optionally undifferentiated cells (e.g., stem cells, progenitor cells, or a combination thereof), and the nuclear layer and the shell layer are each independently made of a biodegradable material. In certain preferred embodiments of the invention, the biodegradable materials in the core and shell layers are capable of reducing or preventing mechanical damage to cells within a bio-brick during manipulation (e.g., bioprinting) and are capable of providing controlled release of substances (e.g., nutrients, extracellular matrix, cytokines, pharmaceutically active ingredients, etc.) to promote cellular activity and function (proliferation, differentiation, migration, secretion or metabolism).

In another aspect, the invention provides a composition (e.g., a bioink) comprising the bioink of the present invention, and optionally, further comprising a carrier (preferably the carrier comprises a bioadhesive).

In another aspect, the present invention provides a method for preparing the bio-brick of the present invention, comprising the steps of:

(1) Providing one or more core layer materials, each independently made of a biodegradable material, and each independently encapsulating the same or different cells or cell combinations; wherein the cells comprise endothelial cells, preferably further comprising undifferentiated cells, such as stem cells, progenitor cells, or a combination thereof;

(2) providing one or more shell materials, each independently made of a biodegradable material;

(3) selecting a core layer material from the one or more core layer materials of step (1) and granulating it, thereby obtaining a first core layer;

(4) optionally coating the product obtained in the preceding step with a core layer material from step (1) or with a shell layer material from step (2);

(5) optionally, repeating step (4) one or more times;

(6) coating the product of the previous step with a shell material from step (2) to produce the bio-brick.

(1) mixing cells with a biodegradable material for forming a nuclear layer to provide a nuclear layer material encapsulating the cells, wherein the cells comprise endothelial cells, preferably further undifferentiated cells, such as stem cells, progenitor cells, or a combination thereof; and

(2) The core layer material is granulated and coated with a biodegradable material for forming a shell layer, thereby preparing the bio-brick.

In another aspect, the present invention provides a method for preparing a composition of the invention (which is, for example, a biological ink) comprising the steps of: the bio-brick of the present invention is mixed with a carrier (which preferably comprises a bio-adhesive).

In another aspect, the invention provides a construct (e.g., a three-dimensional construct, a tissue precursor, a tissue or organ) comprising a biobrick of the invention, or prepared using a biobrick or composition (e.g., a bioink) of the invention.

In another aspect, the invention provides a method of making a construct (e.g., a three-dimensional construct, a tissue precursor, a tissue, or an organ) comprising a microvessel, comprising the step of bioprinting (e.g., 3D bioprinting) with a biobrick or composition (e.g., a bioink) of the invention.

In another aspect, there is also provided a use of the bio-brick of the present invention. For example, the bio-brick of the present invention can be used to culture cells (e.g., for three-dimensional culture of cells); or for growing, proliferating, differentiating, secreting, or migrating cells; or for bioprinting (e.g., 3D bioprinting); or for forming a construct (e.g., a three-dimensional construct) comprising a microvessel, such as a tissue precursor, a tissue, or an organ. The bio-brick or construct of the invention may also be used in various applications, for example in research or medical fields. For example, the bio-brick or construct of the invention may be used for studying stem cell differentiation, for drug discovery, for drug screening, for in vivo or in vitro assays, for implantation into a host, for tissue engineering or for tissue regeneration.

In another aspect, the invention provides a kit comprising a biobrick of the invention, a composition (e.g., a bioink), and/or a construct (e.g., a three-dimensional construct, a tissue precursor, a tissue or an organ).

In another aspect, the invention provides a pharmaceutical composition comprising one or more of the bio-bricks of the invention. In certain preferred embodiments, the pharmaceutical composition is for use in tissue regeneration.

Embodiments of the present invention will be explained in detail below with reference to the drawings and detailed description of the invention. However, those skilled in the art will appreciate that the drawings and detailed description presented below are illustrative of the invention and are not intended to limit the scope of the invention. Various objects and advantageous aspects of the present invention will become apparent to those skilled in the art from the detailed disclosure of the drawings and the detailed description of the invention.

Drawings

Fig. 1A-1E schematically depict exemplary structures of the bio-brick of the present invention, comprising: a cell capable of growth, proliferation, differentiation or migration; a nuclear layer encapsulating the cells, which is made of a biodegradable material and provides a microenvironment for the vital activities of the cells, such as nutrients; and a shell layer for packaging the core layer, which is made of biodegradable material, and provides mechanical protection for the core layer and cells inside and maintains the space state of the biological brick. Furthermore, the shell is permeable, having channels for the exchange of substances inside and outside the bio-brick. In preferred embodiments, the cells may be uniformly dispersed in the nuclear layer, or may be aggregated together, within the nuclear layer.

In particular, fig. 1A schematically depicts a structure of the bio-brick of the present invention comprising a core layer and a shell layer, wherein the core layer is wrapped with cells and the shell layer is located outside the core layer and encapsulates the core layer.

Fig. 1B schematically depicts a structure of the bio-brick of the present invention, which comprises, in order from the inside to the outside: the cell comprises a core layer wrapping cells, a first shell layer encapsulating the core layer, and a second shell layer surrounding the first shell layer.

Fig. 1C schematically depicts a structure of the bio-brick of the present invention, which comprises, in order from the inside to the outside: the cell-free biological filter comprises a first nuclear layer for wrapping cells, a second nuclear layer for wrapping the cells and positioned outside the first nuclear layer, and a first shell layer for packaging the first nuclear layer and the second nuclear layer.

Fig. 1D schematically depicts a structure of the bio-brick of the present invention, comprising, in order from the inside to the outside: the cell-free tissue culture medium comprises a first core layer for wrapping cells, a second core layer for wrapping the cells, a first shell layer for packaging the first core layer and the second core layer, and a second shell layer for surrounding the first shell layer.

FIG. 1E schematically depicts a structure of the bio-brick of the present invention, comprising, in order from the inside to the outside: the cell-encapsulating shell comprises a first core layer for encapsulating cells, a first shell layer for encapsulating the first core layer, a second core layer for encapsulating the cells, and a second shell layer for encapsulating the second core layer.

Fig. 2 schematically depicts one example of a structure of a three-dimensional construct constructed using the bio-brick of the present invention, which includes three layers, i.e., an endothelial cell layer, a smooth muscle cell layer, and a fibroblast cell layer. Wherein the endothelial cell layer is constructed from a bio-brick comprising endothelial cells; the smooth muscle cell layer is constructed by biological bricks containing smooth muscle cells; the fibroblast layer is constructed from a bio-brick containing fibroblasts. The endothelial cell layer, smooth muscle cell layer and fibroblast layer may each be comprised of one or more layers of cells, depending on the particular number of cells contained in the bio-brick used. The gaps between the biological bricks are filled with biological adhesive. In a preferred embodiment, the biological adhesive may further comprise an agent for maintaining, promoting, improving, regulating the vital activity of cells within the biological brick. For example, when the cells in the bio-brick are endothelial cells, the bio-adhesive may further comprise a cytokine that promotes the growth and differentiation of endothelial cells. In a preferred embodiment, the three-dimensional construct of the invention is constructed by a 3D bioprinting method using the bio-brick of the invention. However, without being limited by theory, the three-dimensional constructs of the invention may also be constructed using the bio-brick of the invention by any other known method (e.g., hand-placed methods).

Fig. 3A-3C show phase contrast micrographs of the biobricks prepared using a pelletizer under different instrument parameters, wherein the diameter of the biobrick in fig. 3A is about 120 μm (100 μm on the scale); the diameter of the bio-brick in fig. 3B is about 200 μm (100 μm on the scale); the diameter of the bio-brick in fig. 3C is about 450 μm (200 μm scale). The cells used in the biological brick of fig. 3A-3C are Human Umbilical Vein Endothelial Cells (HUVEC), the main component of the shell layer is calcium alginate, and the main component of the core layer is sodium alginate + type I collagen. These results show that the dimensions of the bio-brick can be controlled by controlling the instrumental parameters of the granulator (e.g., the diameter of the inner and outer nozzles of the concentric nozzle). The size of the biological brick is controllable and can be selected according to the requirement.

Fig. 4 shows a micrograph of a bio-brick a prepared by the method of example 1, in which a highlight represents a shell layer of the bio-brick and the thickness of the shell layer is about 2 μm (scale: 50 μm). The cells used in the bio-brick of fig. 4 are Human Umbilical Vein Endothelial Cells (HUVEC), the main component of the shell layer is calcium alginate, and the main component of the core layer is sodium alginate + type I collagen. The results show that the thickness of the shell can be controlled by controlling the diameter of the inner and outer nozzles of the concentric nozzle of the granulator, the pumping speed of the shell material, and other parameters. The shell thickness of the biological brick is controllable and can be selected according to requirements.

FIGS. 5A-5C show micrographs of a bio-brick prepared by the method of example 1, wherein the bio-brick in FIG. 5A has a cell number of about 50 (100 μm on a scale); the number of cells encapsulated by the bio-brick in fig. 5B is about 8 (100 μm on the scale); the number of cells encapsulated by the bio-brick in FIG. 5C was about 2 (100 μm on the scale). The cells used in the biological brick of fig. 5A-5C are Human Umbilical Vein Endothelial Cells (HUVEC), the main component of the shell layer is calcium alginate, and the main component of the core layer is sodium alginate + type I collagen. These results indicate that the number of cells encapsulated by the bio-brick can be controlled by controlling the cell concentration of the cell suspension. The number of cells contained in the biological brick of the invention is controllable and can be selected according to the needs.

FIGS. 6A-6D show micrographs of Biobrick B1-B4 prepared using a pelletizer, wherein the Biobrick in FIG. 6A is Biobrick B1, which has a diameter of about 600 μm (500 μm on scale); the bio-brick in FIG. 6B is bio-brick B2, which has a diameter of about 500 μm (500 μm on scale); the bio-brick in FIG. 6C is bio-brick B3, which has a diameter of about 500 μm (500 μm on scale); the bio-brick in FIG. 6D is bio-brick B4, which has a diameter of about 500 μm (500 μm on the scale). These results indicate that a variety of suitable biodegradable materials can be used to make the bio-brick of the present invention.

FIG. 6E shows confocal microscopy images of Biobrick B2 prepared with tracker CM-Dil (Red fluorescence) labeled seed cells and with FITC-bearing polylysine as the shell material, where green fluorescence represents the shell and red fluorescence represents the seed cells.

Fig. 7A shows a photomicrograph of a biological ink prepared using the bio-brick of the present invention. Wherein, the biological brick comprises Human Umbilical Vein Endothelial Cells (HUVEC), the main component of the shell layer is calcium alginate, the main component of the core layer is sodium alginate + type I collagen, and the biological brick comprises methyl violet dye; the main components of the biological adhesive are sodium alginate and gelatin. As shown in fig. 7A, the purple staining is only present inside the bio-brick and not in the carrier of the bio-ink (bio-adhesive). This indicates that the shell layer of the bio-brick is able to maintain the integrity of the bio-brick in the bio-ink.

FIG. 7B shows a photomicrograph of a monolayer printed with a biological ink of the invention. Wherein, the biological brick comprises Human Umbilical Vein Endothelial Cells (HUVEC), the main component of the shell layer is calcium alginate, the main component of the core layer is sodium alginate + type I collagen, and the biological brick comprises methyl violet dye; the main components of the biological adhesive are sodium alginate and gelatin. As shown in fig. 7B, the purple staining was only present inside the bio-brick and not in the carrier of the bio-ink (bio-adhesive). This indicates that the shell of the bio-brick is able to maintain the integrity of the bio-brick during the bio-printing process.

Fig. 8 shows the viscosity analysis of the bioadhesive (sodium alginate + gelatin) used. The results show that the viscosity of the bioadhesive used is from 30 to 160Pas at 25 ℃ to 40 ℃; also, as the temperature increases, the viscosity of the bioadhesive decreases.

Fig. 9A to 9D show the results of analysis of cell viability using a confocal microscope in a bio-brick prepared by the method of example 1, wherein the bio-brick was double-stained with calcein (green fluorescence) and propidium iodide (red fluorescence); the cells used are Human Umbilical Vein Endothelial Cells (HUVEC), the main component of the shell layer is calcium alginate, and the main component of the core layer is sodium alginate + type I collagen.

Fig. 9A shows the results of an analysis of cell viability in a bio-brick performed immediately after bio-brick preparation. In fig. 9A, the white circles of each marker represent one bio-brick, and the highlight dots are red fluorescence (representing dead cells) and the highlight dots are green fluorescence (representing live cells). The results of fig. 9A show that more than 98% of the cells in the bio-brick survived after the bio-brick was prepared by the method of example 1.

Fig. 9B shows the results of the analysis of cell viability in the bio-brick after storing the prepared bio-brick at 4 ℃ for 3 hours. In fig. 9B, the white circles of each marker represent a biological tile, and the highlight dots are red fluorescent (representing dead cells) and the highlight dots are green fluorescent (representing live cells). The results in fig. 9B show that the cells in the prepared bio-brick remained highly viable (90% survival) after 3 hours of storage at 4 ℃.

Fig. 9C shows the results of an analysis of cell viability in a bio-brick performed immediately after the bio-brick was prepared as a bio-ink and bioprinted. In fig. 9C, the highlight dots are red fluorescence (representing dead cells) and the highlight dots are green fluorescence (representing live cells). The results in fig. 9C show that the cells in the bio-brick remained highly viable (97% survival) after the bio-brick was prepared as a bio-ink and immediately bioprinted.

FIG. 9D shows the results of cell viability analysis in the prepared bio-brick after 5 days of culture in H-DMEM medium at 37 ℃. In fig. 9D, the highlight dots are red fluorescence (representing dead cells) and the highlight dots are green fluorescence (representing live cells). The results in fig. 9D show that the cells in the prepared bio-brick remained highly viable (95% survival) after 5 days of culture at 37 ℃.

FIGS. 10A-10B show the results of analysis using a confocal microscope to observe adhesion and spreading of cells in a bio-brick prepared by the method of example 1, wherein the bio-brick was double-stained with calcein (green fluorescence) and propidium iodide (red fluorescence); the used cells are HepG2 cells, the main component of the shell layer is calcium alginate, and the main component of the core layer is sodium alginate + I type collagen.

FIG. 10A shows a photograph (magnification: 40 times) observed using a confocal microscope on day 1 of culturing a bio-brick in which cells are rounded without adhering to a stretch. FIG. 10B shows a photograph (magnification: 200 times) observed using a confocal microscope after culturing the bio-brick for 5 days, in which cell adhesion is stretched. The results in FIGS. 10A-10B show that after 5 days of culture, the cells within the bio-brick spread and establish intercellular junctions.

FIG. 11 shows the results of analysis (magnification: 200 times) of cell proliferation in a bio-brick observed using a confocal microscope, wherein the bio-brick was double-stained with DAPI (blue fluorescence) and EdU (red fluorescence); the used cells are HepG2 cells, the main component of the shell layer is calcium alginate, and the main component of the core layer is sodium alginate + I type collagen. The results in fig. 11 show that the cells within the bio-brick are in a proliferative state after 5 days of culture.

FIGS. 12A-12B show the cell proliferation (500 μm on a scale) of cell microspheres prepared by a conventional method during culture. The results showed that cell proliferation was not evident in the cell microspheres after 7 days of culture (FIG. 12B) compared to before culture (FIG. 12A), and the cells were rounded and scattered. FIGS. 12C-12D show the cell proliferation (500 μm on a scale) during culture of the bio-brick prepared by the method of example 1. The results show that after 7 days of culture (fig. 12D) cell proliferation was evident in the bio-brick compared to before culture (fig. 12C), and the cells stretched, adhered, and linked together in the bio-brick. FIG. 12E shows a micrograph (100 μm on a scale) of a biobrick prepared using the method of example 1 after 7 days of culture. The results show that HepG2 cells in the bio-brick are interconnected to form an organic whole. The results of fig. 12A-12E show that the bio-brick of the present invention can better promote the proliferation of cells and the establishment of connections between cells, compared to the cell microspheres prepared by the conventional method.

FIG. 13 shows the results of observation of the bio-brick (scale 100 μm in the figure) after 7 days of culture using a confocal microscope, wherein the bio-brick used comprised HepG2 cells labeled with green fluorescence and HUVEC cells labeled with red fluorescence, and the yellow region in the figure was due to superposition of red fluorescence and green fluorescence, indicating that a junction was established between HepG2 cells and HUVEC cells. The results show that intercellular connections are established between HepG2 cells, between HUVEC cells and between HepG2 cells and HUVEC cells in the biological brick.

FIG. 14A shows the results of observation of the bio-brick (scale 100 μm in the figure) after 7 days of culture using a confocal microscope, wherein the bio-brick used comprises HepG2 cells and HUVEC cells labeled with cell tracker Green CMFDA (Green fluorescence), respectively. The results show that a cellular connection is established between the cells of the two bio-bricks, as indicated by the bridge-like structure in the box.

Fig. 14B shows the results of observation of the bio-brick after 7 days of culture (500 μm on the scale in the figure) using a confocal microscope, in which two kinds of bio-bricks were used: one biobrick contained HepG2 cells labeled with cell tracker Green CMFDA (Green fluorescence) and the other biobrick contained HUVEC cells labeled with tracker CM-Dil (red fluorescence); also, the yellow region in the figure is caused by superposition of red fluorescence and green fluorescence. The results show that a cellular connection was established between the bio-brick expressing red fluorescence and the bio-brick expressing green fluorescence, as shown by the yellow area in the figure.

FIG. 14C shows the results of observation of the bio-brick (500 μm on the scale in the figure) after 7 days of culture using a confocal microscope, wherein the bio-brick used comprises HepG2 cells and HUVEC cells labeled with cell tracker Green CMFDA (Green fluorescence); each white circle in the figure represents a biological brick. The results show that cellular connections are established between the cells of different bio-bricks and form an organic whole.

Fig. 15 schematically depicts a flow chart for bioprinting blood vessels using the bio-brick/bio-ink of the present invention.

Figure 16 shows HE staining results for artificial liver tissue and immunohistochemical staining for albumin obtained using biobrick printing. The HE staining results of fig. 16 show that in the artificial liver tissue obtained using biobrick printing, the cells are arranged in a cord-like arrangement, and the artificial tissue produces a structure similar to a liver lobule, similar to normal liver tissue. In addition, the immunohistochemical staining results of fig. 18 show that liver cells located inside the artificial liver tissue were able to normally secrete Albumin (Albumin), a liver-specific protein, while non-liver cells located at the margin did not express Albumin. The experimental results show that the biological brick can be used for biologically printing artificial liver tissues.

FIG. 17 shows the result of staining a section of the artificial tissue body obtained in example 13 with the CD31 antibody. The results showed that a large number of microvessels appeared in the body of the artificial tissue obtained using the bio-brick printing. The results of these experiments indicate that the prepared bio-brick can be used for bioprinting a construct containing microvessels.

FIGS. 18A-I show microvascular formation printed with different species and ratios of seed cells.

Detailed Description

Definition of terms

In the present invention, unless otherwise specified, scientific and technical terms used herein have the meanings that are commonly understood by those skilled in the art. However, for a better understanding of the present invention, the following provides definitions and explanations of relevant terms in the present specification. To the extent that a definition given in this specification conflicts with a meaning commonly understood by those skilled in the art, the definition in this specification controls.

As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Further, any reference to "or" herein is intended to include "and/or" unless otherwise indicated.

As used herein, the term "bio-brick" is used to refer to a basic unit constructed by the present inventors that can be used in a variety of fields, such as bioprinting (e.g., 3D bioprinting), tissue engineering, regenerative medicine, and the like. In particular, the bio-brick of the invention has a specific structure and composition, i.e. it comprises: the cell comprises a cell, a nuclear layer wrapping the cell, and a shell layer encapsulating the cell and the nuclear layer, wherein the nuclear layer and the shell layer are respectively made of biodegradable materials. The schematic structure of the bio-brick of the present invention can be seen in fig. 1A-1E. In the present invention, the bio-brick is not limited to a specific shape or size, for example, it may be spherical, or any desired shape.

As used herein, the term "bioprinting" refers to: printing with biological materials (including, but not limited to, biomolecules such as proteins, lipids, nucleic acids, and metabolites; cells such as cell solutions, cell-containing gels, cell suspensions, cell concentrates, multicellular aggregates, and multicellular bodies; subcellular structures such as organelles and cell membranes; molecules associated with biomolecules such as synthetic biomolecules or analogs of biomolecules). As used herein, the term "printing" refers to the process of depositing material in accordance with a predetermined pattern. In the present invention, bioprinting is preferably accomplished by a method that is compatible with an automated or semi-automated, computer-aided three-dimensional prototyping apparatus (e.g., bioprinter). However, in the present invention, "printing" (e.g., bioprinting) may be performed by various methods, including, but not limited to, printing using a printer (e.g., a 3D printer or a bioprinter); printing using automated or non-automated mechanical processes (rather than printers); printing is performed by manual placement or manual deposition (e.g., using a pipette).

As used herein, the term "tissue" refers to an aggregate of cells composed of morphologically or similarly, functionally identical populations of cells, and typically also includes non-cellular morphologic material (referred to as intercellular matrix, e.g., matrix, fibers, etc.). The tissue may comprise one or more cells. As used herein, the term "organ" refers to a structure composed of different cells and tissues for performing a certain function or functions. The organ may comprise one or more tissues. "Artificial tissue" refers to a tissue that is not formed in an organism by natural tissue generation or developmental processes. The artificial tissue may be artificially manufactured tissue, for example tissue obtained by a bioprinting method. In the present invention, the terms "artificial tissue" and "tissue construct" are used interchangeably. As used herein, the term "tissue precursor" refers to a collection of cells that, after a culturing, inducing, or manipulating step, is capable of forming a tissue. In the present invention, the tissue precursor may be an artificially manufactured tissue precursor (i.e., an artificial tissue precursor).

In particular, in the present invention, examples of tissues include, but are not limited to: connective tissue (e.g., loose connective tissue, dense connective tissue, elastic tissue, reticulated connective tissue, and adipose tissue), muscle tissue (e.g., skeletal muscle, smooth muscle, and cardiac muscle), genitourinary tissue, gastrointestinal tissue, lung tissue, bone tissue, neural tissue, and epithelial tissue (e.g., monolayer and stratified epithelia), endodermal-derived tissue, mesodermal-derived tissue, and ectodermal-derived tissue.

As used herein, the term "construct" refers to an object constructed using the biobrick of the present invention, which may have a two-dimensional or three-dimensional structure, and may be a tissue precursor, a tissue or an organ.

As used herein, the term "tissue engineering" has the meaning commonly understood by those skilled in the art. In particular, tissue engineering is a interdisciplinary field that applies and combines principles of engineering and life sciences, and generally refers to the use of biological substitutes (e.g., the biological bricks of the present invention) to restore, maintain, or improve tissue function. The rationale for classical tissue engineering is: obtaining a small amount of living tissue from an organism, separating cells (also called seed cells) from the tissue by using a special enzyme or other methods, culturing and amplifying in vitro, and then mixing the amplified cells with a biological material (scaffold) which has good biocompatibility, degradability and absorbability according to a certain proportion to ensure that the cells are adhered on the biological material (scaffold) to form a cell-material compound; the compound is implanted into the damaged part of the organism tissue or organ, and along with the gradual degradation and absorption of the biological material in the body, the implanted cells are continuously proliferated in the body and secrete extracellular matrix, and finally corresponding tissue or organ is formed, thereby achieving the purposes of repairing wound and reconstructing function. The biological brick of the invention has the following remarkable advantages: the cell types and the cell numbers wrapped by the biological bricks are controllable; and the size of the biological brick is controllable; moreover, the core layer and the shell layer of the biological brick are respectively made of biodegradable materials; thus being particularly suitable for tissue engineering.

As used herein, "biocompatible material" refers to a material that is non-toxic to cells (and degradation products thereof) and is compatible with a host (e.g., a human body) after implantation in the host, without causing significant or serious side effects, e.g., toxic effects to the host (e.g., human tissue), without causing immunological rejection, allergic or inflammatory reactions in the host, or the like.

As used herein, "biodegradable material" refers to a material that is capable of being degraded and absorbed by a cell or organism, and whose degradation products are biocompatible. Such materials may be of natural origin (e.g. from animals and plants) or may be synthetically produced.

As used herein, "alginic acid" refers to a class of polysaccharides extracted from brown algae, which are random block copolymers of β -1, 4-D-mannuronic acid (M units) and α -1, 4-L-guluronic acid (G units). Typically, the M and G units in alginic acid are linked by 1,4 glycosidic linkages in combinations of M-M, G-G or M-G to form block copolymers. Alginic acid has the empirical formula of (C)₆H₈O₆)_nAnd its molecular weight is usually 4kDa-1500 kDa. As used herein, "alginate" refers to salts formed from alginic acid, including, but not limited to, sodium alginate, calcium alginate, strontium alginate, barium alginate, and the like.

As used herein, "oxidized alginate" refers to the product formed after an alginate (e.g., sodium alginate) is subjected to an oxidation reaction. Typically, the oxidation reaction will cause the hydroxyl groups of a portion of the uronic acid units in an alginate (e.g. sodium alginate) to be oxidized to aldehyde groups.

As used herein, "G/M value" refers to the molar ratio of alpha-1, 4-L-guluronic acid (G units) to beta-1, 4-D-mannuronic acid (M units) in alginic acid, alginate or oxidized alginate.

As used herein, "degree of oxidation" refers to the molar fraction of uronic acid units oxidized as a total uronic acid units of an alginic acid or an alginate.

As used herein, "viscosity" refers to a measure of the viscosity of a fluid and is an indication of the fluid flow forces versus internal friction phenomena. Two square meter (1 square meter) boards are immersed in a liquid, the distance between the two boards is 1 meter, if a shear stress of 1N is applied to one board, the relative speed between the two boards is 1m/s, and the viscosity of the liquid is 1 Pa.s.

As used herein, "modified degradable polymer" refers to a degradable polymer obtained by chemically and/or physically changing the chemical and/or physical properties of the original polymer. For example, the kind and/or combination of atoms or atomic groups on the main chain or side chain of the original polymer can be changed by chemical reaction, so as to obtain the modified degradable polymer. For example, sodium alginate is subjected to an oxidation reaction to give a modified sodium alginate (i.e., oxidized sodium alginate).

As used herein, the term "mechanically protected" means that the bio-brick or its shell layer has a certain hardness and elastic modulus so as to reduce or prevent the cells encapsulated therein from external mechanical/mechanical damage (e.g., damage caused by shear force, extrusion force, etc. that may be generated during 3D bioprinting).

As used herein, "bioink" refers to a liquid, semi-solid (e.g., gel) or solid composition comprising one or more of the bio-bricks of the present invention. For example, the biological ink of the present invention may be a solution, suspension, gel, or concentrate comprising a biological brick. In a preferred embodiment, the bio-ink of the present invention comprises a bio-brick and a bio-adhesive. In the present invention, biological inks can be used for bioprinting to produce specific planar and/or laminar geometries; and preferably the resulting planar and/or laminar geometries can be further stacked to form three-dimensional constructs of specific shapes and configurations. In addition, the cells within the bio-brick in the bio-ink can perform various desired vital activities before, during, and/or after bio-printing. In a preferred embodiment, the cells within the bio-brick are dormant prior to bioprinting and grow and proliferate after bioprinting to form a robust three-dimensional construct. In a preferred embodiment, the biological ink is an extrudable composition. As used herein, "extrudable" means that the composition is capable of being shaped by being forced (e.g., under pressure) through a nozzle or orifice.

As used herein, "bioadhesive" refers to a material that is compatible with cells and organisms, and is degradable, for adhesive purposes. Specific examples thereof may include, but are not limited to, collagen, fibrin, chitosan, alginate, starch, hyaluronic acid, laminin, elastin, gelatin, polyamino acids (e.g., polylysine), agar, dextran, methylcellulose, polyvinyl alcohol, polyacrylic acid and derivatives thereof (e.g., polymethacrylic acid, copolymers of acrylic acid and methacrylic acid), or any combination thereof.

As used herein, "agglutination" refers to cell-cell adhesion that binds cells, cell aggregates, multicellular bodies, and/or layers thereof. The term may be used interchangeably with "fusion".

As used herein, "layered" refers to a multilayered, bioprinted tissue in which two or more planar layers are combined to increase the overall thickness of the tissue in the z-plane (i.e., the vertical plane). In some embodiments, each planar layer may be substantially similar in structure and/or composition. In other embodiments, each planar layer may be substantially unique in structure and/or composition, i.e., different from each other. Furthermore, within the x-y plane (i.e., the horizontal plane) of each planar layer, a plurality of bio-bricks (or cells therein) and/or void spaces are spatially arranged in a set pattern relative to one another.

As used herein, "one or more layers" means, consisting of at least one planar/tissue layer, wherein each planar/tissue layer is the thickness of one or more cell layers. Since the bio-brick of the present invention may comprise one cell, it may also comprise a plurality of cells (e.g., 100 or 1000). Thus, in some embodiments, the planar/tissue layer is one cell layer thick. In other embodiments, the planar/tissue layer is the thickness of multiple cell layers. In addition, during 3D bioprinting, one layer may be deposited at a time, or multiple layers may be deposited simultaneously. Optionally, each planar/tissue layer comprises a plurality of cell types. In addition, the multiple cell types in each planar/tissue layer are optionally arranged relative to each other in a spatially defined configuration in the x-y plane (i.e., horizontal plane). Furthermore, in some cases, the addition of layers of tissue in the z-plane (i.e., the vertical plane) results in controlled spatial positioning of the cells relative to each other within the layers of tissue such that the spatially defined structure continues in the z-plane.

As used herein, "agent" refers to a chemical agent, biochemical agent, or drug, including, but not limited to, a small molecule compound, hormone, peptide (e.g., oligopeptide or protein), nucleic acid (oligonucleotide, DNA, RNA, or chemically modified nucleic acid), and the like, that has an effect or influence on cellular activity, function, and/or behavior. The agent may be of natural origin, recombinantly produced, or chemically synthesized. "stimulation" refers to a chemical factor (e.g., an agent, an acid, a base, an oxygen concentration, etc.) or a physical factor (e.g., temperature, irradiation, mechanical force, etc.) that has an effect or influence on cellular activity, function, and/or behavior.

As used herein, "subject" refers to an animal, such as a vertebrate. Preferably, the subject is a mammal, e.g., a human, bovine, equine, feline, canine, rodent, or primate. Particularly preferably, the subject is a human. Herein, the term is used interchangeably with "patient", "recipient" and "donor".

As used herein, "different cells" refers to cells of different origin and/or type. For example, bacterial cells and animal cells belong to different cells; cells derived from mouse are different from cells derived from human; murine chondrocytes are distinct from human chondrocytes; human chondrocytes are distinct from human epithelial cells.

As used herein, "endothelial cells," also referred to as "vascular endothelial cells" or "vascular wall endothelial cells," refer to cells that form the inner wall of a blood vessel.

As used herein, a "microvascular," also referred to as a "capillary vessel," is a type of blood vessel connecting the oligodynamic and venules, which is the thinnest (on average about 6-9 μm) and most widely distributed (throughout the body except for cartilage, cornea, hair epithelium, and enamel) in animals. The capillary tube has thin wall and strong permeability, branches are mutually matched into a net, and the material exchange between blood and tissues is facilitated.

Accordingly, in one aspect, the present invention provides a bio-brick comprising: a cell, a nuclear layer encapsulating the cell, and a shell layer encapsulating the cell and the nuclear layer, wherein the cell encapsulated by the nuclear layer comprises an endothelial cell and optionally an undifferentiated cell (e.g., a stem cell, a progenitor cell, or a combination thereof), and the nuclear layer and the shell layer are each made of a biodegradable material. In certain preferred embodiments of the invention, the shell does not comprise cells. In certain preferred embodiments of the invention, the biodegradable materials in the core and shell layers are capable of reducing or preventing mechanical damage to cells within a bio-brick during manipulation (e.g., bioprinting) and are capable of providing controlled release of substances (e.g., nutrients, extracellular matrix, cytokines or pharmaceutically active ingredients, etc.) to promote cellular activity and function (proliferation, differentiation, migration, secretion or metabolism). In certain preferred embodiments, the bio-brick is a basic unit for bioprinting. In certain preferred embodiments, the bio-brick is used for bioprinting. In certain preferred embodiments of the invention, the bio-brick of the invention comprises at least one core layer, such as 1, 2, 3, 4, 5 or more core layers; preferably, the bio-brick comprises at least two core layers, and each core layer is independently made of a biodegradable material and/or each core layer independently encapsulates the same or different cells or cell combinations. In certain preferred embodiments of the invention, the bio-brick comprises at least one shell, such as 1, 2, 3, 4, 5 or more shells; preferably, the bio-brick comprises at least two shells, and each shell is independently made of biodegradable material; preferably, the outermost side of the bio-brick comprises at least one shell layer; preferably, the bio-brick comprises: a core layer and a shell layer; alternatively, one core layer and 2 or more shell layers; or, 2 or more core layers and one shell layer; alternatively, at least 2 core layers and at least 2 shell layers. In certain preferred embodiments of the present invention, the bio-brick of the present invention comprises, in order from the inside to the outside: a core layer and a shell layer; or, a core layer, a first shell layer, and a second shell layer; alternatively, a first core layer, a second core layer, and a shell layer; or, a first core layer, a second core layer, a first shell layer, and a second shell layer; alternatively, the first core layer, the first shell layer, the second core layer, and the second shell layer.

The core layer of the bio-brick provides a spatial structure and microenvironment suitable for cell adhesion and spreading such that cells can normally proliferate, differentiate, migrate, secrete, or metabolize within the structure. The microenvironment refers to the environment in which cells grow, and comprises elements including physical factors such as spatial structure, mechanical strength, temperature, humidity, osmotic pressure, and the like; chemical factors such as ph, ion concentration, etc.; biological factors including cells, cytokines, etc. These elements together constitute the environment in which cells live and dynamically regulate the proliferation, differentiation, migration, secretion and metabolism of cells growing in this environment. In certain embodiments, the nuclear layer is capable of providing a microenvironment, such as spatial structure, nutrients, etc., for the vital activities of the cell. Preferably, the core layers are each independently made of a biodegradable material, and the biodegradable materials are biocompatible.

In the present invention, the use of biodegradable materials to prepare the core layer of the bio-brick is particularly preferred. In particular, for certain uses of the bio-brick (e.g., bioprinting, making constructs, tissue engineering, etc.), the use of non-degradable materials is disadvantageous. This is because, on the one hand, these non-degradable materials will be retained in the obtained constructs or artificial tissues, thus limiting their application; on the other hand, these non-degradable materials will prevent the establishment of cellular connections between cells of different bio-bricks, which is not conducive to the construction of organic monoliths (e.g. artificial tissues). Thus, the use of biodegradable materials in the core layer is particularly advantageous and preferred for the preparation of constructs, artificial tissues, organs with biological bricks.

In embodiments of the invention, the biodegradable material used to prepare the core layer can be naturally occurring (e.g., naturally occurring biodegradable materials derived from animals and plants, such as collagen, fibrin, chitosan, alginate, starch, hyaluronic acid, laminin, agarose, gelatin, dextran, and any combination thereof), synthetically produced, recombinantly produced, modified, or any combination thereof.

In certain preferred embodiments, the biodegradable material used to prepare the core layer is a naturally occurring degradable polymer. Preferably, the degradable polymer is selected from the group consisting of collagen, fibrin, chitosan, alginate (e.g., sodium alginate), starch, hyaluronic acid, laminin, agarose, gelatin, dextran, and any combination thereof.

In certain preferred embodiments, the biodegradable material used to prepare the core layer is a modified degradable polymer, such as a modified alginate, for example an oxidized alginate (e.g., oxidized sodium alginate).

In certain preferred embodiments, the biodegradable material used to prepare the core layer is a synthetic degradable polymer. Such degradable polymers include, but are not limited to, polyphosphazenes, polyacrylic acid and derivatives thereof (e.g., polymethacrylic acid, copolymers of acrylic acid and methacrylic acid), polylactic acid (PLA), polyglycolic acid (PGA), polylactic-glycolic acid copolymer (PLGA), Polyorthoesters (POE), Polycaprolactone (PCL), Polyhydroxybutyrate (PHB), polyamino acids (e.g., polylysine), degradable polyurethanes, and any combination thereof.

In certain preferred embodiments, the biodegradable material used to prepare the core layer comprises a naturally occurring degradable polymer and a synthetic degradable polymer.

In certain preferred embodiments, the biodegradable material used to prepare the core layer is capable of being degraded by an enzyme (e.g., an enzyme secreted by a cell). The degradation rates of different biodegradable materials vary widely, which can range from one month to several years. However, in the present invention, it is particularly preferred that the biodegradable material used for preparing the core layer is degraded within a period of not more than 2 months, for example, within a period of not more than 1 month, for example, within a period of not more than 30 days, not more than 25 days, not more than 20 days, not more than 15 days, not more than 10 days, not more than 5 days, not more than 4 days, not more than 3 days, not more than 2 days, or not more than 1 day. For example, the biodegradable material used to prepare the core layer may degrade over a period of 1-2 days, 2-3 days, 3-4 days, 4-5 days, 5-10 days, 10-15 days, 15-20 days, 20-25 days, 25-30 days, or 30-60 days. The degradation rate is closely related to the molecular composition, molecular weight size, and molecular arrangement (e.g., linear or branched) of the biodegradable material. In general, the higher the molecular weight, the more closely the molecules are arranged, and the longer the degradation time. Thus, the rate of degradation of the core layer can be controlled by the configuration of the composition and/or content of the core layer. For example, to obtain a faster degradation rate, a low content (e.g., less than 0.5%, 1%, 2%, 3%, 4%, or 5%) of biodegradable material, a low molecular weight (e.g., less than 500Da, 1kDa, 2kDa, 3kDa, 5kDa, or 10kDa) of biodegradable material, and/or biodegradable material having a loose molecular arrangement may be used. To obtain a slower degradation rate, a high content (e.g., greater than 0.5%, 1%, 2%, 3%, 4%, or 5%) of biodegradable material, a high molecular weight (e.g., greater than 500Da, 1kDa, 2kDa, 3kDa, 5kDa, or 10kDa) of biodegradable material, and/or biodegradable material with a tight molecular arrangement may be used. In addition, the degradation rate of the biodegradable material can be adjusted by changing the structure (such as multilayer wrapping, surface porosity, porosity size, specific surface area and the like) of the biological brick. In addition, the degradation rate of the biodegradable material can also be adjusted by changing the polymerization mode and the copolymer ratio for synthesizing the material; alternatively, the conditioning may be by cross-linking of the material.

Various biodegradable materials are known to those skilled in the art, and their degradation properties have been extensively studied (see, e.g., Alexander D.Augst, Hyun Joon Kong, David J.Mooney, Alginate Hydrogels as Biomaterials, Macromol. biosci.2006,6, 623-. The person skilled in the art can select suitable biodegradable materials to prepare the core layer according to actual needs.

In certain preferred embodiments, degradation of the nuclear layer is capable of providing nutrients that maintain or promote the vital activity of the cell. In certain preferred embodiments, the degradation products of the core layer are small molecule compounds, such as organic acids, monosaccharides (e.g., glucose), oligosaccharides, amino acids, lipids, and the like. Such degradation products may be involved in metabolic activities of cells, for synthesis of extracellular matrix or conversion to energy required for the activity.

In certain preferred embodiments, the biodegradable materials and their degradation products used to prepare the core layer are non-toxic to the cell and/or non-immunogenic to the host.

In certain preferred embodiments, the biodegradable material used to prepare the core layer is selected from collagen (e.g., type I, type II, type III collagen), fibrin, chitosan, alginate (e.g., sodium alginate), oxidized alginate (e.g., oxidized sodium alginate), starch, hyaluronic acid, laminin, elastin, gelatin, dextran, polyamino acids (e.g., polylysine), agarose, degradable polyurethane, or any combination thereof.

In certain preferred embodiments, the biodegradable material used to prepare the core layer contains an extracellular matrix or analog thereof (e.g., collagen). The use of an extracellular matrix or analogues thereof (e.g. collagen) is able to provide a favourable microenvironment like that in vivo for the vital activities of the cells within the bio-brick, in particular the growth, adhesion, spreading of the cells, and the establishment of intercellular connections, and is thus preferred. For example, the spatial structure of the type I collagen is similar to that of extracellular matrix, and can provide a microenvironment similar to the skeletal structure of the extracellular matrix for cell survival and proliferation and support the realization of cell biological functions. Thus, in certain preferred embodiments, the biodegradable material used to prepare the nuclear layer is or contains type I collagen.

In certain preferred embodiments, the core layer comprises type I collagen and/or alginate, for example comprises type I collagen and sodium alginate. In certain preferred embodiments, the weight ratio of type I collagen to sodium alginate in the core layer is about 1:1, 1:2, 1:4, 1:6, 1:8, 3:25, 1:9, 1:10, 1:20, 1:30, or 1: 50. In certain preferred embodiments, the weight ratio of type I collagen to sodium alginate in the core layer is 1:1-1:2, 1:2-1:4, 1:4-1:6, 1:6-1:8, 1:8-1:9, 1:9-1:10, 1:10-1:20, 1:20-1:30, 1:30-1:50, 1:1-1:5, 1:5-1:10, 1:7-1:10, or 1:8-1: 9. In certain preferred embodiments, the percentage by weight of type I collagen in the nuclear layer is about 0.01%, 0.05%, 0.1%, 0.125%, 0.15%, 0.175%, 0.2%, 0.25%, 0.3%, 0.4%, 0.5%, 1%, 2%, 3%, 4%, or 5%. In certain preferred embodiments, the percentage by weight of type I collagen in the nuclear layer is 0.01% -0.05%, 0.05% -0.1%, 0.1% -0.125%, 0.125% -0.15%, 0.15% -0.175%, 0.175% -0.2%, 0.2% -0.25%, 0.25% -0.3%, 0.3% -0.4%, 0.4% -0.5%, 0.5% -1%, 1% -2%, 2% -3%, 3% -4%, 4% -5%, 0.01% -0.1%, 0.1% -0.2%, 0.125% -0.175%, 0.2% -0.5%, 0.1% -1%, or 0.05% -5%. In certain preferred embodiments, the weight percentage of sodium alginate in the core layer is about 0.1%, 0.5%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, 5%, 7.5%, or 10%. In certain preferred embodiments, the weight percentage of sodium alginate in the core layer is 0.1% -0.5%, 0.5% -1%, 1% -1.25%, 1.25% -1.5%, 1.5% -2%, 2% -3%, 3% -4%, 4% -5%, 5% -7.5%, 7.5% -10%, 0.1% -1%, 1% -1.5%, 1% -2%, 0.5-2.5%, 1% -3%, 5-10%, or 0.5-5%.

In certain preferred embodiments, the core layer comprises sodium alginate. In certain preferred embodiments, the nuclear layer comprises type I collagen. In certain preferred embodiments, the core layer comprises starch. In certain preferred embodiments, the core layer comprises a degradable polyurethane. In certain preferred embodiments, the core layer comprises laminin.

In certain preferred embodiments, the core layer comprises an alginate (e.g., sodium or calcium alginate) and an oxidized alginate (e.g., oxidized sodium alginate). In certain preferred embodiments, the weight ratio of alginate (e.g., sodium alginate or calcium alginate) and oxidized alginate (e.g., oxidized sodium alginate) in the core layer is about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1: 10. In certain preferred embodiments, the weight ratio of alginate (e.g., sodium alginate or calcium alginate) to oxidized alginate (e.g., oxidized sodium alginate) in the core layer is 10:1-9:1, 9:1-8:1, 8:1-7:1, 7:1-6:1, 6:1-5:1, 5:1-4:1, 4:1-3:1, 3:1-2:1, 2:1-1:1, 1:1-1:2, 1:2-1:3, 1:3-1:4, 1:4-1:5, 1:5-1:6, 1:6-1:7, 1:7-1:8, 1:8-1:9, 1:9-1:10, 10:1-5:1, 5:1-1:1, 1:1-1:5, 1:5-1:10, 2:1-1:2, 4:1-1:4, or 10:1-1: 10.

In certain preferred embodiments, the core layer is gel-like.

The shell layer of the biological brick provides mechanical protection for the wrapped cells. In certain preferred embodiments, the biological bricks or shells of biological bricks have a mechanical strength such that a three-dimensional stacking is achieved. In the present invention, it is particularly preferred that the bio-brick and its shell have suitable mechanical protective properties (e.g., have suitable hardness and/or elastic modulus). On the one hand, cells within a bio-brick are prone to damage or death during handling (e.g., during 3D printing) due to damage from external pressure or shear forces. Therefore, if the hardness and/or elastic modulus of the bio-brick and its shell layer are too low, the survival rate of cells in the bio-brick is significantly reduced after manual operation, which in turn causes limitation in the application of the bio-brick or requires the use of a large amount of cells. On the other hand, if the hardness and/or the elastic modulus of the bio-brick and its shell layer are too high, this will result in limited extension, migration of cells within the bio-brick, and prevent the establishment of cellular connections between cells of different bio-bricks, which is not conducive to the construction of organic whole (e.g. artificial tissue). Thus, suitable mechanical protection properties not only enable various operations to be performed on the bio-brick of the present invention (e.g., 3D bioprinting, precise arrangement of the bio-brick, etc.), but also facilitate cell spreading, migration, establishment of cell junctions, and formation of organic constructs (e.g., artificial tissues) within the bio-brick, and are therefore particularly preferred.

In certain preferred embodiments, the bio-brick or the shell of the bio-brick each independently has a hardness of about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.3, or 0.4 GPa. In certain preferred embodiments, the biological brick or shell of a biological brick each independently has a hardness of 0.01 to 0.02, 0.02 to 0.03, 0.03 to 0.04, 0.04 to 0.05, 0.05 to 0.06, 0.06 to 0.07, 0.07 to 0.08, 0.08 to 0.09, 0.09 to 0.1, 0.1 to 0.15, 0.15 to 0.2, 0.2 to 0.3, 0.3 to 0.4, 0.01 to 0.05, 0.05 to 0.1, 0.1 to 0.2, 0.2 to 0.4, 0.05 to 0.15, or 0.06 to 0.1 GPa. In certain preferred embodiments, the biological brick or shell of a biological brick has a hardness of about 0.083 GPa. In certain preferred embodiments, the bio-brick or shell of a bio-brick each independently has an elastic modulus of about 0.01, 0.05, 0.1, 0.5, 0.8, 1, 1.2, 1.4, 1.6, 1.8, 2, 2.4, 2.8, 3.2, 4, 10, 20, 30, 40, 50, 80, or 100 MPa. In certain preferred embodiments, the bio-brick or shell of the bio-brick each independently has an elastic modulus of 0.01 to 0.05, 0.05 to 0.1, 0.1 to 0.5, 0.5 to 0.8, 0.8 to 1, 1 to 1.2, 1.2 to 1.4, 1.4 to 1.6, 1.6 to 1.8, 1.8 to 2, 2 to 2.4, 2.4 to 2.8, 2.8 to 3.2, 3.2 to 4, 4 to 10, 10 to 20, 20 to 30, 30 to 40, 40 to 50, 50 to 80, 80 to 100, 0.5 to 4, 0.5 to 1, 1 to 1.5, 1.5 to 2, 2 to 3, 0.8 to 1.6, 1.4 to 2.4, 0.8 to 3.2, 0.01 to 100, 1 to 100, 10 to 100, or 0.5 to 50 MPa. In certain preferred embodiments, the bio-brick or shell layer of a bio-brick has an elastic modulus of about 1.683 MPa. The mechanical protection (e.g., hardness and elastic modulus) of the shell layer can be controlled by the configuration of the composition and/or content of the shell layer.

In certain preferred embodiments, the shell is also capable of providing a microenvironment for the vital activity of the cell, such as nutrients. Preferably, the shell layers are each independently made of a biodegradable material, and the biodegradable materials are biocompatible.

In the present invention, it is particularly preferable to use a biodegradable material for preparing the shell layer of the bio-brick. In particular, for certain uses of the bio-brick (e.g., bioprinting, making constructs, tissue engineering, etc.), the use of non-degradable materials is disadvantageous. This is because, on the one hand, these non-degradable materials will be retained in the obtained constructs or artificial tissues, thus limiting their application; on the other hand, these non-degradable materials will prevent the establishment of cellular connections between cells of different bio-bricks, which is not conducive to the construction of organic monoliths (e.g. artificial tissues). Thus, the use of biodegradable materials in the shell layer is particularly advantageous and preferred for the preparation of constructs, artificial tissues, organs using bio-bricks.

In embodiments of the invention, the biodegradable material used to prepare the shell layer may be naturally occurring (e.g., naturally occurring biodegradable materials derived from animals and plants, such as collagen, fibrin, chitosan, alginate, starch, hyaluronic acid, laminin, agarose, gelatin, dextran, and any combination thereof), synthetically produced, recombinantly produced, modified, or any combination thereof.

In certain preferred embodiments, the biodegradable material used to prepare the shell layer is a naturally occurring degradable polymer. Preferably, the degradable polymer is selected from the group consisting of collagen, fibrin, chitosan, alginate (e.g., sodium or calcium alginate), starch, hyaluronic acid, laminin, agarose, gelatin, dextran, and any combination thereof.

In certain preferred embodiments, the biodegradable material used to prepare the shell layer is a modified degradable polymer, such as a modified alginate, for example an oxidized alginate (e.g., oxidized sodium alginate).

In certain preferred embodiments, the biodegradable material used to prepare the shell layer is a synthetic degradable polymer. Such degradable polymers include, but are not limited to, polyphosphazenes, polyacrylic acid and derivatives thereof (e.g., polymethacrylic acid, copolymers of acrylic acid and methacrylic acid), polylactic acid (PLA), polyglycolic acid (PGA), polylactic-glycolic acid copolymer (PLGA), Polyorthoesters (POE), Polycaprolactone (PCL), Polyhydroxybutyrate (PHB), polyamino acids (e.g., polylysine), degradable polyurethanes, and any combination thereof.

In certain preferred embodiments, the biodegradable material used to prepare the shell layer is capable of being degraded by an enzyme (e.g., an enzyme secreted by a cell). The degradation rates of different biodegradable materials vary widely, which can range from one month to several years. However, in the present invention, it is particularly preferred that the biodegradable material used for preparing the shell layer is degraded within a period of not more than 1 month, for example, within a period of not more than 30 days, not more than 25 days, not more than 20 days, not more than 15 days, not more than 10 days, not more than 5 days, not more than 4 days, not more than 3 days, not more than 2 days, or not more than 1 day. For example, the biodegradable material used to prepare the shell may degrade within a period of 1-2 days, 2-3 days, 3-4 days, 4-5 days, 5-10 days, 10-15 days, 15-20 days, 20-25 days, or 25-30 days. It is particularly preferred that the biodegradable material used for the shell layer is degraded in a period of not more than 10 days. The degradation rate is closely related to the molecular composition, molecular weight size, and molecular arrangement (e.g., linear or branched) of the biodegradable material. In general, the higher the molecular weight, the more closely the molecules are arranged, and the longer the degradation time. Thus, the rate of degradation of the shell layer can be controlled by the configuration of the composition and/or content of the shell layer. For example, to obtain a faster degradation rate, a low content (e.g., less than 0.5%, 1%, 2%, 3%, 4%, or 5%) of biodegradable material, a low molecular weight (e.g., less than 500Da, 1kDa, 2kDa, 3kDa, 5kDa, or 10kDa) of biodegradable material, and/or biodegradable material having a loose molecular arrangement may be used. To obtain a slower degradation rate, a high content (e.g., greater than 0.5%, 1%, 2%, 3%, 4%, or 5%) of biodegradable material, a high molecular weight (e.g., greater than 500Da, 1kDa, 2kDa, 3kDa, 5kDa, or 10kDa) of biodegradable material, and/or biodegradable material with a tight molecular arrangement may be used. In addition, the degradation rate of the biodegradable material can be adjusted by changing the structure (such as multilayer wrapping, surface porosity, porosity size, specific surface area and the like) of the biological brick. In addition, the degradation rate of the biodegradable material can also be adjusted by changing the polymerization mode and the copolymer ratio for synthesizing the material; alternatively, the conditioning may be by cross-linking of the material. Furthermore, the degradation rate of the biodegradable material used to prepare the shell layer can also be influenced by cellular vital activities. In the present invention, it is particularly preferred that the cells within a bio-brick are capable of growing, expanding, proliferating, migrating, and establishing cellular connections with cells within other bio-bricks to form an organic construct (e.g., an artificial tissue). Thus, in certain preferred embodiments, the shell of the bio-brick degrades over a relatively short period of time (e.g., no more than 30 days, such as no more than 10 days) to facilitate the establishment of cellular connections between different bio-bricks, avoiding the presence of the shell to hinder or affect the establishment of cellular connections between different bio-bricks with respect to each other. In certain preferred embodiments, the shell layer of the bio-brick degrades over a period of no more than 30 days, no more than 25 days, no more than 20 days, no more than 15 days, no more than 10 days, no more than 5 days, no more than 4 days, no more than 3 days, no more than 2 days, or no more than 1 day. For example, the shell of the bio-brick can degrade over a period of 1-2 days, 2-3 days, 3-4 days, 4-5 days, 5-10 days, 10-15 days, 15-20 days, 20-25 days, or 25-30 days.

Various biodegradable materials are known to those skilled in the art, and their degradation properties have been extensively studied. See, e.g., Alexander D.Augst, Hyun Joon Kong, David J.Mooney, Alginate Hydrogels as Biomaterials, Macromol. biosci.2006,6, 623-.

In certain preferred embodiments, degradation of the shell can provide a microenvironment, such as a nutrient, that maintains or promotes vital activities of the cell. In certain preferred embodiments, the degradation products of the shell are small molecule compounds, such as organic acids, monosaccharides (e.g., glucose), oligosaccharides, amino acids, lipids, and the like. Such degradation products may be involved in metabolic activities of cells, for synthesis of extracellular matrix or conversion to energy required for the activity.

In certain preferred embodiments, the biodegradable materials used to prepare the shell layer and their degradation products are non-toxic to the cell and/or non-immunogenic to the host.

In certain preferred embodiments, the biodegradable material used to prepare the shell layer comprises an extracellular matrix or analog thereof (e.g., elastin). The use of an extracellular matrix or an analogue thereof (e.g. elastin) is thus preferred to provide a favourable microenvironment like that in vivo for the vital activities of the cells within the bio-brick, in particular the growth, adhesion, stretching of the cells, and the establishment of intercellular junctions.

In certain preferred embodiments, the biodegradable material used to prepare the shell layer is selected from collagen (e.g., type I, type II, type III collagen), fibrin, chitosan, alginate (e.g., sodium or calcium alginate), oxidized alginate (e.g., oxidized sodium alginate), starch, hyaluronic acid, laminin, elastin, gelatin, dextran, polyamino acids (e.g., polylysine), agarose, or any combination thereof.

In certain preferred embodiments, the shell layer comprises an alginate (e.g., sodium or calcium alginate), e.g., comprises calcium alginate and gelatin, and optionally further comprises elastin.

In certain preferred embodiments, the shell layer comprises an alginate (e.g., sodium or calcium alginate) and gelatin. In certain preferred embodiments, the weight ratio of alginate (e.g., sodium or calcium alginate) to gelatin in the shell layer is about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1: 10. In certain preferred embodiments, the weight ratio of alginate (e.g., sodium alginate or calcium alginate) to gelatin in the shell is 10:1-9:1, 9:1-8:1, 8:1-7:1, 7:1-6:1, 6:1-5:1, 5:1-4:1, 4:1-3:1, 3:1-2:1, 2:1-1:1, 1:1-1:2, 1:2-1:3, 1:3-1:4, 1:4-1:5, 1:5-1:6, 1:6-1:7, 1:7-1:8, 1:8-1:9, 1:9-1:10, 10:1-5:1, 5:1-1:1, 1:1-1:5, 1:5-1:10, 1: 10-1: 10, 2:1-1:2, 4:1-1:4, or 10:1-1: 10. In certain preferred embodiments, the shell layer further comprises elastin. In certain preferred embodiments, the weight ratio of alginate (e.g., sodium or calcium alginate) to elastin in the shell layer is about 1000:1, 500:1, 400:1, 300:1, 250:1, 200:1, 100:1, 50:1, or 10: 1. In certain preferred embodiments, the weight ratio of alginate (e.g., sodium alginate or calcium alginate) to elastin in the shell layer is 10:1-50:1, 50:1-100:1, 100:1-200:1, 200:1-250:1, 250:1-300:1, 300:1-400:1, 400:1-500:1, 500:1-1000:1, 10:1-100:1, 100:1-200:1, 200:1-300:1, 300:1-400:1, 400:1-1000:1, or 100:1-500: 1. In certain preferred embodiments, the weight ratio of gelatin to elastin in the shell layer is about 1000:1, 500:1, 400:1, 300:1, 250:1, 200:1, 100:1, 50:1, or 10: 1. In certain preferred embodiments, the gelatin and elastin are in the shell in a weight ratio of 10:1-50:1, 50:1-100:1, 100:1-200:1, 200:1-250:1, 250:1-300:1, 300:1-400:1, 400:1-500:1, 500:1-1000:1, 10:1-100:1, 100:1-200:1, 200:1-300:1, 300:1-400:1, 400:1-1000:1, or 100:1-500: 1. In certain preferred embodiments, the weight ratio of alginate (e.g., sodium or calcium alginate), gelatin, and elastin in the shell layer is about 250:250: 1. In certain preferred embodiments, the weight percentage of alginate (e.g., sodium or calcium alginate) in the shell layer is about 0.1%, 0.5%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, 5%, 7.5%, or 10%. In certain preferred embodiments, the weight percentage of alginate (e.g., sodium or calcium alginate) in the shell layer is 0.1% -0.5%, 0.5% -1%, 1% -1.25%, 1.25% -1.5%, 1.5% -2%, 2% -3%, 3% -4%, 4% -5%, 5% -7.5%, 7.5% -10%, 0.1% -1%, 1% -1.5%, 1% -2%, 0.5-2.5%, 1% -3%, 5% -10%, or 0.5% -5%. In certain preferred embodiments, the weight percentage of gelatin in the shell layer is about 0.1%, 0.5%, 1%, 1.25%, 1.5%, 2%, 3%, 4%, 5%, 7.5%, or 10%. In certain preferred embodiments, the weight percentage of gelatin in the shell layer is 0.1% -0.5%, 0.5% -1%, 1% -1.25%, 1.25% -1.5%, 1.5% -2%, 2% -3%, 3% -4%, 4% -5%, 5% -7.5%, 7.5% -10%, 0.1% -1%, 1% -1.5%, 1% -2%, 0.5% -2.5%, 1% -3%, 5% -10%, or 0.5% -5%. In certain preferred embodiments, the weight percentage of elastin in the shell layer is about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.1%, 0.15%, 0.2%, or 0.5%. In certain preferred embodiments, the weight percentage of elastin in the shell layer is 0.01% -0.02%, 0.02% -0.03%, 0.03% -0.04%, 0.04% -0.05%, 0.05% -0.06%, 0.06% -0.07%, 0.07% -0.08%, 0.08% -0.1%, 0.1% -0.15%, 0.15% -0.2%, 0.2% -0.5%, 0.01% -0.03%, 0.03% -0.05%, 0.05% -0.08%, 0.08% -0.15%, 0.01% -0.05%, 0.05% -0.1%, 0.03% -0.07%, 0.04% -0.06%, 0.01% -0.1%, 0.1% -0.5%, or 0.01% -0.5%.

In certain preferred embodiments, the shell layer comprises an alginate (e.g., sodium or calcium alginate), e.g., comprises calcium alginate and gelatin, and optionally further comprises elastin. In certain preferred embodiments, the shell layer comprises an oxidized alginate (e.g., oxidized sodium alginate). In certain preferred embodiments, the shell layer comprises alginate (e.g., sodium or calcium alginate) and agarose.

In certain preferred embodiments, oxidized alginates (e.g., oxidized sodium alginate and oxidized calcium alginate) can be used to prepare the shell/shell of the bio-brick, and the rate of degradation can be adjusted by controlling the degree of oxidation of the alginate, so that the rate of degradation of the shell/shell matches the rate of growth of the cells encapsulated therein.

Thus, in certain preferred embodiments, at least one shell layer of a bio-brick of the present invention comprises an oxidized alginate (e.g., oxidized sodium alginate and/or oxidized calcium alginate), thereby enabling control of the rate of degradation of the bio-brick (or its shell layer) (e.g., by controlling the degree of oxidation of the alginate). In certain preferred embodiments, at least one shell layer (e.g., all shell layers) of a bio-brick of the present invention comprises an oxidized alginate (e.g., oxidized sodium alginate and/or oxidized calcium alginate). In certain preferred embodiments, the outermost shell layer of the bio-brick of the present invention comprises an oxidized alginate (e.g., oxidized sodium alginate and/or oxidized calcium alginate). In certain preferred embodiments, in the bio-brick of the present invention, only the outermost shell layer comprises oxidized alginate (e.g., oxidized sodium alginate and/or oxidized calcium alginate).

In certain preferred embodiments, the oxidized alginate comprises oxidized sodium alginate and/or oxidized calcium alginate. In certain preferred embodiments, the oxidized alginate comprises oxidized sodium alginate. In certain preferred embodiments, the oxidized alginate comprises oxidized calcium alginate. In certain preferred embodiments, the oxidized alginate comprises oxidized sodium alginate and oxidized calcium alginate.

In certain preferred embodiments, the oxidized alginate has a molecular weight of 4kDa to 1500 kDa. In certain preferred embodiments, the oxidized alginate has a molecular weight of 4-10kDa, 10-20kDa, 20-30kDa, 30-40kDa, 40-50kDa, 50-60kDa, 60-70kDa, 70-80kDa, 80-90kDa, 90-100kDa, 100-200kDa, 200-300kDa, 300-400kDa, 400-500kDa, 500-600kDa, 700-800kDa, 800-900kDa, 900-1000kDa, 1100-1200kDa, 1200-1300kDa, 1300-1400kDa, or 1400-1500-kDa. In certain preferred embodiments, the molecular weight of the oxidized alginate is from 32k to 250k Da. In certain preferred embodiments, the oxidized alginate is water soluble.

In certain preferred embodiments, the oxidized alginate has a G/M value of from 0.2 to 5. In certain preferred embodiments, the oxidized alginate has a G/M value of 0.2 to 0.3, 0.3 to 0.4, 0.4 to 0.5, 0.5 to 0.6, 0.6 to 0.7, 0.7 to 0.8, 0.8 to 0.9, 0.9 to 1.0, 1.0 to 1.5, 1.5 to 2.0, 2.0 to 2.5, 2.5 to 3.0, 3.0 to 3.5, 3.5 to 4.0, 4.0 to 4.5, or 4.5 to 5.0. In certain preferred embodiments, the oxidized alginate has a G/M value of from 0.2 to 2.5.

In certain preferred embodiments, the oxidized alginate has a degree of oxidation of 1 to 40%. In certain preferred embodiments, the oxidized alginate has a degree of oxidation of 1-2%, 2-3%, 3-4%, 4-5%, 5-6%, 6-7%, 7-8%, 8-9%, 9-10%, 11-12%, 12-13%, 13-14%, 14-15%, 15-16%, 16-17%, 17-18%, 18-19%, 19-20%, 20-25%, 25-30%, 30-35%, or 35-40%. In certain preferred embodiments, the oxidized alginate has a degree of oxidation of 2.5 to 4.4%, 4.4 to 8.8%, 8.8 to 17.6%, or 17.6 to 22%.

In certain preferred embodiments, the oxidized alginate used to prepare the shell layer has a viscosity of 100-3000 mPas. In some preferred embodiments, the viscosity of the oxidized alginate used for preparing the shell layer is 100-200-, 200-300-, 300-400-, 500-600-, 700-, 800-900-, 900-1000-, 1000-1100-, 1100-1200-, 1300-1400-, 1400-1500-, 1600-, 1700-, 1800-, 1900-, 2000-, 2100-, 2200-, 2300-, 2400-2500-, 2600-, 2700-, 2800-, 2900-, or 3000 mPa-s. In certain preferred embodiments, the oxidized alginate used to prepare the shell layer has a viscosity of 200-2000 mPas.

In certain preferred embodiments, the oxidized alginate is obtained by oxidizing alginate extracted from algae (e.g., brown algae, such as kelp and gulfweed).

In certain preferred embodiments, at least one shell layer of the bio-brick of the present invention comprises 1 to 25% (wt) oxidized alginate. In certain preferred embodiments, at least one shell layer of a bio-brick of the present invention comprises 1-2%, 2-3%, 3-4%, 4-5%, 5-6%, 6-7%, 7-8%, 8-9%, 9-10%, 10-15%, 15-20%, 20-25% (wt) oxidized alginate. In certain preferred embodiments, at least one shell layer of the bio-brick of the present invention comprises at least 5% (wt) oxidized alginate.

In certain preferred embodiments, at least one shell layer of a bio-brick of the present invention comprises an oxidized alginate (e.g., an oxidized alginate as defined above), and an alginate (e.g., sodium alginate and/or calcium alginate).

In certain preferred embodiments, the alginate comprised in the at least one shell has a molecular weight of 4kDa to 1500 kDa. In certain preferred embodiments, the alginate contained in the at least one shell has a molecular weight of 4-10kDa, 10-20kDa, 20-30kDa, 30-40kDa, 40-50kDa, 50-60kDa, 60-70kDa, 70-80kDa, 80-90kDa, 90-100kDa, 100-200kDa, 200-300kDa, 300-400kDa, 400-500kDa, 500-600kDa, 700-800kDa, 800-900kDa, 900-1000kDa, 1100-1200kDa, 1200-1300kDa, 1300-1400kDa, or 1400-1500-kDa. In certain preferred embodiments, the alginate comprised in the at least one shell layer has a molecular weight of 32k-250k Da.

In certain preferred embodiments, the alginate comprised in said at least one shell layer has a G/M value of from 0.2 to 5. In certain preferred embodiments, the alginate contained in the at least one shell has a G/M value of 0.2 to 0.3, 0.3 to 0.4, 0.4 to 0.5, 0.5 to 0.6, 0.6 to 0.7, 0.7 to 0.8, 0.8 to 0.9, 0.9 to 1.0, 1.0 to 1.5, 1.5 to 2.0, 2.0 to 2.5, 2.5 to 3.0, 3.0 to 3.5, 3.5 to 4.0, 4.0 to 4.5, or 4.5 to 5.0. In certain preferred embodiments, the alginate comprised in said at least one shell layer has a G/M value of 0.2 to 2.5.

In certain preferred embodiments, the alginate used to prepare the at least one shell has a viscosity of 100-3000mPa s. In certain preferred embodiments, the alginate used to prepare the at least one shell has a viscosity of 100-. In certain preferred embodiments, the alginate used to prepare the at least one shell has a viscosity of 200-2000 mPas.

In certain preferred embodiments, the mass ratio of alginate to oxidized alginate in the at least one shell is from 1:9 to 9: 1. In certain preferred embodiments, the mass ratio of alginate to oxidized alginate in the at least one shell is 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2, 9: 1.

In certain preferred embodiments, the shell layer comprises an alginate (e.g., sodium or calcium alginate) and an oxidized alginate (e.g., oxidized sodium alginate). In certain preferred embodiments, the weight ratio of alginate (e.g., sodium alginate or calcium alginate) to oxidized alginate (e.g., oxidized sodium alginate) in the shell layer is about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1: 10. In certain preferred embodiments, the weight ratio of alginate (e.g., sodium alginate or calcium alginate) to oxidized alginate (e.g., oxidized sodium alginate) in the shell is 10:1-9:1, 9:1-8:1, 8:1-7:1, 7:1-6:1, 6:1-5:1, 5:1-4:1, 4:1-3:1, 3:1-2:1, 2:1-1:1, 1:1-1:2, 1:2-1:3, 1:3-1:4, 1:4-1:5, 1:5-1:6, 1:6-1:7, 1:7-1:8, 1:8-1:9, 1:9-1:10, 10:1-5:1, 5:1-1:1, 1:1-1:5, 1:5, 1:5-1:10, 2:1-1:2, 4:1-1:4, or 10:1-1: 10.

In certain preferred embodiments, the at least one shell layer is completely degraded in no more than 28 days. In certain preferred embodiments, the at least one shell layer is completely degraded in no more than 21 days, no more than 14 days, no more than 12 days, no more than 10 days, no more than 9 days, no more than 8 days, no more than 7 days, no more than 6 days, no more than 5 days, no more than 4 days, no more than 3 days, or no more than 2 days. In certain preferred embodiments, the at least one shell layer is completely degraded within 2 to 5 days, 2 to 6 days, 2 to 8 days, 2 to 10 days, 2 to 12 days, or 2 to 14 days.

In certain preferred embodiments, the viscosity of the at least one shell layer is 100-3000 mPas. In some preferred embodiments, the viscosity of the at least one shell layer is 100-. In certain preferred embodiments, the viscosity of the at least one shell layer is 200-2000 mPas.

In certain preferred embodiments, the biodegradable materials used to prepare the core and shell layers may be the same or different. However, it is particularly preferred that the core layer and the shell layer have different compositions depending on their intended purpose. Without being bound by theory, it is generally believed that the shell layer provides the primary mechanical protection, while the core layer provides the primary nutrients and microenvironment required for cellular life activities. Thus, in certain preferred embodiments, the core layer has more nutrients than the shell layer. In certain preferred embodiments, the shell layer has a lower degradation rate, but a higher hardness and/or elastic modulus, than the core layer. In certain preferred embodiments, the shell does not comprise cells.

Thus, in certain preferred embodiments, the core layer and the shell layer are made of different biodegradable materials. For example, in certain preferred embodiments, the biodegradable material used to prepare the core layer is sodium alginate and optionally type I collagen; and the biodegradable material used for preparing the shell layer is sodium alginate and optional elastin. In certain preferred embodiments, the biodegradable material used to prepare the core layer is starch; and the biodegradable material for preparing the shell layer is sodium alginate. In certain preferred embodiments, the biodegradable material used to prepare the core layer is type I collagen; and the biodegradable material for preparing the shell layer is polylysine. In certain preferred embodiments, the biodegradable material used to prepare the core layer is type I collagen; and the biodegradable material for preparing the shell layer is sodium alginate. In certain preferred embodiments, the biodegradable material used to prepare the core layer is a polyurethane; and the biodegradable material for preparing the shell layer is sodium alginate. In certain preferred embodiments, the biodegradable material used to prepare the core layer is sodium alginate; and the biodegradable material for preparing the shell layer is polylysine.

In certain preferred embodiments, the core layer and the shell layer each comprise the same biodegradable material in different weight ratios. In other words, the core layer and the shell layer may be made of the same biodegradable material, but contain the biodegradable material in different weight ratios. For example, in certain preferred embodiments, both the core layer and the shell layer are made of sodium alginate; but the core layer contains no more than 2% (e.g. 1.5%) sodium alginate and the shell layer contains more than 4% (e.g. 5%) sodium alginate. Not more than 2% (e.g., 1.5%) sodium alginate can provide excellent conditions for cell growth, proliferation, differentiation or migration in the nuclear layer (cells are generally difficult to grow and survive in conditions exceeding 2% sodium alginate); while more than 4% (e.g. 5%) of sodium alginate can provide sufficient hardness and elasticity to the shell layer.

In certain preferred embodiments, the core layer and the shell layer comprise a combination selected from the group consisting of:

	core layer material	Shell material
			Combination
1	Type I collagen	Sodium alginate
			Combination 2	Type I collagen	Oxidized sodium alginate
Combination
	3	Type I collagen	Sodium alginate + oxidized sodium alginate (the concentration ratio of the two is 9:1)
Combination 4				Type I collagen	Sodium alginate + oxidized sodium alginate (concentration ratio of the two is 7:3)
	Combination 5	Laminin	Sodium alginate + agarose (concentration ratio of the two is 8:2)
Combination 6				Starch	Oxidized sodium alginate
	Combination 7	Starch	Sodium alginate + oxidized sodium alginate (concentration ratio of the two is 7:3)
Combination 8				Degradable polyurethanes	Oxidized sodium alginate
	Combination 9	Degradable polyurethanes	Sodium alginate + oxidized sodium alginate (the concentration ratio of the two is 9:1)
Assembly 10				Degradable polyurethanes	Sodium alginate + gelatin (85: 15 concentration ratio)

In certain preferred embodiments, the shell layers are each independently permeable. For example, the shell is permeable to water, oxygen, and nutrients (sugars such as glucose, fats, proteins, amino acids, short peptides, minerals, vitamins, cytokines, nucleotides, etc.).

It is believed that the use of a semi-permeable (i.e., selectively permeable) shell may be advantageous because it allows nutrients such as water, oxygen, glucose, minerals, and amino acids to permeate the shell, enter the core, and be provided to the cells, and prevents substances harmful to the cells (e.g., antibody proteins from the host immune system) from entering the core. However, in the bio-brick of the present invention, the use of a permeable shell is preferred and advantageous. In particular, the permeable shell allows for easier and smoother exchange of various nutrients (including large and small molecule nutrients such as glucose, fats, proteins, amino acids, short peptides, minerals, vitamins, cytokines, nucleotides, etc.) to avoid local areas of the cell from receiving sufficient nutrients. For example, when a large size artificial tissue is constructed using the bio-brick of the present invention, the permeable shell layer will facilitate the exchange of various nutrients and the availability of sufficient nutrients to the cells within the bio-brick in the inner/core region of the artificial tissue. In addition, the permeable shell layer is beneficial to the signal transmission of cells between different biological bricks and the establishment of cell connection. In particular, cells secrete a variety of substances (including certain components of the extracellular matrix and a variety of signaling molecules) during their growth, communicate signals and/or substances with neighboring, even distant cells, and thereby influence or regulate the vital activities of the cells themselves and of neighboring, even distant cells. Thus, if a permselective shell is used, signal transmission and/or material communication between cells may be affected/hindered, for example, certain macromolecular signaling materials (e.g., cytokine proteins) secreted by cells may not permeate the shell, which may hinder the transmission of cell signals and the establishment of cell junctions between different bio-bricks, which is not conducive to the construction of organic whole bodies (e.g., artificial tissues). Thus, the use of a permeable shell is preferred for the bio-brick of the present invention. In the present invention, the expression "permeable shell" means that various small and large molecular species (e.g., proteins) are able to freely pass through the shell. For example, in certain preferred embodiments, the shell is transparent to molecules having a molecular weight below 5000 kDa. For example, in certain embodiments, the shell is transparent to molecules having a molecular weight below 200kDa or a molecular weight in the range of 200kDa to 300kDa, 300kDa to 400kDa, 400kDa to 500kDa, 500kDa to 800kDa, 800kDa to 1000kDa, 1000kDa to 1500kDa, 1500kDa to 2000kDa, 2000kDa to 3000kDa, 3000kDa to 4000kDa, or 4000kDa to 5000 kDa. In certain embodiments, the shell layer is transparent to immunoglobulins (e.g., IgG, IgM, IgA, IgD, IgE).

In certain preferred embodiments, the shell layers each independently have channels or pores for the exchange of material inside and outside the bio-brick. In certain preferred embodiments, nutrients (carbohydrates such as glucose, fats, proteins, amino acids, short peptides, minerals, vitamins, cytokines, nucleotides, etc.) diffuse through the channels or pores into the bio-brick. In certain preferred embodiments, the diameter of the channel is at least 10, 20, 50, 100, 150, 200, 250, 300, 350, 400, or 500 nm. In certain preferred embodiments, the diameter of the channels is, for example, from 1nm to 5 μm; 10nm-2 μm; 100nm-1 μm; 200 nm, 800nm, etc. In certain preferred embodiments, the pores have a diameter of at least 100, 200, 400, 600, 800, 1000, 1500, 2000, 4000, or 5000 nm.

The thickness of the shell layer of the bio-brick of the present invention can be selected according to actual needs without particular limitation. For example, the shell of the bio-brick of the invention may each independently have a thickness of 1 to 20 μm, such as 5 to 15 μm, such as 8 to 12 μm. In certain preferred embodiments, the shell of the bio-brick of the present invention may each independently have a thickness of about 0.1, 0.5, 1, 2, 5, 10, 15, 20, 25, 30, or 50 μm. In certain preferred embodiments, the shell of the bio-brick of the present invention can each independently have a thickness of 0.1-0.5, 0.5-1, 1-2, 2-5, 5-10, 10-15, 15-20, 20-25, 25-30, 30-50, 50-100, 100-200, 200-300, 300-400, 400-500, 0.1-1, 1-5, 1-10, 5-10, 10-20, 10-30, 5-20, or 1-20 μm.

In certain preferred embodiments, the shell of the bio-brick of the present invention does not comprise cells.

In certain preferred embodiments, the core layer and/or the shell layer each independently further comprise additional agents, e.g., nutrients, extracellular matrix, cytokines, and/or pharmaceutically active ingredients. Preferably, the additional agent is capable of modulating (e.g., promoting) proliferation, differentiation, migration, secretion and/or metabolism of the cell. In certain preferred embodiments, the nuclear layer comprises at least one (e.g., 1, 2, 3, 4, 5, or more) additional agent capable of modulating (e.g., promoting) proliferation, differentiation, migration, secretion, and/or metabolism of the cell. In certain preferred embodiments, the core layer is capable of releasing the additional agent in a controlled manner.

In certain preferred embodiments, the nutrients include, but are not limited to, nucleotides, amino acids, polypeptides, carbohydrates (e.g., monosaccharides, oligosaccharides, polysaccharides), lipids, vitamins, and the like.

In certain preferred embodiments, the extracellular matrix is selected from polysaccharides, such as glycosaminoglycans, proteoglycans; structural proteins such as collagen and elastin; adhesion proteins, such as fibronectin and laminin.

In certain preferred embodiments, the cytokine may be a cytokine for regulating proliferation, differentiation, migration, secretion and/or metabolism of a cell, including but not limited to:

-cytokines associated with cell growth, such as insulin, insulin-like growth factors (e.g. IGF-i, IGF-ii), transforming growth factors (e.g. TGF α and TGF β), vascular endothelial growth factor, epidermal growth factor, fibroblast growth factor, platelet derived growth factor, osteosarcoma derived growth factor, growth hormone release inhibitory factor, nerve growth factor, interleukins (e.g. IL-1, IL-11, IL-3), erythropoiesis factor, colony stimulating factor, cortisol, thyroxine, or any combination thereof;

-cytokines associated with cell differentiation, such as Oct3/4, Sox2, Klf4, C-Myc, GATA4, TSP1, sodium beta-glycerophosphate, dexamethasone, vitamin C, insulin, IBMX, indomethazinc, platelet-derived growth factor BB (PDGF-BB), 5-azacytidine, or any combination thereof;

-cytokines associated with cell migration, such as cyclic adenosine monophosphate, phosphatidylinositol triphosphate, stromal cell-derived factor-1, N-cadherin, nuclear factor kb, osteonectin, thromboxane a2, Ras, or any combination thereof; and/or

Cytokines associated with cell metabolism, such as insulin growth factor 1, TRIP-Br2, DKK-1, sRANKL, OPG, TRACP-5b, ALP, SIRT1(2-7), PGC-1 α, PGC-1 β, OPG, IL-3, IL-4, IL-6, TGF- β, PGE2, G-CSF, TNF- α, or any combination thereof.

In certain preferred embodiments, the pharmaceutically active ingredient is an agent capable of modulating (e.g., promoting) proliferation, differentiation, migration, secretion and/or metabolism of a cell. In certain preferred embodiments, the pharmaceutically active ingredient is selected from the group consisting of rhIL-2, rhIL-11, rhEPO, IFN- α, IFN- β, IFN- γ, G-CSF, GM-CSF, rHuEPO, sTNF-R1, and rhTNF- α.

The number of cells contained in the core layer of the biological brick can be adjusted according to actual needsThe selection is made without particular limitation. For example, the core layer of the bio-brick of the present invention may each independently comprise 1 to 10⁶Each cell, e.g., 10-900, 20-800, 30-700, 40-600, 50-500, 60-400, 70-300, 80-200, 10-100, 10-10³Root of Chinese character, 10-10⁴Root of Chinese character, 10-10⁵Root of Chinese character, 10-10⁶And (4) cells. In certain preferred embodiments, the core layers of the bio-brick of the present invention each independently comprise at least 1, 2, 4, 6, 8, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10, 6, 8, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000 ⁴、2x10⁴、3x10⁴、4x10⁴、5x10⁴、6x10⁴、7x10⁴、8x10⁴、9x10⁴、10⁵、2x10⁵、3x10⁵、4x10⁵、5x10⁵、6x10⁵、7x10⁵、8x10⁵、9x10⁵Or 10⁶And (4) cells. In some preferred embodiments, the core layer of the biological brick of the present invention may independently comprise 1-2, 2-4, 4-6, 6-8, 8-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, 150-200, 200-300, 300-400, 400-500, 500-1000, 1000-2000, 2000-3000, 3000-4000, 4000-5000, 5000-10⁴、10⁴-2x10⁴、2x10⁴-3x10⁴、3x10⁴-4x10⁴、4x10⁴-5x10⁴、5x10⁴-10⁵、10⁵-2x10⁵、2x10⁵-3x10⁵、3x10⁵-4x10⁵、4x10⁵-5x10⁵、5x10⁵-10⁶1-10, 2-5, 5-10, 10-20, 20-30, 30-50, 2-25, 25-50, 2-50, 50-100, 100-200, 50-250, 250-500, 500-2000, 2-100, 2-500, or 2-2000 cells.

Without being limited by theory, the bio-brick of the present invention may comprise any kind and type of cells. In certain preferred embodiments, the bio-brick of the present invention may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more types of cells. For example, the cell may be a bacterium, a yeast, a plant cell or an animal cell, such as a mammalian cell, preferably a human cell. Preferably, the cells are adherent cells, such as differentiated adherent cells or undifferentiated adherent cells. Preferably, the cell is a pluripotent stem cell. In certain preferred embodiments, the adherent cells are derived from a tissue selected from the group consisting of: connective tissue (e.g., loose connective tissue, dense connective tissue, elastic tissue, reticulated connective tissue, and adipose tissue), muscle tissue (e.g., skeletal muscle, smooth muscle, and cardiac muscle), genitourinary tissue, gastrointestinal tissue, lung tissue, bone tissue, neural tissue, and epithelial tissue (e.g., monolayer and stratified epithelia), endodermal-derived tissue, mesodermal-derived tissue, and ectodermal-derived tissue.

In certain preferred embodiments, the adherent cells are selected from the group consisting of muscle cells (e.g., skeletal muscle cells, cardiac muscle cells, smooth muscle cells, and myoblasts), connective tissue cells (e.g., osteocytes, chondrocytes, fibroblasts, and cells differentiated into osteoblasts, chondrocytes, or lymphoid tissue), bone marrow cells, endothelial cells, skin cells, epithelial cells, breast cells, vascular cells, blood cells, lymphocytes, nerve cells, schwann cells, gastrointestinal cells, liver cells, pancreatic cells, lung cells, tracheal cells, corneal cells, urogenital cells, kidney cells, adipocytes, parenchymal cells, pericytes, mesothelial cells, stromal cells, undifferentiated cells (e.g., stem cells and progenitor cells), endodermal-derived cells, mesodermal-derived cells, ectodermal-derived cells, cancer-derived cells, a cell line, an induced pluripotent stem cell (iPS), or any combination thereof.

The selection of suitable cells can be made according to actual needs. For example, in certain preferred embodiments, the bio-brick comprises cardiomyocytes and is used to produce cardiac tissue. In certain preferred embodiments, the bio-brick comprises endothelial cells, smooth muscle cells and fibroblasts, and is used to produce blood vessels. In certain preferred embodiments, the bio-brick comprises endothelial cells and is used to produce skin tissue.

The size of the bio-brick of the present invention can be selected according to actual needs without particular limitation. The size of a spherical bio-brick can usually be well defined by its diameter. The term "diameter" cannot be used to describe structures that are not spherical, under strict definition. However, in the present invention, the term "diameter" is also used to describe the size of the non-spherical bio-brick. In this case, the term "diameter" means the diameter of a spherical biological brick having the same volume as a non-spherical biological brick. In other words, in the present invention, the diameter of a spherical bio-brick is used to describe the size of a non-spherical bio-brick having the same volume. Thus, in certain preferred embodiments, the size (i.e., diameter as defined herein) of the inventive biobricks can be 20-2000 μm, such as 30-1900 μm, 40-1800 μm, 50-1700 μm, 60-1600 μm, 70-1500 μm, 80-1400 μm, 90-1300 μm, 100-1200 μm, 200-1000 μm, 300-800 μm, 400-600 μm, 100-500 μm. In some preferred embodiments, the size (i.e., the diameter defined herein) of the biological brick of the present invention can be 20-30, 30-50, 50-100, 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, 450-500, 500-600, 600-700, 700-800, 800-900, 900-1000, 1000-1500, 1500-2000, 20-50, 20-100, 100-200, 200-400, 500-600, 600-800, 800-1000, or 1000-2000 μm. In certain preferred embodiments, the dimensions (i.e., diameters as defined herein) of the present bio-brick are at least 20, 30, 50, 100, 120, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, or 2000 μm.

The shape of the bio-brick of the present invention can be selected according to actual needs without particular limitation. For example, the bio-brick of the present invention can be spherical, or any desired shape (e.g., cube, rectangular prism, hexagonal prism, cylinder, or irregular shape). For example, some shapes (e.g., spheres, cubes, rectangular prisms, hexagonal prisms) can be used to achieve close packing of bio-bricks in a construct.

In certain preferred embodiments, the bio-brick of the present invention is solid or semi-solid. In certain preferred embodiments, the bio-brick of the present invention is in a gel state. For example, the core layer and/or shell layer of the bio-brick of the present invention may be in a gel state. In certain preferred embodiments, the bio-brick of the present invention comprises a hydrogel. In certain preferred embodiments, the hydrogel comprises alginate, agarose, gelatin, chitosan, or other water-soluble or hydrophilic polymers.

In certain preferred embodiments, the bio-brick of the present invention is present in the form of a mixture. In such embodiments, the bio-brick may be contacted or fused with another bio-brick in the mixture. In certain preferred embodiments, the bio-brick of the present invention is an isolated bio-brick. For example, in certain embodiments, the bio-brick is not in direct contact with other bio-bricks. In certain preferred embodiments, the isolated bio-brick of the present invention is provided in a container.

The bio-brick of the present invention can be prepared using various methods. For example, in certain preferred embodiments, the biobricks of the present invention can be prepared using a process for making microspheres, such as using a pelletizer. In certain preferred embodiments, the bio-brick of the present invention is prepared under aseptic conditions. In certain preferred embodiments, the biobricks of the present invention are made in a GMP workshop. In certain preferred embodiments, the bio-brick of the present invention is prepared immediately prior to use. In certain preferred embodiments, the biobricks of the present invention are stored at 4 ℃ after preparation, e.g., for 3 hours, 6 hours, 12 hours, 1 day, 2 days, or 3 days.

In certain preferred embodiments, the bio-brick of the present invention is capable of reducing mechanical damage to cells during bioprinting. For example, in certain preferred embodiments, the biobrick of the present invention is capable of reducing mechanical damage to cells by at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 70%, 80%, or 90% as compared to using the cells directly for bioprinting, using the same bioprinter and the same printing conditions. In certain preferred embodiments, the bio-brick of the present invention is capable of retaining the biological activity (e.g., proliferation, differentiation, migration, secretion, and/or metabolism) of cells within the bio-brick during the bioprinting process. In certain preferred embodiments, at least 80%, 85%, 87.5%, 90%, 92.5%, 95%, or 98% of the cells within the bio-brick survive for at least 24 hours after bioprinting. In certain preferred embodiments, at least 90% of the cells within the bio-brick survive at least 3 hours, 6 hours, 12 hours, 1 day, 2 days, 4 days, or 7 days after bioprinting. In certain preferred embodiments, at least 80%, 85%, 87.5%, 90%, 92.5%, 95%, or 98% of the cells within a biological tile are capable of proliferating and/or differentiating 24 hours after bioprinting. In certain preferred embodiments, at least 80%, 85%, 87.5%, 90%, 92.5%, 95%, or 98% of the cells within the bio-brick have normal metabolism after 24 hours of bioprinting. In certain preferred embodiments, at least 80%, 85%, 87.5%, 90%, 92.5%, 95%, or 98% of the cells within a bio-brick are capable of migrating after 24 hours of bioprinting. In certain preferred embodiments, at least 80%, 85%, 87.5%, 90%, 92.5%, 95%, or 98% of the cells within a biological tile are capable of secreting after 24 hours of bioprinting.

The schematic structure of the bio-brick of the present invention is shown in fig. 1A-1E. As shown in fig. 1A to 1E, the bio-brick of the present invention comprises: a cell capable of growth, proliferation, differentiation or migration; a nuclear layer encapsulating the cells, which is made of a biodegradable material and provides a microenvironment for the vital activities of the cells, such as nutrients; and a shell layer encapsulating the core layer, made of a biodegradable material, and providing mechanical protection to the inner core layer and cells. In certain preferred embodiments, the shell is permeable, having channels for the exchange of substances inside and outside the bio-brick. In certain preferred embodiments, the cells may be uniformly dispersed in the nuclear layer, or may be aggregated together, within the nuclear layer.

In certain preferred embodiments, the bio-brick of the present invention comprises at least one core layer. In certain preferred embodiments, the bio-brick of the present invention comprises at least two core layers. For example, a bio-brick of the present invention can include 1, 2, 3, 4, 5, or more nuclear layers.

In certain preferred embodiments, each core layer of the bio-brick of the present invention is independently made of a biodegradable material or a combination of biodegradable materials as defined above. In other words, where the present bio-brick comprises at least two nuclear layers, each nuclear layer can be independently made of the same or different biodegradable material or combination of biodegradable materials. For example, if the bio-brick of the present invention comprises 2 core layers, the 2 core layers may be made of the same biodegradable material or a combination of biodegradable materials, or may be made of different biodegradable materials or a combination of biodegradable materials. If the bio-brick of the present invention comprises 3 core layers, these 3 core layers can be made of the same biodegradable material or a combination of biodegradable materials; or can be made of 3 different biodegradable materials or a combination of biodegradable materials; or 2 of the core layers are made of the same biodegradable material or combination of biodegradable materials and the 3 rd core layer is made of another biodegradable material or combination of biodegradable materials. In certain preferred embodiments, each core layer of the present bio-brick has a different composition.

In certain preferred embodiments, each of the core layers of the bio-brick of the present invention independently encapsulates a cell. In other words, where the present bio-brick comprises at least two nuclear layers, each nuclear layer may independently encapsulate the same or different cells or combination of cells. For example, if the bio-brick of the present invention comprises 2 core layers, then the 2 core layers may encapsulate the same cell or combination of cells, or may encapsulate different cells or combinations of cells. If the bio-brick of the present invention comprises 3 nuclear layers, then these 3 nuclear layers may encapsulate the same cell or combination of cells; or may encapsulate 3 different cells or combinations of cells; or 2 of the nuclear layers wrap the same cell or combination of cells and the 3 rd nuclear layer wraps another cell or combination of cells.

In certain embodiments, the endothelial cells encapsulated by the core layer in the bio-brick of the present invention are animal endothelial cells, preferably human endothelial cells or rat endothelial cells. The endothelial cells comprise vein endothelial cells and artery endothelial cells. When the endothelial cells are human endothelial cells, human umbilical vein endothelial cells are preferred. When the endothelial cells are rat endothelial cells, primary cultured rat vascular endothelial cells are preferred. Preferably, the endothelial cells encapsulated by the nuclear layer are of the same origin as the undifferentiated cells and/or additional cells, e.g., both derived from human, or both derived from rat.

In some preferred embodiments, the core layer in the bio-brick of the present invention encapsulates undifferentiated cells, such as stem cells, progenitor cells, or a combination thereof. In some aspects, the stem cell is a pluripotent stem cell, such as an induced pluripotent stem cell. In some aspects, the nuclear layer encapsulated stem cells include mesenchymal stem cells, such as bone marrow, adipose, umbilical cord blood, and/or placenta-derived mesenchymal stem cells; preferably, the mesenchymal stem cells are obtained from animals, such as mammals, e.g., humans, apes, gorillas, cows, pigs, dogs, sheep and goats.

In certain embodiments, the cells encapsulated by the nuclear layer further comprise additional cells derived from a tissue selected from the group consisting of: connective tissue (e.g., loose connective tissue, dense connective tissue, elastic tissue, reticulated connective tissue, and adipose tissue), muscle tissue (e.g., skeletal muscle, smooth muscle, and cardiac muscle), genitourinary tissue, gastrointestinal tissue, lung tissue, bone tissue, neural tissue, and epithelial tissue (e.g., monolayer and stratified epithelia), endodermal-derived tissue, mesodermal-derived tissue, and ectodermal-derived tissue; for example, the additional cells are selected from muscle cells (e.g., skeletal muscle cells, cardiac muscle cells, smooth muscle cells, and myoblasts), connective tissue cells (e.g., osteocytes, chondrocytes, fibroblasts, and cells differentiated into osteoblasts, chondrocytes, or lymphoid tissue), bone marrow cells, skin cells, epithelial cells, breast cells, vascular cells, blood cells, lymphocytes, nerve cells, schwann cells, gastrointestinal cells, hepatocytes, pancreatic cells, lung cells, tracheal cells, corneal cells, urogenital cells, kidney cells, adipocytes, parenchyma cells, pericytes, mesothelial cells, stromal cells, endodermal-derived cells, mesodermal-derived cells, ectodermal-derived cells, cancer-derived cells, cell lines, or any combination thereof; more preferably, the additional cells are hepatocytes.

In certain embodiments, the endothelial cells and the undifferentiated cells are encapsulated in the same nuclear layer or different nuclear layers, e.g., the endothelial cells are in a first nuclear layer and the undifferentiated cells are in a second nuclear layer, or vice versa.

In certain embodiments, the endothelial cells, the undifferentiated cells, and the additional cells are encapsulated in the same nuclear layer or different nuclear layers, e.g., wherein two cells are located in the same nuclear layer (e.g., a first nuclear layer) and a third is located in another nuclear layer (e.g., a second nuclear layer).

Furthermore, each core layer of the bio-brick of the present invention independently comprises one or more cells, e.g., each core layer of the bio-brick of the present invention independently can comprise 1 to 10⁶Each cell, e.g., 10-900, 20-800, 30-700, 40-600, 50-500, 60-400, 70-300, 80-200, 10-100, 10-10³Root of Chinese character, 10-10⁴Root of Chinese character, 10-10⁵Root of Chinese character, 10-10⁶And (4) cells. In certain preferred embodiments, each core layer of a bio-brick of the present invention independently comprises at least 1, 2, 4, 6, 8, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10, 6, 8, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000 ⁴、2x10⁴、3x10⁴、4x10⁴、5x10⁴、6x10⁴、7x10⁴、8x10⁴、9x10⁴、10⁵、2x10⁵、3x10⁵、4x10⁵、5x10⁵、6x10⁵、7x10⁵、8x10⁵、9x10⁵Or 10⁶And (4) cells.

In certain embodiments, endothelial cells comprise 1% -100% of the total number of cells in the bio-brick of the present invention, e.g., 2% -90%, 3% -80%, 4% -70%, 5% -60%, 5.5% -50%, 6% -40%, 6.5% -30%, 7% -20%, 7.5% -19%, 8% -18%, 8.5% -17%, 9% -16%, 9.1% -15%, 9.2% -14%, 9.3% -13%, 9.4% -12%, 9.5% -11.5%, 9.6% -11%, 9.7% -10.9%, 9.8% -10.8%, 9.9% -10.7%, 9.9% -10.6%, 9.9% -10.5%, 9.9% -10.4%, 9.9% -10.3%, 9.9% -10.2%, 9.9% -10.1%, Or 10.0%;

in certain embodiments, in the biobrick of the present invention, undifferentiated cells (e.g., stem cells, progenitor cells, or a combination thereof) comprise 0% -99% of the total number of cells, e.g., 1% -90%, 5% -80%, 10% -70%, 15% -65%, 20% -60%, 25% -55%, 30% -50%, 35% -45%, 36% -44%, 37% -43%, 38% -42%, 39% -41%, 39.1%, 39.2%, 39.3%, 39.4%, 39.5%, 39.6%, 39.7%, 39.8%, 39.9%, 40.0%, 40.1%, 40.2%, 40.3%, 40.4%, 40.5%, 40.6%, 40.7%, 40.8%, or 40.9%.

The bio-brick of the present invention comprises a proportion of endothelial cells, preferably also undifferentiated cells. In preferred embodiments, the ratio of endothelial cells to undifferentiated cells is about 1:20 to about 1:1, e.g., about 1:19, about 1:18, about 1:17, about 1:16, about 1:15, about 1:14, about 1:13, about 1:12, about 1:11, about 1:10, about 1:9, about 1:8, about 1:7, about 1:6, about 1:5, about 1:4, about 1:3, about 1:2, or about 1: 1.5; preferably, the ratio of endothelial cells to undifferentiated cells is about 1:15, about 1:14, about 1:13, about 1:12, about 1:11.5, about 1:11, about 1:10.5, about 1:10, about 1:9.5, about 1:9, about 1:8.5, about 1:8, about 1:7, about 1: 6; more preferably, the ratio of endothelial cells to undifferentiated cells is about 1:10.

In a further preferred embodiment, the endothelial cells are human umbilical vein endothelial cells, the undifferentiated cells are bone marrow-derived mesenchymal stem cells, and the ratio of the human umbilical vein endothelial cells to the bone marrow-derived mesenchymal stem cells is about 1:10 to form a plurality of microvessels.

Optionally, the bio-brick further comprises additional cells, wherein the ratio of the number of additional cells to the number of endothelial cells is about 1: 1; more preferably, the additional cells are hepatocytes; most preferably, the ratio of the human umbilical vein endothelial cells, hepatocytes and bone marrow-derived mesenchymal stem cells is about 1:1:10 to form a plurality of microvessels.

Generally, the choice of biodegradable material used to prepare the core layer is independent of the choice of cells encapsulated by the core layer. Thus, the different nuclear layers of the biological brick of the invention can: (1) made of the same biodegradable material or combination of biodegradable materials, and wrapping the same cell or combination of cells; or (2) made of the same biodegradable material or a combination of biodegradable materials, and encapsulating different cells or cell combinations; or (3) made of different biodegradable materials or a combination of biodegradable materials, and encapsulating the same cell or combination of cells; or (4) made of different biodegradable materials or combinations of biodegradable materials and encapsulating different cells or combinations of cells. However, it is particularly preferred that the core layer is prepared by selecting a suitable biodegradable material or combination of biodegradable materials to provide optimal conditions for growth, proliferation, differentiation or migration of cells, depending on the cell or combination of cells used and the intended purpose.

In certain preferred embodiments, the bio-brick of the present invention comprises at least one shell layer. In certain preferred embodiments, the bio-brick of the present invention comprises at least two shell layers. For example, a bio-brick of the present invention may comprise 1, 2, 3, 4, 5 or more shells.

In certain preferred embodiments, each shell of the bio-brick of the present invention is independently made of a biodegradable material or a combination of biodegradable materials as defined above. In other words, in case the bio-brick of the present invention comprises at least two shells, each shell may independently be made of the same or different biodegradable material or combination of biodegradable materials. For example, if the bio-brick of the present invention comprises 2 shells, the 2 shells may be made of the same biodegradable material or a combination of biodegradable materials, or may be made of different biodegradable materials or a combination of biodegradable materials. If the bio-brick of the present invention comprises 3 shells, these 3 shells can be made of the same biodegradable material or a combination of biodegradable materials; or can be made of 3 different biodegradable materials or a combination of biodegradable materials; or 2 of them are made of the same biodegradable material or a combination of biodegradable materials and the 3 rd shell is made of another biodegradable material or a combination of biodegradable materials. In certain preferred embodiments, the individual shells of the bio-brick of the present invention have different compositions.

In certain preferred embodiments, each of the shell layers of the bioceramic brick of the invention is optionally treated (e.g., with a shell fixative, e.g., to improve the mechanical properties of the shell layer). In certain preferred embodiments, each shell of the bio-brick of the present invention is treated. In certain preferred embodiments, the shell layer located on the outermost side of the bio-brick of the present invention is treated.

The number and arrangement of the core layer and the shell layer in the biological brick of the invention are not particularly limited. However, it is particularly preferred that the outermost side of the bio-brick comprises at least one shell layer. In certain preferred embodiments, the bio-brick of the present invention comprises a core layer and a shell layer. In certain preferred embodiments, the bio-brick of the present invention comprises one core layer and 2 or more shell layers. In certain preferred embodiments, the bio-brick of the present invention comprises 2 or more core layers and one shell layer. In certain preferred embodiments, the bio-brick of the present invention comprises at least 2 core layers and at least 2 shell layers. In certain preferred embodiments, the bio-brick of the present invention comprises, in order from the inside to the outside, a core layer, a first shell layer, and a second shell layer. In certain preferred embodiments, the bio-brick of the present invention comprises, in order from the inside out, a first core layer, a second core layer, and a shell layer. In certain preferred embodiments, the bio-brick of the present invention comprises, in order from the inside to the outside, a first core layer, a second core layer, a first shell layer, and a second shell layer. In certain preferred embodiments, the bio-brick of the present invention comprises, in order from the inside out, a first core layer, a first shell layer, a second core layer, and a second shell layer. FIGS. 1A-1E of the present specification schematically depict various configurations of the bio-brick of the present invention.

In another aspect, the invention provides a plurality of isolated bio-bricks. In certain preferred embodiments, the present invention provides a plurality of isolated bio-bricks, wherein the bio-bricks are isolated from each other. In certain preferred embodiments, the present invention provides a plurality of isolated bio-bricks, and wherein at least two of the isolated bio-bricks are different. In certain preferred embodiments, each isolated bio-brick individually comprises a different agent or combination of agents that promote cell proliferation, differentiation, migration, metabolism, secretion, or any combination thereof. In certain preferred embodiments, each isolated bio-brick individually comprises at least one stem cell. In certain preferred embodiments, each isolated bio-brick individually comprises a different type of stem cell. In certain preferred embodiments, each of the plurality of isolated bio-bricks comprises the same stem cells. In certain preferred embodiments, the plurality of isolated bio-bricks are each contained in a different container. In certain preferred embodiments, the plurality of isolated bio-bricks are provided in a single container. Suitable containers include, but are not limited to, dishes (e.g., tissue culture dishes or cell culture dishes), bottles, tubes (e.g., test tubes, centrifuge tubes, microcentrifuge tubes, etc.), wells of multi-well plates, and the like. In certain preferred embodiments, the plurality of isolated bio-bricks are used in a parallel assay or a high throughput assay.

In another aspect, the invention provides a container comprising a plurality of isolated bio-bricks. In certain preferred embodiments, the container further comprises a liquid or semi-liquid composition. In certain preferred embodiments, the liquid or semi-liquid composition comprises inorganic salts, culture media, buffers, or other components used to culture the bio-brick or perform experiments using the bio-brick. In certain preferred embodiments, the liquid or semi-liquid composition comprises an agent or combination of agents capable of promoting cell proliferation, differentiation, migration, metabolism, secretion, or signaling. In certain preferred embodiments, the liquid or semi-liquid composition comprises a compound (e.g., a surfactant) that facilitates the separation of the bio-brick. In certain preferred embodiments, the liquid or semi-liquid composition comprises a stabilizer or preservative. In certain preferred embodiments, the bio-brick is dispersed in the liquid or semi-liquid composition.

In certain preferred embodiments, the container comprises at least two different separated bio-bricks. Different bio-bricks may differ in one or more of the following: the size of the biological brick; the shape of the biological brick; the number of cells involved; the type of cell contained; composition of the core layer (including type and content of components); composition of the shell (including type and content of components); additional agents (including type and amount) contained in the core layer and/or shell layer; and/or, any other parameter discussed above. In certain preferred embodiments, each isolated bio-brick individually comprises a different agent or combination of agents that promote cell proliferation, differentiation, migration, metabolism, secretion, or any combination thereof. In certain preferred embodiments, each isolated bio-brick individually comprises at least one stem cell. In certain preferred embodiments, each isolated bio-brick individually comprises a different type of stem cell. In certain preferred embodiments, the plurality of isolated bio-bricks each comprise the same stem cells. In certain preferred embodiments, the plurality of isolated bio-bricks are each contained in a different container. In certain preferred embodiments, the plurality of isolated bio-bricks are provided in a single container. In certain preferred embodiments, the container is selected from, but is not limited to, a dish (e.g., a tissue culture dish or a cell culture dish), a bottle, a tube (e.g., a test tube, a centrifuge tube, a microcentrifuge tube, etc.), a well of a multi-well plate, and the like.

In certain preferred embodiments, the plurality of isolated bio-bricks are used in tissue engineering. In certain preferred embodiments, the plurality of isolated bio-bricks are used in an in vitro or in vivo assay. In certain preferred embodiments, the plurality of isolated bio-bricks are used to study cell signaling. In certain preferred embodiments, the plurality of isolated bio-bricks are used to study stem cell differentiation.

In another aspect, the present invention provides a composition comprising the bio-brick of the present invention. In certain preferred embodiments, the compositions of the present invention comprise a bio-brick and a carrier (which preferably comprises a bioadhesive). Particularly preferably, such compositions are useful as bioink for bioprinting. Thus, in certain preferred embodiments, the present invention provides a bioink comprising the bioink of the present invention, and optionally a carrier (which preferably comprises a bioadhesive). In certain preferred embodiments, the carrier comprises, or consists of, a bioadhesive. In certain preferred embodiments, the bioink of the present invention is used for bioprinting.

In certain preferred embodiments, the carrier (e.g., bioadhesive) and its degradation products are non-toxic to the cell and/or non-immunogenic to the host. In certain preferred embodiments, the carrier (e.g., bioadhesive) comprises a biodegradable material. In certain preferred embodiments, the biodegradable material in the carrier (e.g., bioadhesive) is biocompatible.

In certain preferred embodiments, degradation of the biodegradable material in the carrier (e.g., bioadhesive) can provide a microenvironment, such as nutrients, that maintain or promote the vital activity of the cells within the bio-brick. In certain preferred embodiments, the degradation products are small molecule compounds, such as organic acids, monosaccharides (e.g., glucose), oligosaccharides, amino acids, lipids, and the like. Such degradation products may be involved in metabolic activities of cells (e.g. for the synthesis of extracellular matrix), for the synthesis of extracellular matrix or for conversion to energy required for the activity.

In certain preferred embodiments, the biodegradable material in the carrier (e.g., bioadhesive) is naturally occurring (e.g., naturally occurring biodegradable materials derived from animals and plants, such as collagen, fibrin, chitosan, alginate, starch, hyaluronic acid, laminin, agarose, gelatin, dextran, and any combination thereof), synthetically produced, recombinantly produced, modified, or any combination thereof.

In certain preferred embodiments, the biodegradable material in the carrier (e.g., bioadhesive) is a naturally occurring degradable polymer. Preferably, the degradable polymer is selected from the group consisting of collagen, fibrin, chitosan, alginate, starch, hyaluronic acid, laminin, gelatin, dextran, elastin, and any combination thereof.

In certain preferred embodiments, the biodegradable material in the carrier (e.g., bioadhesive) is a modified degradable polymer, such as a modified alginate, such as an oxidized alginate (e.g., oxidized sodium alginate).

In certain preferred embodiments, the biodegradable material in the carrier (e.g., bioadhesive) is a synthetic degradable polymer. Such degradable polymers include, but are not limited to, polyphosphazenes, polyacrylic acid and derivatives thereof (e.g., polymethacrylic acid, copolymers of acrylic acid and methacrylic acid), polylactic acid (PLA), polyglycolic acid (PGA), polylactic-glycolic acid copolymer (PLGA), Polyorthoesters (POE), Polycaprolactone (PCL), Polyhydroxybutyrate (PHB), polyamino acids (e.g., polylysine), degradable polyurethanes, and any combination thereof.

In certain preferred embodiments, the biodegradable material in the carrier (e.g., bioadhesive) is selected from the group consisting of collagen, fibrin, chitosan, alginates (e.g., sodium or calcium alginate), oxidized alginates (e.g., oxidized sodium alginate), starch, hyaluronic acid, laminin, elastin, gelatin, polyamino acids (e.g., polylysine), agarose, dextran, methylcellulose, oxidized alginates, polyvinyl alcohol, polyacrylic acid and derivatives thereof (e.g., polyacrylic acid or esters thereof, polymethacrylic acid or esters thereof), polyacrylamide, poly-N-substituted acrylamide, or any combination thereof. In certain preferred embodiments, the carrier (e.g., bioadhesive) comprises sodium alginate. In certain preferred embodiments, the carrier (e.g., bioadhesive) comprises an alginate (e.g., sodium or calcium alginate) and an oxidized alginate (e.g., oxidized sodium alginate). In certain preferred embodiments, the weight ratio of alginate (e.g., sodium alginate or calcium alginate) and oxidized alginate (e.g., oxidized sodium alginate) in the carrier is about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1: 10. In certain preferred embodiments, the weight ratio of alginate (e.g., sodium alginate or calcium alginate) to oxidized alginate (e.g., oxidized sodium alginate) in the carrier is 10:1-9:1, 9:1-8:1, 8:1-7:1, 7:1-6:1, 6:1-5:1, 5:1-4:1, 4:1-3:1, 3:1-2:1, 2:1-1:1, 1:1-1:2, 1:2-1:3, 1:3-1:4, 1:4-1:5, 1:5-1:6, 1:6-1:7, 1:7-1:8, 1:8-1:9, 1:9-1:10, 10:1-5:1, 5:1-1:1, 1:1-1:5, 1:5, 1:5-1:10, 2:1-1:2, 4:1-1:4, or 10:1-1: 10.

In certain preferred embodiments, the carrier (e.g., bioadhesive) comprises the same biodegradable material in a different concentration, or a combination of the same biodegradable materials in a different weight ratio, than the core or shell layer of the bio-brick. In certain preferred embodiments, the carrier (e.g., bioadhesive) comprises a different biodegradable material than the core or shell layer of the bio-brick.

In certain preferred embodiments, the carrier further comprises water, an inorganic salt, a pH buffer, a stabilizer, a preservative, or any combination thereof.

In certain preferred embodiments, the carrier (e.g., bioadhesive) facilitates placement of the bio-brick on a construct (e.g., three-dimensional construct, tissue precursor, or tissue) and/or affixes the bio-brick to a construct (e.g., three-dimensional construct, tissue precursor, or tissue).

In certain preferred embodiments, the carrier (e.g., bioadhesive) is a liquid or semi-liquid (e.g., gel). In certain preferred embodiments, the viscosity of the carrier (e.g., bioadhesive) is from 1 to 1000Pas, such as from 30 to 160 Pas. In certain preferred embodiments, the viscosity of the carrier (e.g., bioadhesive) is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 30, 50, 80, 100, 200, 300, 400, 500, 800, or 1000 Pas. In certain preferred embodiments, the carrier (e.g., bioadhesive) has a viscosity of 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-12, 12-14, 14-16, 16-18, 18-20, 20-25, 25-30, 30-50, 50-80, 80-100, 100-200, 200-300, 300-400, 400-500, 500-800, or 800-1000, 1-3, 3-8, 8-16, 3-10, 10-20, 20-50, 50-160 Pas.

In certain preferred embodiments, the composition (e.g., bioink) consists of, or consists essentially of, a biobrick of the present invention. In certain preferred embodiments, the composition (e.g., bioinock) comprises at least about 50% of the bio-brick (w/w by weight). In certain preferred embodiments, the composition (e.g., bioinock) comprises at least about 10%, 20%, 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of the bio-brick (w/w). In certain preferred embodiments, the composition (e.g., bioinock) comprises 10% -20%, 20% -30%, 30% -40%, 40% -50%, 50% -55%, 55% -60%, 60% -65%, 65% -70%, 70% -75%, 75% -80%, 80% -85%, 85% -90%, 90% -95%, 95% -100%, 50% -60%, 60% -70%, 70% -80%, 80% -90%, 90% -100%, 50% -75%, 75% -100%, or 50% -100% of a bio-brick (w/w). In certain preferred embodiments, the composition (e.g., bioink) is substantially free of liquid other than the liquid contained in the bio-brick, e.g., has less than about 1%, 2.5%, 5%, 7.5%, or 10% liquid.

In certain preferred embodiments, the composition (e.g., bioink) comprises one or more biobricks. In certain preferred embodiments, the composition (e.g., bioink) comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 biobricks. Different types of bio-brick may differ in one or more of the following: the size of the biological brick; the shape of the biological brick; the number of cells involved; the type of cell contained; composition of the core layer (including type and content of components); composition of the shell (including type and content of components); additional agents (including type and amount) contained in the core layer and/or shell layer; and/or, any other parameter discussed above.

In certain preferred embodiments, the mean size (i.e., diameter as defined herein) of the bio-brick in the composition (e.g., bio-ink) is about 20, 30, 50, 100, 120, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, or 2000 μm. In some preferred embodiments, the average size of the biological bricks in the composition (e.g., biological ink) is 20-30, 30-50, 50-100, 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, 450-500, 500-600, 600-700, 700-800, 800-900, 900-1000, 1000-1500, 1500-2000, 20-50, 20-100, 100-200, 200-400, 500-600, 600-800, 800-1000, 1000-2000, 20-100, 100-500, 500-1000, 300-800, 30-50, 30-200, 30-500, 30-1000, 30-2000, or 20-2000 μm. In certain preferred embodiments, the extent of variation in the dimensions of the bio-brick in the composition (e.g., bio-ink) is less than 1%, 5%, 10%, 15%, 20%, 25%, 30%, or 35% of the average dimension of the bio-brick. In certain preferred embodiments, the bio-brick in the composition (e.g., bio-ink) comprises an average number of cells of at least 1, 2, 4, 6, 8, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10 ⁴、2x10⁴、3x10⁴、4x10⁴、5x10⁴、6x10⁴、7x10⁴、8x10⁴、9x10⁴、10⁵、2x10⁵、3x10⁵、4x10⁵、5x10⁵、6x10⁵、7x10⁵、8x10⁵、9x10⁵Or 10⁶And (4) cells. In certain preferred embodiments, the biological brick in the composition (e.g., biological ink) comprises an average number of cells that is 1-2, 2-4, 4-6, 6-8, 8-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, 150-200, 200-300, 300-400, 400-500, 500-1000, 1000-2000, 2000-3000, 3000-4000, 4000-5000, 5000-10-200-2000-200-500-1000-2000-3000-4000-5000-10-60-40-⁴、10⁴-2x10⁴、2x10⁴-3x10⁴、3x10⁴-4x10⁴、4x10⁴-5x10⁴、5x10⁴-10⁵、10⁵-2x10⁵、2x10⁵-3x10⁵、3x10⁵-4x10⁵、4x10⁵-5x10⁵、5x10⁵-10⁶1-10, 2-5, 5-10, 10-20, 20-30, 30-50, 2-25, 25-50, 2-50, 50-100, 100-200, 50-250, 250-500, 500-2000 cells. In certain preferred embodiments, in the compositions (e.g., bioink) of the present invention, the degree of variation in cell number between biological tiles of the same type is less than 1%, 5%, 10%, 15%, 20%, 25%, 30%, or 35% of the average cell number of biological tiles of the same type.

In certain preferred embodiments, the compositions of the present invention (e.g., bioink) are prepared by mixing a plurality of bio-bricks. In certain preferred embodiments, the compositions (e.g., bioink) of the present invention are prepared by mixing one or more biobricks with the carriers (e.g., bioadhesives) discussed above. In certain preferred embodiments, the compositions (e.g., bioinocks) of the present invention are prepared under sterile conditions. In certain preferred embodiments, the compositions of the present invention (e.g., bioinocks) are prepared in a GMP workshop. In certain preferred embodiments, the compositions of the present invention (e.g., bioinocks) are prepared immediately prior to use. In certain preferred embodiments, the compositions of the invention (e.g., bioinocks) are stored at 4 ℃ after preparation, e.g., for 3 hours, 6 hours, 12 hours, 1 day, 2 days, or 3 days. In certain preferred embodiments, the compositions of the invention (e.g., bioinocks) are used to bioprint constructs (e.g., three-dimensional constructs, tissue precursors, tissues). In certain preferred embodiments, the compositions of the present invention (e.g., bioink) are used in bioprinting with other biocompatible materials, inks or compositions.

As described above, the shell of the bio-brick of the present invention is permeable. Thus, in certain preferred embodiments, the carrier (e.g., bioadhesive) may comprise additional agents, for example, nutrients, extracellular matrix, cytokines and/or pharmaceutically active ingredients. Preferably, the additional agent is capable of modulating (e.g., promoting) proliferation, differentiation, migration, secretion and/or metabolism of the cell. In certain preferred embodiments, the carrier (e.g., bioadhesive) comprises at least one (e.g., 1, 2, 3, 4, 5 or more) additional agent capable of modulating (e.g., promoting) proliferation, differentiation, migration, secretion and/or metabolism of cells. In certain preferred embodiments, the carrier (e.g., bioadhesive) is capable of releasing the additional agent in a controlled manner.

In certain preferred embodiments, the carrier (e.g., bioadhesive) may include nutrients (including, but not limited to, nucleotides, amino acids, polypeptides, carbohydrates (e.g., monosaccharides, oligosaccharides, polysaccharides), lipids, vitamins, cell culture media, etc.) that maintain or promote the vital activity of the cell. In certain preferred embodiments, the carrier (e.g., bioadhesive) may include a substance that improves or modulates the vital activity of the cell, such as a cytokine, an extracellular matrix, an anti-apoptotic agent, an antioxidant, a pharmaceutically active ingredient, or any combination thereof.

The compositions (e.g., bioink) of the present invention may comprise one type of bio-brick (which is also referred to as homogeneous or monomorphic ink), or may comprise more than one type of bio-brick (which is also referred to as heterogeneous or polymorphic ink). In certain preferred embodiments, the bioink of the present invention comprises at least about 10% (w/w), at least about 20% (w/w), at least about 30% (w/w), at least about 40% (w/w), at least about 50% (w/w), at least about 60% (w/w), at least about 70% (w/w), at least about 80% (w/w), at least about 90% (w/w) of the bioink. In certain preferred embodiments, the bioink of the present invention comprises 10% -90% (w/w), 20% -80% (w/w), 30% -70% (w/w), 40% -60% (w/w), for example about 50% of the bioink.

In certain preferred embodiments, the compositions (e.g., bioinocks) of the present invention are liquid, semi-solid (e.g., gels) or solid compositions, such as solutions, suspensions, gels, or concentrates. In certain preferred embodiments, the viscosity of the vehicle (e.g., bioadhesive) and/or composition (e.g., bioink) of the present invention is from 1 to 1000Pas, such as from 30 to 160Pas, such as from 40 to 120Pas, from 50 to 150Pas, from 80 to 100 Pas. In certain preferred embodiments, the compositions of the present invention (e.g., bioink) are extrudable compositions. Thus, the compositions of the present invention (e.g., bioink) can be used for bioprinting to produce specific planar and/or laminar geometries; and preferably the resulting planar and/or laminar geometries can be further stacked to form constructs (e.g., three-dimensional constructs) having specific shapes and configurations. Thus, the compositions (e.g., bioinocks) of the invention can be used to form constructs (e.g., three-dimensional constructs, tissue precursors, tissues or organs), such as constructs comprising microvessels.

The bio-brick of the present invention can be prepared using various methods. For example, in certain preferred embodiments, the biobricks of the present invention can be prepared using a method for making microspheres, for example using an apparatus for preparing microspheres, such as a pelletizer.

Thus, in another aspect, the present invention provides a method of making a bio-brick of the present invention, comprising the steps of:

(5) optionally, repeating step (4) one or more times;

In certain preferred embodiments, in step (1), the cells, the biodegradable material for forming the nuclear layer, and the desired additional agent (e.g., nutrients, extracellular matrix, cytokines, and/or pharmaceutically active ingredients) are homogeneously mixed, thereby obtaining the nuclear layer material. In certain preferred embodiments, the shell material of step (2) does not comprise cells.

In certain preferred embodiments, in steps (3) to (6), granulation and coating are carried out using an apparatus for preparing microspheres, such as a pelletizer.

In certain preferred embodiments, after each performance of step (4), if the outermost layer of the obtained product is coated as a shell material, the following steps are optionally performed: the outermost coating is treated (e.g., with a shell fixative, e.g., to improve the mechanical properties of the shell).

In certain preferred embodiments, after step (6), the outermost shell of the resulting bio-brick is treated (e.g., with a shell fixative, e.g., to improve the mechanical properties of the shell).

In certain preferred embodiments, in step (6), the product of step (3) or (4) or (5) is coated with the shell material comprising oxidized alginate from step (2). In certain preferred embodiments, in steps (4) - (6), only the shell material used in step (6) comprises oxidized alginate.

In certain preferred embodiments, the methods of the present invention are performed under sterile conditions. In certain preferred embodiments, the methods of the invention are performed in a GMP workshop. In certain preferred embodiments, the bio-brick is prepared using the methods of the present invention immediately prior to use. In certain preferred embodiments, after step (2), the obtained bio-brick is stored at 4 ℃, e.g., for 3 hours, 6 hours, 12 hours, 1 day, 2 days, or 3 days.

In certain preferred embodiments, the core layer material is capable of providing a microenvironment (e.g., nutrients) for the vital activities of the cells. In certain preferred embodiments, the core layer materials are each independently made of a biodegradable material, and the biodegradable materials are biocompatible. In certain preferred embodiments, the biodegradable material used to prepare the core layer material is naturally occurring (e.g., naturally occurring biodegradable material derived from animals and plants), synthesized, recombinantly produced, modified, or any combination thereof.

In certain preferred embodiments, the biodegradable material used to prepare the core layer material comprises:

naturally occurring degradable polymers such as collagen, fibrin, chitosan, alginates (e.g., sodium alginate), starch, hyaluronic acid, laminin, agarose, gelatin, dextran, and any combination thereof; and/or the presence of a gas in the gas,

modified degradable polymers, such as modified alginates, e.g., oxidized alginates (e.g., oxidized sodium alginate); and/or the presence of a gas in the gas,

synthetic degradable polymers such as polyphosphazenes, polyacrylic acid and its derivatives (e.g., polymethacrylic acid, copolymers of acrylic acid and methacrylic acid), polylactic acid (PLA), polyglycolic acid (PGA), polylactic-glycolic acid copolymer (PLGA), Polyorthoesters (POE), Polycaprolactone (PCL), Polyhydroxybutyrate (PHB), polyamino acids (e.g., polylysine), degradable polyurethanes, and any combination thereof.

In certain preferred embodiments, the biodegradable material used to prepare the core layer material is capable of being degraded by an enzyme (e.g., an enzyme secreted by a cell). In certain preferred embodiments, the biodegradable material used to prepare the core layer material degrades over a period of no more than 2 months, such as over a period of no more than 30 days, no more than 25 days, no more than 20 days, no more than 15 days, no more than 10 days, no more than 5 days, no more than 4 days, no more than 3 days, no more than 2 days, or no more than 1 day. For example, the biodegradable material used to prepare the core layer material may degrade over a period of 1-2 days, 2-3 days, 3-4 days, 4-5 days, 5-10 days, 10-15 days, 15-20 days, 20-25 days, 25-30 days, or 30-60 days. In certain preferred embodiments, degradation of the nuclear layer material can provide nutrients that maintain or promote the vital activity of the cells.

In certain preferred embodiments, the biodegradable material used to prepare the core layer material contains an extracellular matrix or analog thereof (e.g., collagen). The use of an extracellular matrix or analogues thereof (e.g. collagen) is able to provide a favourable microenvironment like that in vivo for the vital activities of the cells within the bio-brick, in particular the growth, adhesion, spreading of the cells, and the establishment of intercellular connections, and is thus preferred. For example, in certain preferred embodiments, the biodegradable material used to prepare the core layer material is or contains type I collagen.

In certain preferred embodiments, the biodegradable material used to prepare the core layer material is selected from the group consisting of collagen (e.g., type I, type II, type III collagen), fibrin, chitosan, alginate (e.g., sodium alginate), oxidized alginate (e.g., oxidized sodium alginate), starch, hyaluronic acid, laminin, elastin, gelatin, polyamino acids (e.g., polylysine), dextran, agarose, degradable polyurethane, or any combination thereof. Preferably, the core layer material comprises type I collagen and/or alginate, for example comprises type I collagen and/or sodium alginate; alternatively, a laminin is included; alternatively, a starch is included; alternatively, a degradable polyurethane is included; alternatively, an alginate (e.g., sodium alginate) and an oxidized alginate (e.g., oxidized sodium alginate) are included. In certain preferred embodiments, the core layer material is gel-like.

In certain preferred embodiments, the shell material is capable of providing mechanical protection to cells encapsulated by the core material. In certain preferred embodiments, the shell materials each independently have a hardness of 0.01 to 0.4GPa, such as a hardness of 0.01 to 0.02, 0.02 to 0.03, 0.03 to 0.04, 0.04 to 0.05, 0.05 to 0.06, 0.06 to 0.07, 0.07 to 0.08, 0.08 to 0.09, 0.09 to 0.1, 0.1 to 0.15, 0.15 to 0.2, 0.2 to 0.3, 0.3 to 0.4, 0.01 to 0.05, 0.05 to 0.1, 0.1 to 0.2, 0.2 to 0.4, 0.05 to 0.15, or 0.06 to 0.1 GPa; and/or has an elastic modulus of 0.01 to 100MPa, such as an elastic modulus of 0.01 to 0.05, 0.05 to 0.1, 0.1 to 0.5, 0.5 to 0.8, 0.8 to 1, 1 to 1.2, 1.2 to 1.4, 1.4 to 1.6, 1.6 to 1.8, 1.8 to 2, 2 to 2.4, 2.4 to 2.8, 2.8 to 3.2, 3.2 to 4, 4 to 10, 10 to 20, 20 to 30, 30 to 40, 40 to 50, 50 to 80, 80 to 100, 0.5 to 4, 0.5 to 1, 1 to 1.5, 1.5 to 2, 2 to 3, 0.8 to 1.6, 1.4 to 2.4, 0.8 to 3.2, 0.01 to 100, 1 to 100, 10 to 100MPa, or 0.5 to 50 MPa.

In certain preferred embodiments, the shell material is capable of providing a microenvironment, such as nutrients, for the vital activities of the cells. In certain preferred embodiments, the shell materials are each independently made of a biodegradable material, and the biodegradable materials are biocompatible. In certain preferred embodiments, the different shell materials differ in composition. In certain preferred embodiments, the biodegradable material used to prepare the shell material is naturally occurring (e.g., naturally occurring biodegradable material derived from animals and plants), synthesized, recombinantly produced, modified, or any combination thereof.

In certain preferred embodiments, the biodegradable material used to prepare the shell material comprises:

naturally occurring degradable polymers such as collagen, fibrin, chitosan, alginates (e.g., sodium or calcium alginate), starch, hyaluronic acid, laminin, agarose, gelatin, dextran, and any combination thereof; and/or the presence of a gas in the gas,

In certain preferred embodiments, the biodegradable material used to prepare the shell material is capable of being degraded by an enzyme (e.g., an enzyme secreted by a cell). In certain preferred embodiments, the biodegradable material used to prepare the shell material degrades over a period of no more than 1 month, such as no more than 30 days, no more than 25 days, no more than 20 days, no more than 15 days, no more than 10 days, no more than 5 days, no more than 4 days, no more than 3 days, no more than 2 days, or no more than 1 day. For example, the biodegradable material used to prepare the shell material may degrade within a period of 1-2 days, 2-3 days, 3-4 days, 4-5 days, 5-10 days, 10-15 days, 15-20 days, 20-25 days, or 25-30 days. It is particularly preferred that the biodegradable material used to prepare the shell material degrades in a period of no more than 10 days. In certain preferred embodiments, degradation of the shell material is capable of providing nutrients that maintain or promote the vital activity of the cell. In certain preferred embodiments, the biodegradable material used to prepare the shell material comprises an extracellular matrix or analog thereof (e.g., elastin).

In certain preferred embodiments, the biodegradable material used to prepare the shell material is selected from the group consisting of collagen (e.g., type I, type II, type III collagen), fibrin, chitosan, alginate (e.g., sodium or calcium alginate), oxidized alginate (e.g., oxidized sodium alginate), starch, hyaluronic acid, laminin, elastin, gelatin, polyamino acids (e.g., polylysine), dextran, agarose, or any combination thereof.

In certain preferred embodiments, the shell material comprises an alginate (e.g., sodium or calcium alginate), e.g., comprises calcium alginate and gelatin, optionally further comprising elastin; alternatively, an oxidized alginate (e.g., oxidized sodium alginate); alternatively, comprising an alginate (e.g., sodium or calcium alginate) and an oxidized alginate (e.g., oxidized sodium alginate); alternatively, it comprises alginate (e.g. sodium or calcium alginate) and agarose.

In certain preferred embodiments, the shell materials are each independently permeable; for example, the shell material is permeable to water, oxygen, and nutrients (sugars such as glucose, fats, proteins, amino acids, short peptides, minerals, vitamins, cytokines, nucleotides). In certain preferred embodiments, the shell material is transparent to molecules having a molecular weight below 5000 kDa. For example, in certain embodiments, the shell material is transparent to molecules having a molecular weight below 200kDa or in the range of 200kDa to 300kDa, 300kDa to 400kDa, 400kDa to 500kDa, 500kDa to 800kDa, 800kDa to 1000kDa, 1000kDa to 1500kDa, 1500kDa to 2000kDa, 2000kDa to 3000kDa, 3000kDa to 4000kDa, or 4000kDa to 5000 kDa. In certain embodiments, the shell material is transparent to immunoglobulins (e.g., IgG, IgM, IgA, IgD, IgE).

In another aspect, the present invention provides a method of making a bio-brick of the present invention, comprising the steps of:

(1) mixing the cells with a biodegradable material for forming a nuclear layer to provide a nuclear layer material encapsulating the cells; and

In certain preferred embodiments, in step (1), the cells, the biodegradable material for forming the nuclear layer, and optionally the desired additional agents (e.g., nutrients, extracellular matrix, cytokines, and/or pharmaceutically active ingredients) are homogeneously mixed.

In certain preferred embodiments, in step (2), the biodegradable material for forming the shell layer comprises an oxidized alginate. In certain preferred embodiments, in step (2), granulation and coating are carried out using an apparatus for preparing microspheres or, for example, a pelletizer.

In certain preferred embodiments, the method further comprises the following step after step (2): the shell of the bio-brick is treated (e.g., with a shell fixative, e.g., to improve the mechanical protective properties of the shell).

In another aspect, the present invention provides a bio-brick obtained by the above method.

In another aspect, the present invention provides a method of preparing a composition (e.g., a biological ink) of the present invention, comprising the steps of: the bio-brick of the present invention is mixed with a carrier (e.g., a bio-adhesive). In certain preferred embodiments, the composition (e.g., a biological ink) and/or the carrier (e.g., a bioadhesive) have any one or more of the technical features as defined above.

In another aspect, the invention provides a construct comprising a microvessel, comprising or prepared using a bio-brick or bio-ink of the invention. In certain preferred embodiments, the construct is a three-dimensional construct, a tissue precursor, a tissue or an organ. In certain preferred embodiments, the construct is a live construct.

In certain preferred embodiments, the construct comprises a plurality of biological bricks. In certain preferred embodiments, the bio-bricks are arranged in a predetermined pattern. In certain preferred embodiments, the predetermined pattern is based on the structure and cell distribution pattern of the native tissue or organ. In certain preferred embodiments, the construct comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 biological bricks. In certain preferred embodiments, the bio-brick comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 different cell types. In certain preferred embodiments, the construct (e.g., three-dimensional construct, tissue precursor, tissue or organ) has a size of at least 30 μm, 50 μm, 100 μm, 200 μm, 500 μm, 1mm, 2mm, 5mm, 1cm, 2cm, 5cm, 10cm, 20cm, or 50 cm. In certain preferred embodiments, the construct is further cultured to produce an organ (e.g., heart, liver, kidney) or functional unit thereof.

In certain preferred embodiments, at least one portion of the construct is bioprinted. Bioprinted constructs are generally obtained by methods using rapid prototyping techniques. Rapid prototyping is based on three-dimensional, automated, computer-assisted deposition of cells/bio-bricks/bio-ink and optionally confinement materials onto a biocompatible surface (e.g. consisting of hydrogel and/or porous membrane) by a three-dimensional delivery device (e.g. bioprinter). As used herein, the term "engineered" when used in reference to a tissue and/or organ means: according to the computer script, cells, cell solutions, cell suspensions, gels or slurries containing cells, cell concentrates, multicellular aggregates, bio-bricks, and layers thereof are placed by a computer-aided apparatus (e.g., a bioprinter) to form a three-dimensional structure. In further embodiments, the computer feet are, for example, one or more computer programs, computer applications, or computer modules. In still further embodiments, the three-dimensional tissue structure is formed by post-printing fusion of cells, multicellular bodies, or biological bricks.

While there are many methods that can be used to arrange cells, multicellular aggregates, biological tiles, and/or layers thereof on a biocompatible surface to create a three-dimensional structure (e.g., manual placement), placement by automated, computer-assisted machines (e.g., bioprinters) is advantageous. The use of bioprinters to deliver cells, multicellular bodies, biobricks is advantageous, and its advantages include: the rapid, precise and reproducible placement of cells, multicellular bodies, bio-bricks to produce constructs exhibiting a planned or predetermined orientation or pattern of cells, multicellular aggregates, bio-bricks and/or layers thereof having various compositions.

In some embodiments, the bioprinting process is continuous and/or substantially continuous. Non-limiting examples of continuous bioprinting methods are: biological ink (e.g., bio-brick combined with a bio-adhesive or extrusion compound) is dispensed from a bio-printer via a dispensing tip (e.g., syringe, capillary, etc.) connected to the biological ink reservoir. In a further non-limiting embodiment, the continuous bioprinting method is dispensing a biological ink in a repeating pattern of functional units. In various embodiments, the repeating functional units have any suitable geometry, including, for example: circular, square, rectangular, triangular, polygonal, and irregular geometries, resulting in one or more tissue layers having a planar geometry obtained by spatial patterning of unique biological inks and/or interstitial spaces. In further embodiments, a repeating pattern of bioprinted functional units comprises one layer, with multiple layers being bioprinted (e.g., stacked) adjacent to form an engineered tissue or organ having a layered geometry. In various embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more layers are bioprinted (e.g., stacked) adjacent to each other to form an engineered tissue or organ. In further embodiments, one or more layers of tissue having a lamellar geometry also have a planar geometry.

In addition to inkjet bioprinting techniques, the biobrick of the present invention can be used to construct three-dimensional constructs using low temperature sedimentation molding techniques or uv curing molding techniques. For a detailed description of inkjet bioprinting techniques, low temperature sedimentation molding techniques, and uv curing molding techniques, see, for example, 25th anaerobic article: Engineering Hydrogels for Biosimulation, which is incorporated herein by reference in its entirety.

Thus, in certain preferred embodiments, the construct has a predetermined structure. In particular, the bio-brick of the present invention may be used for printing or stacking in a predetermined pattern to form a construct having a predetermined structure.

In certain preferred embodiments, the construct has one or more layers of structure. It is further preferred that each layer structure is constructed from one or more layers of bio-brick. The bio-brick used for the different structural layers may be the same or different. For example, the construct may have a three-layered structure similar to a blood vessel, i.e., an endothelial cell layer, a smooth muscle cell layer, and a fibroblast cell layer.

In certain preferred embodiments, the construct is formed by the aggregation of cells within a biological brick. In particular, in embodiments of the invention, the core and shell layers of the bio-brick, and the carrier (e.g., bioadhesive) are each made of a biodegradable material. Thus, after bioprinting, cells within the bio-brick begin to grow, proliferate, differentiate, secrete and/or migrate under the stimulation of various active substances inside/outside the bio-brick; the core and shell layers of the bio-brick and the carrier (e.g., bio-adhesive) begin to degrade continuously; the cells are gradually condensed/fused to establish connection (including cell connection inside the biological bricks and cell connection between the biological bricks); in addition, extracellular matrixes secreted by the cells are fused into a whole; thus, all cells that are precisely aligned after printing fuse to form an organically aligned, integrated three-dimensional construct (e.g., a tissue or organ with biological function, such as a tissue or organ containing microvessels).

In certain preferred embodiments, the construct is a microtissue block. For example, such pieces of microtissue may be on the order of micrometers to centimeters in size, e.g., 1 μm-1cm, e.g., 10 μm-5mm, 50 μm-1mm, 100 μm-800 μm, 300 μm-600 μm. In certain preferred embodiments, the size of the pieces of microtissue may be at least 30 μm, 50 μm, 100 μm, 200 μm, 500 μm, 1mm, 2mm, 5mm, 1cm, 2cm, 5cm, 10cm, 20cm, or 50 cm.

In certain preferred embodiments, the construct may be further cultured. In certain preferred embodiments, cells in the bio-brick of the construct grow, proliferate, differentiate, secrete, and/or migrate; and the biodegradable material of the core layer and/or the shell layer of the bio-brick is at least partially degraded. In certain preferred embodiments, the cells within the bio-brick proliferate at least 2, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 10000, 20000, 50000, or 100000-fold after culture. In certain preferred embodiments, the bio-brick of the construct comprises stem cells. Preferably, the stem cells are capable of differentiating to produce at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 different cells. In certain preferred embodiments, the biodegradable material of the core layer and/or the shell layer of the bio-brick is degraded by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%. In certain preferred embodiments, after culturing, the cells between different bio-bricks in the construct are linked to each other and the biodegradable material of the core layer and/or the shell layer of the bio-brick is at least partially degraded. In certain preferred embodiments, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the cells are attached to each other between different bio-bricks. In certain preferred embodiments, the biodegradable material in the carrier (e.g., bioadhesive) is degraded by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%. In certain preferred embodiments, degradation products of the biodegradable material in the core layer and/or the shell layer and/or the carrier provide nutrients or extracellular matrix material to the cells. In certain preferred embodiments, the construct is cultured for at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 25, or 30 days, e.g., 1-3, 3-5, 5-7, 7-10, 10-14, 14-21, 21-28, 1-7, 7-14, 1-14, or 14-28 days, to obtain a microtissue mass, a tissue precursor, a tissue, or an organ. In certain preferred embodiments, the construct is cultured in a 3D incubator. In certain preferred embodiments, the construct is cultured in a bioreactor. In certain preferred embodiments, the construct is subjected to a physical stimulus (e.g., pressure, shear, light, heat, etc.) during the culturing process. In certain preferred embodiments, the construct is subjected to a chemical stimulus (e.g., hormones, cytokines, chemical agents, etc.) during the culturing process.

A schematic structure of one example of a three-dimensional construct constructed using the bio-brick of the present invention is shown in fig. 2. As shown in fig. 2, the three-dimensional construct includes three layers, i.e., an endothelial cell layer, a smooth muscle cell layer, and a fibroblast cell layer. Wherein the endothelial cell layer is constructed from a bio-brick comprising endothelial cells; the smooth muscle cell layer is constructed by biological bricks containing smooth muscle cells; the fibroblast layer is constructed from a bio-brick containing fibroblasts. The endothelial cell layer, smooth muscle cell layer and fibroblast layer may each be comprised of one or more layers of cells, depending on the particular number of cells contained in the bio-brick used. The gaps between the bio-bricks are filled with a carrier (which contains a bio-adhesive). In a preferred embodiment, the carrier may further comprise an agent that maintains, promotes, ameliorates, modulates the vital activity of the cells within the bio-brick. For example, when the cells in the bio-brick are endothelial cells, the carrier may further comprise a cytokine that promotes the growth and differentiation of endothelial cells. When the cells in the bio-brick are smooth muscle cells, the carrier may further comprise cytokines that promote the growth and differentiation of the smooth muscle cells. When the cells in the bio-brick are fibroblasts, the carrier may further comprise cytokines for promoting the growth and differentiation of the fibroblasts. In certain preferred embodiments, the three-dimensional constructs of the invention are constructed by a 3D bioprinting process using the biobricks of the invention. However, without being limited by theory, the three-dimensional constructs of the invention may also be constructed using the bio-brick of the invention by any other known method (e.g., hand-placed methods).

In another aspect, the invention provides a method of making a construct, such as a three-dimensional construct, a tissue precursor, a tissue or an organ, comprising a step of bioprinting with a bio-brick of the invention or a composition of the invention (e.g., a bio-ink). In certain preferred embodiments, the methods of the invention produce constructs, e.g., three-dimensional constructs, artificial tissues or precursors thereof, having a predetermined pattern. In certain preferred embodiments, the methods of the present invention employ a composition (e.g., a biological ink). In certain preferred embodiments, the methods of the invention employ at least 2 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10) compositions (e.g., bioinocks). Different types of compositions (e.g., biological inks) may differ in one or more of the following: the type of bio-brick included; the type of vector contained; the content ratio of the biological brick to the carrier; and/or the content ratio between different types of bio-bricks. In certain preferred embodiments, the bioprinting step in the methods of the present invention is continuous and/or substantially continuous. In certain preferred embodiments, the methods of the invention comprise bioprinting a plurality of layers in series to obtain a three-dimensional construct having a predetermined pattern comprising a plurality of layers, wherein each layer is bioprinted with a composition of the invention (e.g., a biologica ink) according to the predetermined pattern, e.g., with a composition comprising a biological brick comprising endothelial cells (e.g., a biologica ink) and/or one or more additional compositions (e.g., a biologica ink) comprising a second biological brick comprising cells selected according to the desired construct, e.g., tissue type. In certain preferred embodiments, the methods of the invention comprise bioprinting a plurality of segments in series to obtain a three-dimensional construct having a predetermined pattern comprising a plurality of segments, wherein each segment is bioprinted with a composition of the invention (e.g., a biologica ink) according to the predetermined pattern, e.g., with a composition comprising a biological brick comprising endothelial cells (e.g., a biologica ink) and/or one or more additional compositions (e.g., a biologica ink) comprising a second biological brick comprising cells selected according to the desired construct, e.g., tissue type. In certain preferred embodiments, the carrier in the composition (e.g., bioink) comprises a bioadhesive that bonds together the bio-bricks in the layers, segments, and/or constructs. In certain preferred embodiments, the carrier in the composition (e.g., a biological ink) comprises a biological adhesive that immobilizes the biological tile in a layer, segment, and/or construct. In certain preferred embodiments, the predetermined pattern is defined by a stent. In certain preferred embodiments, the compositions of the present invention (e.g., bioink) are printed onto a stent. Preferably, the stent has a predetermined pattern. In certain preferred embodiments, the scaffold is an artificial structure comprising a biodegradable material capable of supporting a bio-brick in a composition (e.g., a bio-ink) to form an artificial tissue or tissue precursor. In certain preferred embodiments, the methods of making constructs of the present invention do not use a scaffold.

In certain preferred embodiments, the method of making a construct of the invention further comprises the step of making a composition of the invention (e.g., a biological ink) using a biological brick of the invention and optionally a carrier (e.g., a biological adhesive). In certain preferred embodiments, the methods of making constructs of the present invention further comprise bioprinting with other biocompatible materials, inks or compositions. In certain preferred embodiments, the method of making a construct of the present invention further comprises modeling the structure of the construct (e.g., a three-dimensional construct) based on the shape and/or cellular arrangement of the native tissue or organ.

The method of making the constructs of the present invention is compatible with other bioprinting methods known in the art. For example, the method of the present invention can be used in bioprinters developed by Cyfuse, Organovo and envisionTEC. Three major bioprinters, namely, inkjet type bioprinters, extrusion type bioprinters and laser-assisted bioprinters have been developed (see Murph SV and Atala A. (2014) Nature Biotechnology,32(8): 773-. Alternatively, the method of making the constructs of the invention may be used in bioprinting methods using automated or non-automated mechanical processes (rather than a printer), or bioprinting methods using manual placement or manual deposition methods (e.g., using a pipette). In certain preferred embodiments, bioprinting is performed by inkjet means. In certain preferred embodiments, bioprinting is performed by means of extrusion. In certain preferred embodiments, bioprinting is performed by manual placement or manual deposition.

In certain preferred embodiments, bioprinting is performed in vivo using the biological brick or composition (e.g., biological ink) of the present invention. In certain preferred embodiments, bioprinting is performed directly on a subject (e.g., a human subject). In certain preferred embodiments, bioprinting is performed directly at the site of injury to a tissue (e.g., skin tissue) of the subject. In certain preferred embodiments, the tissue is damaged by trauma, infection, disease, or aging. In certain preferred embodiments, bioprinting is performed directly at the site of injury to a tissue (e.g., skin tissue) of a subject based on information about the cell distribution of the tissue or tissue injury site. In certain preferred embodiments, the cell distribution information includes, but is not limited to, different cell layers of the tissue or tissue injury site, types of cells of each layer, ratios of different cells in each layer, and cell distribution patterns in each layer. In certain preferred embodiments, information on the cell distribution of the tissue or tissue damage site is obtained prior to bioprinting. In certain preferred embodiments, the method further comprises obtaining information on the cell distribution of the tissue or tissue damage site, and then bioprinting based on the cell distribution information. In certain preferred embodiments, the cells in the composition (e.g., biological ink) for bioprinting on a subject are derived from the subject. In certain preferred embodiments, the cells in the composition (e.g., bioinoch) used for bioprinting on a subject are derived from other subjects having similar or identical characteristics (e.g., species, age, gender, genetic information, etc.) as the subject. In certain preferred embodiments, the cells in the composition (e.g., biological ink) used for bioprinting on a subject are derived from allogeneic sources. In certain preferred embodiments, the cells in the composition (e.g., biological ink) used for bioprinting on a subject are derived from a cell line. In certain preferred embodiments, bioprinting is performed in vitro using the bio-brick or composition (e.g., bio-ink) of the invention.

The method of making the construct of the invention does not mechanically damage cells in the composition (e.g., biological ink) or within the biological tile. In certain preferred embodiments, at least 80%, 85%, 87.5%, 90%, 92.5%, 95%, or 98% of the cells in the composition (e.g., bioink) or within the bio-brick survive bioprinting. In certain preferred embodiments, at least 90% of the cells in the composition (e.g., bioink) or within the bio-brick survive at least 3 hours, 6 hours, 12 hours, 1 day, 2 days, 4 days, or 7 days after bioprinting. In certain preferred embodiments, at least 80%, 85%, 87.5%, 90%, 92.5%, 95%, or 98% of the cells in the composition (e.g., bioink) or within the bio-brick are capable of proliferating and/or differentiating after bioprinting. In certain preferred embodiments, at least 80%, 85%, 87.5%, 90%, 92.5%, 95%, or 98% of the cells in the composition (e.g., bioink) or within the bio-brick have normal metabolism after bioprinting. In certain preferred embodiments, at least 80%, 85%, 87.5%, 90%, 92.5%, 95%, or 98% of the cells in the composition (e.g., bioink) or within the bio-brick are capable of migrating after bioprinting. In certain preferred embodiments, at least 80%, 85%, 87.5%, 90%, 92.5%, 95%, or 98% of the cells in the composition (e.g., bioink) or within the bio-brick are capable of secretion following bioprinting.

In certain preferred embodiments, the methods of making constructs of the invention further comprise culturing under conditions that allow proliferation, differentiation, migration, secretion and/or metabolism of cells within the bio-brickThe obtained construct. The culture conditions depend on the type of cells used, the type of bio-brick used, the structure and shape of the construct, and the like. The skilled person will be able to select suitable culture conditions, e.g.medium, pH, temperature, CO₂Level and duration. General tissue and cell culture conditions can be found, for example, in Doyle, Alan, and J.Bryan Griffiths, eds.cell and tissue culture: laboratory procedures in biological technology.New York: Wiley, 1998. In certain preferred embodiments, the obtained construct is cultured for at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 25, or 30 days, e.g., to obtain an artificial tissue or a precursor thereof. In certain preferred embodiments, the resulting construct is cultured for 1-3, 3-5, 5-7, 7-10, 10-14, 14-21, 21-28, 1-7, 7-14, 1-14, or 14-28 days, e.g., to obtain an artificial tissue or a precursor thereof. In certain preferred embodiments, the obtained construct is cultured in a 3D incubator. In certain preferred embodiments, the obtained construct is cultured in a bioreactor. In certain preferred embodiments, 5% CO is at 37 deg.C ₂Culturing the obtained construct under the conditions of (1). In certain preferred embodiments, the construct is subjected to a physical stimulus (e.g., pressure, shear, light, heat, etc.) during the culturing process. In certain preferred embodiments, the construct is subjected to a chemical stimulus (e.g., hormones, cytokines, chemical agents, etc.) during the culturing process. In certain preferred embodiments, the biodegradable material in the core layer and/or the shell layer of the bio-brick and/or the carrier is at least partially degraded during the culturing process. Preferably, the degradation products of such biodegradable materials provide nutrients and/or extracellular matrix to the cells in the bio-brick. In certain preferred embodiments, the secretion of the cell during culture is incorporated into the extracellular matrix of the construct. In certain preferred embodiments, the cells within the bio-brick are linked to each other during the culturing process. In certain preferred embodiments, the cells between the bio-bricks are connected to each other during the culturing process. In certain preferred embodiments, the construct has, after cultureHigh cell density (e.g., at least 100, 200, 500, 1000, 2000, 5000, 10000, 20000, 50000, or 100000 cells/mm) ³). In certain preferred embodiments, the cells within the bio-brick proliferate at least 2, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 10000, 20000, 50000, or 100000-fold after culture.

The constructs produced by the methods of the invention can have any predetermined pattern, for example, any predetermined shape. For example, the construct may be a sheet-like structure (e.g., an oblong, square, circular, oval, hexagonal, or irregularly shaped sheet-like structure), or a hollow tubular structure, or a hollow three-dimensional structure (e.g., a hollow cube, hollow sphere, hollow rectangular prism, hollow cylinder, or hollow irregularly shaped three-dimensional structure), or a solid three-dimensional structure (e.g., a solid cube, solid sphere, solid rectangular prism, solid cylinder, or solid irregularly shaped three-dimensional structure), or any combination thereof. In certain preferred embodiments, the shape of the construct mimics the shape of a native tissue or organ. In certain preferred embodiments, the construct is at least 30 μm, 50 μm, 100 μm, 200 μm, 500 μm, 1mm, 2mm, 5mm, 1cm, 2cm, 5cm, 10cm, 20cm, or 50cm in size.

Unlike prior art methods, the cells between different bio-bricks in a construct are not interconnected to each other just at the time the bioprinting step is completed. Further culturing of the construct will result in the cells first growing, proliferating, differentiating, secreting and/or migrating within the shell of the bio-brick; subsequently, during the culturing process, as the biodegradable material within the bio-brick (e.g., the biodegradable material in the core layer and the shell layer) degrades, the cells can break through the shell layer of the bio-brick. Thus, an accurate cell arrangement can be achieved in the bio-brick based construct, which in turn enables the generation of more complex tissues or organs.

In another aspect, the invention provides constructs made by the above methods. In certain preferred embodiments, the construct is a three-dimensional construct, a tissue precursor, a tissue or an organ. In certain preferred embodiments, the construct is a live construct.

In another aspect, the invention provides the use of the bio-brick of the invention, e.g., for culturing cells (e.g., for three-dimensional culturing of cells); or for growing, proliferating, differentiating, secreting, or migrating cells; or for bioprinting (e.g., 3D bioprinting); or for forming a construct (e.g., a three-dimensional construct), such as a tissue precursor, a tissue, or an organ. In certain preferred embodiments, the biobrick of the present invention is used to prepare a construct (e.g., a three-dimensional construct), such as a tissue precursor, tissue, or organ, by bioprinting.

In another aspect, the invention provides the use of a composition of the invention (e.g., a biological ink) for bioprinting (e.g., 3D bioprinting); or for forming a construct (e.g., a three-dimensional construct), such as a tissue precursor, a tissue, or an organ. In certain preferred embodiments, the compositions of the invention (e.g., bioink) are used to prepare constructs (e.g., three-dimensional constructs), such as tissue precursors, tissues or organs, by bioprinting.

In another aspect, the invention provides the use of a bio-brick or construct (e.g., a three-dimensional construct, such as a tissue precursor, tissue, or organ) of the invention. The bio-brick or construct of the invention may be used in various applications, for example in research or medical fields. For example, the bio-brick or construct of the invention may be used for studying stem cell (e.g. MSC) differentiation, for drug discovery, for drug screening, for in vivo or in vitro assays, for implantation into a host, for tissue engineering or for tissue regeneration. The bio-brick or construct of the invention may also be used for the preparation of kits for various applications, for example for applications in the research or medical field. For example, the bio-brick or construct of the invention may be used for studying stem cell (e.g. MSC) differentiation, for drug discovery, for drug screening, for in vivo or in vitro assays, for implantation into a host, for tissue engineering or for tissue regeneration.

In certain preferred embodiments, the biobrick or construct of the invention is useful for tissue engineering. In certain preferred embodiments, the bio-brick provides a unique microenvironment for the cells within the bio-brick, thereby allowing study of the effects/influences of the culture conditions (e.g., three-dimensional culture conditions), such as study of the effects of the culture conditions (e.g., three-dimensional culture conditions) on cell proliferation, differentiation, metabolism, migration, secretion, tissue development, or organogenesis. In certain preferred embodiments, the constructs of the invention are useful for studying stem cell differentiation.

In certain preferred embodiments, the bio-brick or construct of the invention can be used in vitro assays. In certain preferred embodiments, the in vitro assay is a method for detecting or measuring the presence or activity of a substance (e.g., a chemical agent, biochemical agent, drug, etc.) in a biological sample (e.g., a cell aggregate, a tissue, an organ, an organism, etc.). In certain preferred embodiments, the in vitro assay is qualitative. In certain preferred embodiments, the in vitro assay is quantitative. Exemplary in vitro assays include, but are not limited to, image-based assays, assays for secreted proteins, expression of markers and production of proteins. In certain preferred embodiments, the in vitro assay is used to detect or measure one or more of: molecular binding (including radioligand binding), molecular uptake, activity (e.g., enzymatic activity and receptor activity, etc.), gene expression, protein expression, receptor agonism, receptor antagonism, cell signaling, apoptosis, chemosensitivity, transfection, cell migration, chemotaxis, cell viability, cell proliferation, safety, efficacy, metabolism, toxicity and abuse liability. In certain preferred embodiments, the in vitro assay is an immunoassay, such as a competitive immunoassay and a non-competitive immunoassay. In certain preferred embodiments, the in vitro assay is an enzyme-linked immunosorbent assay. In certain preferred embodiments, the bio-brick or construct of the present invention provides a molecule, cell population or tissue that is measured or detected in an in vitro assay. In certain preferred embodiments, in vitro assays are used in basic research to discover, develop, or study any molecule, cell, or structure or mechanism of action thereof. Exemplary applications of in vitro assays include, but are not limited to, developing three-dimensional culture systems, studying signaling pathways, stem cell induction and differentiation, cell-cell interactions, and the like.

In certain preferred embodiments, the bio-brick or construct of the present invention can be used for drug screening or drug discovery. In certain preferred embodiments, the bio-brick or construct of the invention is used to prepare an array, microarray or chip of cells, multi-cell aggregate or tissue for drug screening or drug discovery. In certain preferred embodiments, the bio-brick or construct of the invention is present in the pores of a porous container. Preferably, the container is compatible with automated drug screening methods and/or devices. In certain preferred embodiments, the biobrick or construct of the invention is used in drug screening or drug discovery to study or develop drugs that can be used to treat disease. Preferably, the disease includes, but is not limited to, infectious diseases, hematological diseases, neoplastic diseases, pediatric diseases, cardiovascular diseases, central nervous system diseases, neurological diseases, digestive diseases, hepatology diseases, urology diseases, infertility, ophthalmic diseases, nephrology diseases, orthopedic diseases, pain, respiratory diseases, skin diseases, immune diseases, psychiatric diseases.

In certain preferred embodiments, the biobrick or construct of the invention is used in an in vivo assay. In certain preferred embodiments, the biological brick or construct of the invention is used as a xenograft in a subject (e.g., an animal model). In certain preferred embodiments, the biological brick or construct of the invention is used as a graft for implantation into a subject.

In certain preferred embodiments, the bio-brick or construct of the invention is used to analyze a change (e.g., a morphological change or a functional change) in a cell in response to a stimulus or agent in vivo. In such embodiments, the cells in the bio-brick are exposed to the stimulus or agent, and a change (e.g., a morphological change or a functional change) in the cells in the bio-brick is assessed. In certain preferred embodiments, the bio-brick is located within a subject.

In certain preferred embodiments, the biobrick or construct of the invention is used to study stem cell differentiation. In certain preferred embodiments, the biological brick or construct of the invention is used to assess the effect of a factor (e.g., a chemical agent, such as a chemical compound; a physical stimulus, such as radiation or heat) on a tissue or cells in a tissue. In certain preferred embodiments, the biobrick or construct of the invention is used for three-dimensional tissue culture. In certain preferred embodiments, the biological brick or construct of the invention is used to repair damaged tissue in a subject.

In certain preferred embodiments, the bio-brick of the present invention is used for bioprinting directly in a subject. In certain preferred embodiments, bioprinting is performed based on cell distribution information of the tissue. In certain preferred embodiments, the bio-brick is printed onto a scaffold in a subject. In certain preferred embodiments, the subject is an animal model.

In certain preferred embodiments, the bio-brick of the present invention is used to study the effects of the microenvironment in vivo, as the cells in the bio-brick are capable of proliferating, differentiating, migrating, metabolizing, secreting, or developing in the subject. In certain preferred embodiments, the bio-brick of the present invention is used to study the effect of a compound (e.g., a drug) on cells in a bio-brick or construct in vivo.

In certain preferred embodiments, the biobrick or construct of the invention is used for tissue regeneration. In certain preferred embodiments, the biobrick or construct of the invention is used for in vivo tissue or organ transplantation. In certain preferred embodiments, the bio-brick or construct of the invention is used to protect, repair or replace damaged, diseased or failing tissues or organs in a subject (e.g., a human). In certain preferred embodiments, the biobrick or construct of the invention is used to produce cells (e.g., stem cells, progenitor cells, precursor cells, immune cells, etc.) for use in cell therapy. In certain preferred embodiments, the bio-brick or construct of the invention is used to produce a biologically active molecule (e.g., hormone, growth factor, cytokine, ligand, etc.). Preferably, the bioactive molecule can be used to induce tissue regeneration in a subject (e.g., a human) receiving a biological brick or construct of the invention or a product thereof (e.g., a cell or bioactive molecule).

In another aspect, the invention provides a method of analyzing a change (e.g., a morphological change or a functional change) in a cell (e.g., an endothelial cell or a stem cell, such as an umbilical vein endothelial cell or an MSC cell) in response to a stimulus or agent, comprising exposing the cell in a bio-brick of the invention to the stimulus or agent and assessing the change (e.g., a morphological change or a functional change) in the cell in the bio-brick. In certain preferred embodiments, the cellular functions include, but are not limited to, cellular activity, cellular behavior, subcellular organelle dynamics and activity, and the function and activity of intracellular molecules. Examples of cellular functions include, but are not limited to, proliferation, survival, gene expression, toxicity, differentiation, metabolism, migration, secretion, signaling, apoptosis, necrosis, death, chemotaxis, molecular localization, molecular binding, and the like. In certain preferred embodiments, the stimulus or agent is provided in the core layer of the bio-brick. In certain preferred embodiments, the bio-brick is an isolated bio-brick. In certain preferred embodiments, the isolated bio-brick is provided in a container. In certain preferred embodiments, the stimulus or agent is provided in a container. In certain preferred embodiments, in the methods, a plurality of isolated biological tiles are analyzed in parallel (e.g., simultaneously) and/or in a high-throughput manner. In certain preferred embodiments, the bio-brick is placed in a subject. In certain preferred embodiments, the stimulus or agent is a drug. In certain preferred embodiments, the method is used to determine the efficacy of the drug. In certain preferred embodiments, the methods are used to screen drugs. In certain preferred embodiments, the cells in the bio-brick are derived from a subject in need of the drug.

In another aspect, the invention provides a method for studying stem cell differentiation comprising using a bio-brick of the invention comprising stem cells (e.g., MSC cells). In certain preferred embodiments, a plurality of isolated bio-bricks are used to study stem cell differentiation. Preferably, each isolated bio-brick comprises at least one stem cell. In certain preferred embodiments, at least two of the plurality of isolated bio-bricks are different, thereby allowing at least two different stem cell differentiation conditions to be studied simultaneously. In certain preferred embodiments, the at least two isolated bio-bricks each comprise different types of stem cells. In certain preferred embodiments, the plurality of isolated bio-bricks each comprise the same type of stem cells. In certain preferred embodiments, the at least two isolated bio-bricks each comprise a different agent or combination of agents that promote cell proliferation, differentiation, migration, metabolism, secretion, signaling, or any combination thereof. In certain preferred embodiments, the plurality of isolated bio-bricks are analyzed in a parallel (e.g., simultaneous) and/or high throughput manner.

In another aspect, the invention provides a method of assessing the effect of a factor (e.g., a chemical agent, such as a compound; a physical stimulus, such as radiation or heat) on a tissue or cells in a tissue, comprising exposing a construct (e.g., a three-dimensional construct, a tissue precursor, a tissue or organ) of the invention to the factor, and assessing the change (e.g., a morphological change or a functional change) of cells in the construct in response to the factor, thereby determining the effect of the factor on the tissue or cells in the tissue. In certain preferred embodiments, the compound is a drug. In certain preferred embodiments, the method is used to determine the efficacy of the drug. In certain preferred embodiments, the methods are used to screen drugs. In certain preferred embodiments, the cells in the bio-brick are derived from a subject in need of the drug.

In another aspect, the invention provides a method for three-dimensional tissue culture comprising providing a bio-brick comprising cells to be cultured (e.g., endothelial cells or stem cells, such as umbilical vein endothelial cells or MSC cells) and reagents or other components for tissue culture or cell culture, and culturing the bio-brick under suitable conditions. In certain preferred embodiments, the cells in the bio-brick produce cells found naturally in tissue. In certain preferred embodiments, the cell is a stem cell. In certain preferred embodiments, in the methods, a plurality of bio-bricks are used to study three-dimensional tissue culture conditions. In certain preferred embodiments, in the methods, a plurality of isolated bio-bricks are analyzed in parallel (e.g., simultaneously) or in a high throughput manner. In certain preferred embodiments, the methods described use at least two bio-bricks. In certain preferred embodiments, the at least two bio-bricks are different, allowing for the simultaneous study of at least two tissue culture conditions. In certain preferred embodiments, the bio-brick is provided in a container. In certain preferred embodiments, the container comprising the bio-brick is used in a three-dimensional tissue culture process.

In another aspect, the invention provides a method of repairing damaged tissue in a subject comprising bioprinting directly at the site of damage to the tissue in the subject using a biological tile or composition (e.g., biological ink) of the invention. In certain preferred embodiments, the bioprinting is performed on a scaffold placed at the site of tissue damage. In certain preferred embodiments, the method comprises obtaining cell distribution information of the tissue or tissue damage site, and then bioprinting based on the cell distribution information. In certain preferred embodiments, the cells in a biological tile or composition (e.g., biological ink) for bioprinting on a subject are derived from the subject. In certain preferred embodiments, the cells in a biological brick or composition (e.g., biological ink) for bioprinting on a subject are derived from other subjects having similar or identical characteristics (e.g., species, age, gender, genetic information, etc.) as the subject. In certain preferred embodiments, the cells in the biological brick or composition (e.g., biological ink) used for bioprinting on a subject are derived from allogeneic sources. In certain preferred embodiments, the cells in the biological brick or composition (e.g., biological ink) used for bioprinting on a subject are derived from a cell line. In certain preferred embodiments, the bio-brick or the bio-brick in the composition comprises stem cells.

In another aspect, the invention provides a pharmaceutical composition comprising one or more of the bio-bricks of the invention. In certain preferred embodiments, the pharmaceutical composition is for use in tissue regeneration. In certain preferred embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, excipient, stabilizer or other agent capable of providing advantageous properties for administration of the pharmaceutical composition (e.g., to a human subject). Suitable pharmaceutical carriers include, for example, sterile water, saline, dextrose, condensation products of castor oil and ethylene oxide, liquid acids, lower alcohols, oils (e.g., corn oil, peanut oil, sesame oil; which optionally also contain emulsifying agents, such as mono-or di-glycerides of fatty acids, or phospholipids such as lecithin), glycols, polyalkylene glycols, sodium alginate, poly (vinyl pyrrolidone), and the like. The carrier may optionally further comprise adjuvants, preservatives, stabilizers, wetting agents, emulsifiers, penetration enhancers, and the like. In certain preferred embodiments, the pharmaceutical composition is sterile. Furthermore, the viscosity of the pharmaceutical combination can be controlled and maintained by the selection of suitable solvents or excipients.

In certain preferred embodiments, excipients and diluents may include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, water, saline solution, syrup, methyl cellulose, methyl and propyl hydroxybenzoates, talc, magnesium stearate, and mineral oil. In certain preferred embodiments, the pharmaceutical composition is formulated to have a pH of 4.5-9.0, 5.0-8.0, 6.5-7.5, or 6.5-7.0. In certain preferred embodiments, the pharmaceutical composition is isotonic with blood.

In certain preferred embodiments, the pharmaceutical composition is used to treat a subject, e.g., a human subject, in need of protection, repair, or replacement of tissue (e.g., skin). In certain preferred embodiments, the present invention provides a method of protecting a tissue comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition of the present invention. In certain preferred embodiments, the present invention provides a method of repairing damaged tissue comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition of the present invention. In certain preferred embodiments, the present invention provides a method of replacing a tissue (e.g., damaged tissue, defective tissue) comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition of the present invention. In certain preferred embodiments, the tissue is skin. In certain preferred embodiments, the subject is a human. In certain preferred embodiments, the pharmaceutical composition is for use in tissue regeneration. In certain preferred embodiments, the pharmaceutical composition is for use in cell therapy. In certain preferred embodiments, the present invention provides cell therapy comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition of the present invention. In certain preferred embodiments, an effective amount of the pharmaceutical composition is sufficient to improve a tissue condition (e.g., integrity, health, appearance, etc.) by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%. The effective amount of the pharmaceutical composition can be determined according to the actual situation. In certain preferred embodiments, the effective amount of the pharmaceutical composition comprises at least 1, 5, 10, 20, 50, 100, 200, 500, 1000 bio-bricks.

The pharmaceutical compositions of the present invention may be administered by any suitable means. Exemplary modes of administration include, but are not limited to, intravenous, intra-arterial, intraperitoneal, intrapulmonary, intravesicular, intramuscular, intratracheal, subcutaneous, intraocular, intrathecal, transdermal or topical administration. In certain preferred embodiments, the pharmaceutical composition is used by surgical implantation. In certain preferred embodiments, the pharmaceutical composition is administered once. In certain preferred embodiments, the pharmaceutical composition is administered multiple times. In certain preferred embodiments, the pharmaceutical composition is administered at a frequency selected from the group consisting of: three times a day, twice a day, once every two days, once every 3 days, once a week, once every two weeks, once every three weeks, once a month, once every two months, once every 3 months, once every six months or once a year.

In another aspect, the present invention provides the use of the bio-brick of the present invention for the preparation of the above-mentioned pharmaceutical composition. In certain preferred embodiments, the pharmaceutical composition is for use in tissue regeneration, or in vivo tissue or organ transplantation.

In certain preferred embodiments, the kit comprises a biobrick of the invention, e.g., for use in bioprinting a construct (e.g., a three-dimensional construct, a tissue precursor, a tissue or an organ). In certain preferred embodiments, the kit comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 bio-bricks. Different types of bio-brick may differ in one or more of the following: the size of the biological brick; the shape of the biological brick; the number of cells involved; the type of cell contained; composition of the core layer (including type and content of components); composition of the shell (including type and content of components); additional agents (including type and amount) contained in the core layer and/or shell layer; and/or, any other parameter discussed above. In certain preferred embodiments, the kit further comprises a carrier (e.g., a bioadhesive) that can be mixed with the bio-brick for bioprinting. In certain preferred embodiments, the kit further comprises a model defining a bioprint pattern. In certain preferred embodiments, the model is based on the native structure and cell arrangement pattern of the construct to be printed.

In certain preferred embodiments, the kit comprises a composition of the invention (e.g., a bioinock), for example, for bioprinting a construct (e.g., a three-dimensional construct, a tissue precursor, a tissue or an organ). In certain preferred embodiments, the composition (e.g., bioink) comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 bioink. In certain preferred embodiments, the kit comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 compositions (e.g., bioinocks). In certain preferred embodiments, the kit further comprises a carrier (e.g., a bioadhesive). In certain preferred embodiments, the kit further comprises a model defining a bioprint pattern. In certain preferred embodiments, the model is based on the native structure and cell arrangement pattern of the construct to be printed.

In certain preferred embodiments, the kit further comprises additional components, such as containers, culture media, buffers, and/or other reagents required for bioprinting. In certain preferred embodiments, the kit further comprises instructions for use that describe methods of producing the construct (e.g., a three-dimensional construct, a tissue precursor, a tissue or organ), including, for example, steps of bioprinting and culture conditions.

In certain preferred embodiments, the kit comprises a construct of the invention. In certain preferred embodiments, the constructs of the invention are prepared (e.g., by bioprinting) using the biological bricks or compositions (e.g., biological inks) of the invention. In certain preferred embodiments, the kit further comprises, medium, buffers, and/or other reagents necessary for culturing the construct. In certain preferred embodiments, the kit further comprises instructions for use that describe a method of culturing the construct. In certain preferred embodiments, the kit is for use in regenerative medicine, such as in vivo transplantation or cell therapy. In certain preferred embodiments, the kit is for use in an in vitro assay or drug screening. In certain preferred embodiments, the kit further comprises additional reagents required for in vitro assays, drug screening, or regenerative medicine (e.g., in vivo transplantation or cell therapy), and/or instructions for use. In certain preferred embodiments, the kit further comprises a scaffold, or a material used to prepare a scaffold.

In certain preferred embodiments, the kits are useful for analyzing changes in cells in response to stimuli or agents (e.g., morphological changes or functional changes), for drug screening or drug discovery, for treating a subject in need thereof, for studying stem cell differentiation, for assessing the effect of factors (e.g., chemical agents, such as compounds; physical stimuli, such as radiation or heat) on tissues or cells in tissues, for three-dimensional tissue culture, for repairing damaged tissues in a subject.

The kits of the invention may be placed in any suitable package. Such packages include, but are not limited to, bottles, cans, and flexible packaging (e.g., mylar or plastic bags).

In another aspect, the invention provides the use of a biobrick, composition (e.g., a biological ink), and/or construct (e.g., a three-dimensional construct, tissue precursor, tissue, or organ) of the invention to prepare a kit that can be used for the various applications discussed above. For example, the kit can be used to analyze changes in cells in response to stimuli or agents (e.g., morphological changes or functional changes), for drug screening or drug discovery, for treating a subject in need thereof, for studying stem cell differentiation, for assessing the effect of factors (e.g., chemical agents, such as compounds; physical stimuli, such as radiation or heat) on tissues or cells in tissues, for three-dimensional tissue culture, for repairing damaged tissues in a subject.

Advantageous effects of the invention

Compared with the prior art, the technical scheme of the invention has the following beneficial effects:

(1) the cell type and the cell number of the biological brick are controllable, and the structure and the size of the biological brick are also controllable, so that the biological brick can be used for preparing standardized and controllable biological ink. In particular, the bio-brick of the present invention may comprise 1 to 10 ⁶Individual cells, for example 1 to thousands of cells, and optionally, may comprise different cell types in predetermined ratios.

(2) In the biological brick, substances in the biological brick, such as cell factors and biodegradable materials, can be adjusted to provide specific micro-environments for different types of cells, so that the growth and functions of the cells can be regulated; this further enables the regulation of cells of different regions, or of different cells of the same region, within complex constructs such as tissues and organs.

(3) In the bio-brick of the present invention, the bio-brick provides a suitable microenvironment (e.g., growth factors or nutrients required for growth and differentiation of specific cells, spatial structures suitable for proliferation and differentiation of cells, physical factors such as mechanical stimulation and the like that promote normal biological functions of cells, trophoblast cells that assist or regulate differentiation of stem cells, and the like) for vital activities of specific cells, so that different cell types can be cultured in the same culture system or the same stem cells can be differentiated and cultured into different cell types in the same culture system.

(4) The biological brick provided by the invention has a shell-core structure, provides effective mechanical protection for cells, and effectively reduces or avoids the cells from external mechanical damage/mechanical damage (for example, in a biological printing process), thereby ensuring the survival rate of the cells in the printing process (up to more than 90%). Furthermore, the shell of the bio-brick of the invention can also be used as a biodegradable scaffold for cells, which makes it possible to dispense with providing the cells with a biodegradable surface (for example, a hydrogel surface used in the Organovo technique) during the bioprinting process.

(5) The biological brick and the biological ink can realize the accurate arrangement of cells in the biological printing process and realize the accurate biological printing of tissues or organs. In particular, different types of bio-brick can be customized as desired, which can have different structures, use different types of cells, use different types of cytokines, and/or use different types of biodegradable materials. Subsequently, various types of bio-bricks can be used for bio-printing according to a predetermined pattern, thereby obtaining a construct composed of bio-bricks (cells) arranged according to the predetermined pattern, and finally achieving precise arrangement of the bio-bricks (cells). Furthermore, the bio-brick of the invention also enables a significant increase of the cell density within the obtained construct, without destroying the intended/precise arrangement of the bio-brick (cells), since the cells are first propagated within the bio-brick.

(6) By adding different cell factors/medicinal active ingredients, the invention can regulate and control the proliferation, differentiation, migration and metabolism of cells in various biological bricks.

(7) The bio-brick comprising endothelial cells of the present invention can be used to form an artificial tissue or organ comprising microvasculature. The formed microvasculature can be used as a channel for obtaining nutrients and discharging metabolites from cells in tissues or organs, so that the cells in the microvasculature can survive, and the tissue block has biological functions.

Detailed Description

The invention will now be described with reference to the following examples, which are intended to illustrate the invention, but not to limit it.

The reagents, kits or apparatuses whose sources are not indicated in the examples are all conventional products commercially available on the market. The examples are given by way of illustration and are not intended to limit the scope of the invention as claimed.

EXAMPLE 1 preparation of Biobricks

This example provides an exemplary method of making a bio-brick. The preparation method of the biological brick should be carried out under aseptic conditions. Furthermore, if the bio-brick is intended to be applied to the human body, the bio-safety level of its manufacturing process should reach GMP plant level.

The apparatus used in the process was a granulator (BUCHI, encapulator, B-395Pro) equipped with concentric nozzles having the following diameters: inner layer nozzle of 200 μm; outer layer nozzle, 300 μm.

The materials used in the method are as follows:

(1) material for producing a core layer

Type I collagen: 4mg/ml, neutralized with sterile 1M NaOH;

sodium alginate: dissolving and diluting with deionized water;

vascular endothelial growth factor VEGF;

type I collagen was mixed with a 2% (w/v) (i.e., 2g/100ml, hereinafter the same) sodium alginate solution in a ratio of 1:1 (by weight) for preparing a core layer.

(2) Material for preparing shell layer

4% sodium alginate;

elastin;

a shell fixative, i.e., 0.1mol/L CaCl₂And (3) solution.

(3) The cells used were: human Umbilical Vein Endothelial Cells (HUVEC) (purchased from ATCC).

The procedure for the preparation of the bio-brick was as follows (the following experimental procedures were all performed on ice):

mu.l NaOH solution was mixed with 750. mu. l I collagen, and 130. mu.l vascular endothelial cell suspension (cell concentration 1X 10) was added thereto⁵Pieces/ml, suspended in PBS), to obtain 1ml of cell wrap. Then, the cell-encapsulating solution was mixed with 1ml of 2% sodium alginate (containing VEGF at a final concentration of 20 ng/ml) to uniformly disperse the cells, thereby obtaining a cell-encapsulating nuclear layer material.

100ng of elastin (elastin, final concentration 50ng/ml) was added to 2ml of 4% sodium alginate solution and mixed well, and the mixture was used as shell material for preparing shell of bio-brick. Furthermore, 300ml of 0.1mol/L CaCl was taken₂The solution was placed in a beaker for fixation of the shell material.

The core layer material and the shell layer material prepared as above were placed in 2-piece 5ml syringes, respectively. The pressure, dispersion force, pump speed, etc. of the pelletizer are set according to the manufacturer's instructions, and then the core and shell materials are pelletized and coated. The diameter of the inner nozzle of the granulator was set to 200 μm and the diameter of the outer nozzle was set to 300 μm. Collecting the obtained biological brick particles in a container with 300ml of 0.1mol/L CaCl ₂And (5) fixing the solution in a beaker for 5min to prepare the biological brick. The prepared biological brick can be stored at 4 ℃ or can be directly used for 3D biological printing.

Example 2 characterization of Biobricks

This example specifically analyzes the properties of the bio-brick prepared by the method of example 1, including the size of the bio-brick, the thickness and mechanical protection of the shell layer, the number of cells contained, and the like.

The biobrick prepared by the method of example 1 was observed using a microscope, and the results are shown in fig. 3A to 3C. Fig. 3A-3C show photomicrographs of the biobricks produced using a pelletizer under different instrument parameters (diameters of the inner and outer nozzles of the concentric nozzle), wherein the diameter of the biobrick in fig. 3A is about 120 μm (100 μm on the scale); the diameter of the bio-brick in fig. 3B is about 200 μm (100 μm on the scale); the diameter of the bio-brick in fig. 3C is about 450 μm (200 μm scale). These results show that the dimensions of the bio-brick can be controlled by controlling the instrumental parameters of the granulator (e.g., the diameter of the inner and outer nozzles of the concentric nozzle). The size of the biological brick is controllable and can be selected according to the requirement.

The shell thickness of the bio-brick prepared by the method of example 1 was further observed using a microscope, and the result is shown in fig. 4. Fig. 4 shows a micrograph of a bio-brick prepared by the method of example 1, in which a highlighted portion represents a shell layer of the bio-brick, and the thickness of the shell layer is about 2 μm (scale: 50 μm). The results show that the thickness of the shell can be controlled by controlling the diameter of the inner and outer nozzles of the concentric nozzle of the granulator, the pumping speed of the shell material, and other parameters. The shell thickness of the biological brick is controllable and can be selected according to requirements.

The number of cells contained in the bio-brick prepared by the method of example 1 was further observed using a microscope. The results are shown in FIGS. 5A-5C. FIGS. 5A-5C show micrographs of a bio-brick prepared by the method of example 1, wherein the bio-brick in FIG. 5A has a cell number of about 50 (100 μm on a scale); the number of cells encapsulated by the bio-brick in fig. 5B is about 8 (100 μm on the scale); the number of cells encapsulated by the bio-brick in FIG. 5C was about 2 (100 μm on the scale). These results indicate that the number of cells encapsulated by the bio-brick can be controlled by controlling the cell concentration of the cell suspension. The number of cells contained in the biological brick of the invention is controllable and can be selected according to the needs.

In addition, the mechanical properties of the bio-brick (about 400 μm in size) prepared by the method of example 1 were also examined using a nano-indenter model Hysitron (Haimao) TI-950, USA, according to the manufacturer's instructions. The test results showed that the hardness of the bio-brick of the batch was about 0.083GPa on average and the elastic modulus was about 1.683MPa on average.

These results show that the biological brick of the invention has excellent mechanical protection performance, and can effectively prevent cells in the biological brick from being subjected to external mechanical damage/mechanical damage. Furthermore, it has been found that the mechanical protection of the bio-brick can be controlled by controlling parameters such as the thickness of the shell and the material of the shell of the bio-brick (data not shown). The mechanical protection performance of the biological brick is controllable and can be selected according to the requirement.

Example 3 preparation of other types of Biobricks

Other types of bio-bricks (i.e., bio-bricks B1-B4) were also prepared using a similar method to example 1, using a pelletizer, from the following starting materials.

In addition, in order to observe the structure of the prepared bio-brick more clearly, the seed cells used for preparing bio-brick B2 were also labeled using tracker CM-Dil (red fluorescence); furthermore, polylysine with FITC (Green fluorescence) was used as a shell material for the preparation of Biobrick B2. Subsequently, the bio-brick B2 prepared with seed cells and shell material each bearing a label was observed using a confocal microscope. The results are shown in fig. 6E. FIG. 6E shows confocal microscopy images of Biobrick B2 prepared with labeled seed cells and shell material, where green fluorescence represents the shell and red fluorescence represents the seed cells.

Example 4 preparation of Biobrick with Shell containing oxidized alginate

This example provides an exemplary method for making a bio-brick having a shell comprising an oxidized alginate. The preparation method of the biological brick should be carried out under aseptic conditions. Furthermore, if the bio-brick is intended to be applied to the human body, the bio-safety level of its manufacturing process should reach GMP plant level.

The materials used in the method are as follows:

(1) material for producing a core layer

Type I collagen: 4mg/ml, neutralized with sterile 1M NaOH;

(2) material for preparing shell layer

The sodium alginate oxide solution with the specified concentration or the mixed solution containing the sodium alginate oxide with the specified concentration and other shell materials;

a shell fixative, i.e., 0.1mol/L CaCl₂And (3) solution.

(3) The cells used were: human Umbilical Vein Endothelial Cells (HUVECs) (purchased from ATCC), liver cancer cells (HepG2, purchased from ATCC), human fibroblasts (purchased from ATCC), rat mesenchymal stem cells (MSC, primary).

(1) Mu.l NaOH solution was mixed with 750. mu. l I collagen, and 130. mu.l cell suspension (cell concentration 1X 10) was added thereto⁵Pieces/ml, suspended in PBS), to obtain 1ml of cell envelope, which was used as a nuclear layer material.

(2) 50ml of 5 wt% sodium alginate oxide solution is prepared and used as a shell layer material.

(3) 300ml of 0.1M CaCl is prepared₂The solution is placed in a beaker for fixing the shell materialAnd (4) determining.

(4) The core layer material prepared as above was placed in a 2ml syringe and 50ml of the shell layer material was placed in a wrapping bottle of a pelletizer, and then, pelletization and coating were performed with the core layer material and the shell layer material.

(5) Collecting the product of the step (4) in a container with 300ml of 0.1mol/L CaCl₂And (5) fixing the solution in a beaker for 5min to prepare the biological brick. The prepared biological brick can be stored at 4 ℃ or can be directly used for 3D biological printing.

Example 5 characterization of Biobricks with Shell containing oxidized alginate

This example specifically analyzes the properties of the bio-brick prepared by the method of example 4, including the size of the bio-brick, the thickness and mechanical protection of the shell layer, the number of cells contained, and the like.

The biobrick prepared by the method of example 4 was observed using a microscope. During the preparation process, different dimensions of bio-brick were prepared using different instrument parameters of the granulator (e.g., the diameter of the inner and outer nozzles of the concentric nozzle). The results show that the dimensions of the bio-brick can be controlled by controlling the instrumental parameters of the pelletizer (e.g., the diameter of the inner and outer nozzles of the concentric nozzle). The size of the biological brick is controllable and can be selected according to the requirement.

The shell thickness of the bio-brick prepared by the method of example 4 was further observed using a microscope. The results show that the thickness of the shell can be controlled by controlling the diameter of the inner and outer nozzles of the concentric nozzle of the granulator, the pumping speed of the shell material, and other parameters. The shell thickness of the biological brick is controllable and can be selected according to requirements.

The number of cells contained in the bio-brick prepared by the method of example 4 was further observed using a microscope. The results show that the cell number wrapped by the biological brick can be controlled by controlling the cell concentration of the cell suspension. The number of cells contained in the biological brick of the invention is controllable and can be selected according to the needs.

In addition, the mechanical properties of the bio-brick prepared by the method of example 4 were also examined using a Hysitron model TI-950 nanoindenter, USA, according to the manufacturer's instructions. The result shows that the biological brick has excellent mechanical protection performance, and can effectively prevent cells in the biological brick from being subjected to external mechanical damage/mechanical damage. Furthermore, it has been found that the mechanical protection of the bio-brick can be controlled by controlling parameters such as the thickness of the shell and the material of the shell of the bio-brick (data not shown). The mechanical protection performance of the biological brick is controllable and can be selected according to the requirement.

Example 6 Regulation of degradation Rate of Biobrick Shell

In this example, the shell degradation rate of the bio-brick was investigated. The bio-brick used in this example was prepared essentially as described in example 4, with the instrument parameters (e.g., diameter of inner and outer nozzles of concentric nozzles), cells (type and number), core layer material, and shell layer material of the pelletizer used being adjusted according to the experimental setup. Also, in this example, the shell degradation rate of the prepared bio-brick was measured by the following method: and (3) culturing the biological bricks in an incubator at 37 ℃, detecting the mass of the biological bricks at a specified time point, and determining the weight loss rate of the biological bricks. In addition, a weight loss rate-time curve can be drawn as a degradation curve of the shell layer of the biological brick.

First, we examined the type and number of cells used, and the effect of the degree of oxidation of oxidized sodium alginate on the rate of degradation of the bioceramic shell.

The bio-brick was prepared according to the method described in example 4, wherein the cells used were HUVEC, HepG2 and MSC; the cell density used was 4X 10⁶/mL，6×10⁶Per mL, or 12X 10⁶Per mL; the nuclear layer material is I type collagen wrapping cells; the shell layer material used is 5 wt% of oxidized sodium alginate, and the oxidation degree of the oxidized sodium alginate is 2.5%, 4.4%, 8.8%, 17.6% or 22%. Subsequently, the shell degradation rate of the prepared bio-brick was measured according to the above-described method. The measurement results are shown in table 1.

Table 1.

The results show that the type and number of cells used for preparing the bio-brick and the oxidation degree of the oxidized sodium alginate can influence the degradation speed of the shell layer of the bio-brick. Specifically, (1) the faster the growth and proliferation rate of the cells, the faster the degradation rate of the shell of the bio-brick. For example, HUVEC/HepG2 cells grew and proliferated faster than MSCs, and thus, under equivalent conditions, the shell of the biobrick containing HUVEC/HepG2 degraded faster than the biobricks containing MSCs, as shown in biobricks 4 and 9. (2) The greater the number of cells, the faster the degradation rate of the bio-brick shell, for example, as shown in bio-bricks 5 and 7. (3) The higher the degree of oxidation of the oxidized sodium alginate, the faster the shell of the bio-brick will degrade, for example, as shown in bio-bricks 4-6, or bio-bricks 9 and 11.

Secondly, the influence of the concentration of oxidized sodium alginate in the shell layer of the biological brick on the degradation speed of the shell layer of the biological brick is detected.

The bio-brick was prepared as described in example 4, wherein the core material used was type I collagen encapsulating the cells; the shell material used was oxidized sodium alginate at the indicated concentration (5%, 6%, 7%, 8%, 9%, or 10%) and the degree of oxidation of oxidized sodium alginate was 8.8%. Subsequently, the shell degradation rate of the prepared bio-brick was measured according to the above-described method. The results are shown in Table 2.

TABLE 2

The experimental result shows that the concentration of oxidized sodium alginate in the shell layer of the biological brick can influence the degradation speed of the shell layer of the biological brick. In particular, the higher the concentration of oxidized sodium alginate, the slower the degradation rate of the bio-brick shell.

In addition, we have also investigated the effect of the presence of other biodegradable materials (e.g., sodium alginate) in the bioceramic shell on the rate of degradation of the bioceramic shell. In particular, sodium alginate and oxidized sodium alginate in different proportions are used for preparing the shell layer of the biological brick, and the influence of the proportion of the sodium alginate and the oxidized sodium alginate on the degradation speed of the shell layer of the biological brick is researched.

The bio-brick was prepared as described in example 4, wherein the core material used was type I collagen encapsulating the cells; the shell layer material used is Oxidized Sodium Alginate (OSA) with a specified ratio and Sodium Alginate (SA) with a specified ratio, and the total concentration of the Oxidized Sodium Alginate (OSA) and the Sodium Alginate (SA) is 5%. Subsequently, the shell degradation rate of the prepared bio-brick was measured according to the above-described method.

The result shows that the degradation speed of the shell layer of the biological brick is reduced due to the reduction of the content of the oxidized sodium alginate in the shell layer of the biological brick. Particularly, the higher the proportion of the oxidized sodium alginate in the shell layer is, the faster the degradation speed of the shell layer of the biological brick is; on the contrary, the lower the proportion of the oxidized sodium alginate in the shell layer, the slower the degradation speed of the shell layer of the biological brick. The results are shown in Table 3.

TABLE 3

Furthermore, we examined the effect of the type of cells used on the degradation rate of the bioceramic shell.

The bio-brick was prepared according to the method described in example 4, wherein the cells used were MSC, HUVEC, HepG2 or fibroblasts; also, in the preparation of the bio-brick, the same cell density (e.g., 6 × 10) is used⁶mL), the same core layer material (e.g. type I collagen), the same shell layer material (e.g. 5 wt% oxidized sodium alginate, and the degree of oxidation of oxidized sodium alginate is 8.8%), and the same instrument parameters of the granulator are used. Subsequently, the shell drop of the prepared bio-brick containing different types of cells was determined according to the method described aboveAnd (5) solving the speed.

The results show that the type of cells used to prepare the bio-brick can affect the rate of degradation of the bio-brick shell. Specifically, the faster the growth and proliferation rate of the cells, the faster the degradation rate of the shell of the bio-brick. For example, HUVEC/HepG2 cells grew and proliferated faster than MSCs, and thus, under equivalent conditions, the shell of the biobrick containing HUVEC/HepG2 degraded faster than the biobrick containing MSCs.

In addition, we examined the effect of the number of cells used on the degradation rate of the bioceramic shell.

The bio-brick was prepared as described in example 4, wherein the cell density used was 4X 10⁶/mL，6×10⁶/mL，8×10⁶/mL，12×10⁶/mL，16×10⁶Per mL, or 24X 10⁶Per mL; also, in the preparation of the bio-brick, the same cells (e.g., HepG2 cells), the same core layer material (e.g., type I collagen), the same shell layer material (e.g., 5 wt% oxidized sodium alginate, and the degree of oxidation of oxidized sodium alginate is 8.8%), and the same instrument parameters of the granulator were used. Subsequently, the shell degradation rate of the prepared bio-bricks containing different numbers of cells was determined according to the method described above.

The results show that the number of cells used to prepare the bio-brick can affect the rate of degradation of the bio-brick shell. Specifically, the greater the number of cells, the faster the degradation rate of the bioceramic shell. Conversely, the smaller the number of cells, the slower the degradation rate of the shell of the bio-brick.

In addition, the influence of the shell thickness of the prepared biological brick on the degradation speed of the shell of the biological brick is also detected.

The bio-brick was prepared according to the method described in example 4, wherein the same cells (e.g., HepG2 cells) and the same cell density (e.g., 6X 10) were used in the preparation of the bio-brick ⁶mL), the same core layer material (e.g. type I collagen), the same shell layer material (e.g. 5 wt% oxidized sodium alginate, and the degree of oxidation of oxidized sodium alginate is 8.8%), but by adjusting the granulationInstrumental parameters of the apparatus (e.g., diameters of inner and outer nozzles of concentric nozzles) bio-brick with different shell thicknesses were prepared. Subsequently, the shell degradation rate of the prepared bio-bricks having different shell thicknesses was measured according to the above-described method.

The results show that the shell thickness of the bio-brick can affect the time required for complete degradation of the shell of the bio-brick. Specifically, the thicker the shell of the bio-brick, the longer the time it takes for the shell to completely degrade.

Example 7 preparation and characterization of biological ink

This example prepared a bio-ink for bio-printing by uniformly mixing a bio-brick prepared according to the method described in example 1 with a bio-binder. The biological adhesive is sodium alginate + gelatin.

Immediately after the biological ink was prepared, observation was performed using a phase contrast microscope. For the convenience of observation, methyl violet dye is added into the nuclear layer when the biological brick is prepared. The observation results are shown in fig. 7A.

Fig. 7A shows a photomicrograph of a biological ink prepared using the bio-brick of the present invention. Wherein, the biological brick comprises Human Umbilical Vein Endothelial Cells (HUVEC), the main component of the shell layer is calcium alginate, the main component of the core layer is sodium alginate + type I collagen, and the biological brick comprises methyl violet dye; the main components of the biological adhesive are sodium alginate and gelatin. In addition, because the biological brick and the biological adhesive have the same partial components, the biological brick is added with methyl violet dye for the convenience of observation. Thus, in fig. 7A, the bio-brick appears purple. As shown in fig. 7A, the purple staining is only present inside the bio-brick and not in the carrier of the bio-ink (bio-adhesive). This indicates that the shell layer of the bio-brick is able to maintain the integrity of the bio-brick in the bio-ink.

Further, the bioink prepared as above was printed as a single cell layer (width about 250) μm and observed using a microscope. The observation results are shown in fig. 7B.

FIG. 7B shows a photomicrograph of a monolayer printed with a biological ink of the invention. Wherein, the biological brick comprises Human Umbilical Vein Endothelial Cells (HUVEC), the main component of the shell layer is calcium alginate, the main component of the core layer is sodium alginate + type I collagen, and the biological brick comprises methyl violet dye; the main components of the biological adhesive are sodium alginate and gelatin. In fig. 7B, the bio-brick is shown purple due to the presence of methyl violet dye. As shown in fig. 7B, the purple staining was only present inside the bio-brick and not in the carrier of the bio-ink (bio-adhesive). This indicates that the shell of the bio-brick is able to maintain the integrity of the bio-brick during the bio-printing process.

To further characterize the biological ink, the viscosity of the bioadhesive was measured as a function of temperature (25 ℃ C. -40 ℃ C.) using a viscometer. The results are shown in FIG. 8.

Fig. 8 shows the viscosity analysis of the bioadhesive (sodium alginate + gelatin) used. The results show that the viscosity of the bioadhesive used is from 30 to 160Pas at 25 ℃ to 40 ℃; also, as the temperature increases, the viscosity of the bioadhesive decreases. In addition, it has also been found that the viscosity of the bio-adhesive after mixing with the bio-brick (i.e., bio-ink) does not change significantly (data not shown). The viscosity of the biological ink is primarily dependent on the viscosity of the carrier (e.g., bioadhesive).

The viscosity of the bio-ink/bio-adhesive can be adjusted by controlling the type and amount of components of the bio-adhesive. Typically, bioink inks having viscosities in the range of 1-1000Pas are compatible with bioprinters. Thus, the biological ink of the present invention can be used in bioprinting systems known in the art at temperatures of 4-40 ℃.

Example 8 cell-related Performance analysis of BioTile/Bioink

Viability of cells

In this experiment, the cell activity in the bio-brick was examined by staining. The reagents used were as follows:

Calcein CaAM (company: Invitrogen, cat # C3100MP), used for live cell staining, was able to label the cell plasma and showed green fluorescence. The using method comprises the following steps: 50ug of calcein was dissolved in 10ul of DMSO, then 10ml of PBS was added and mixed well. The final concentration of calcein in the obtained solution was 5 mmol/l.

Propidium iodide nucleic acid dye (company: Invitrogen, cat # P1304MP), used for dead cell staining, was able to label the nucleus of the cell, showing red fluorescence. The using method comprises the following steps: propidium iodide nucleic acid dye was diluted to 1mg/ml with double distilled water as a stock solution; the stock solution was then diluted to a final concentration of 500nM with PBS at a ratio of 1:3000 and used as a working solution.

The dyeing method comprises the following steps:

the bio-brick prepared by the method of example 1 (comprising HUVEC, 100 cells/bio-brick) was placed in 1ml CaAM and incubated at 37 ℃ for 1 h; then 1ml propidium iodide nucleic acid dye was added and stained for 15 min. Thereafter, the staining results of the bio-brick were observed using a confocal laser microscope. The results are shown in FIGS. 9A-9D.

Fig. 9A shows the results of an analysis of cell viability in a bio-brick performed immediately after bio-brick preparation. In fig. 9A, the white circles of each marker represent one bio-brick, and the highlight dots are red fluorescence (representing dead cells) and the highlight dots are green fluorescence (representing live cells). And (3) performing color clustering statistics on red and green by using image pro plus software, and calculating the number, the area, the average optical density, the diameter and the accumulated optical density of the red light spots and the green light spots, so as to determine the number of red and green pixel points and calculate the cell survival rate. The cell survival rate is the number of living cells/(number of living cells + number of dead cells). The results of fig. 9A show that more than 98% of the cells in the bio-brick survived after the bio-brick was prepared by the method of example 1.

Fig. 9B shows the results of the analysis of cell viability in the bio-brick after storing the prepared bio-brick at 4 ℃ for 3 hours. In fig. 9B, the white circles of each marker represent a biological tile, and the highlight dots are red fluorescent (representing dead cells) and the highlight dots are green fluorescent (representing live cells). Cell viability was calculated using image pro plus software as shown in figure 9A. The results in fig. 9B show that the cells in the prepared bio-brick remained highly viable (90% survival) after 3 hours of storage at 4 ℃.

Fig. 9C shows the results of an analysis of cell viability in a bio-brick performed immediately after the bio-brick was prepared as a bio-ink and bioprinted. In fig. 9C, the highlight dots are red fluorescence (representing dead cells) and the highlight dots are green fluorescence (representing live cells). Cell viability was calculated using image pro plus software as shown in figure 9A. The results in fig. 9C show that the cells in the bio-brick remained highly viable (97% survival) after the bio-brick was prepared as a bio-ink and immediately bioprinted.

FIG. 9D shows the results of cell viability analysis in the prepared bio-brick after 5 days of culture in H-DMEM medium at 37 ℃. In fig. 9D, the highlight dots are red fluorescence (representing dead cells) and the highlight dots are green fluorescence (representing live cells). Cell viability was calculated using image pro plus software as shown in figure 9A. The results in fig. 9D show that the cells in the prepared bio-brick remained highly viable (95% survival) after 5 days of culture at 37 ℃.

Cell adhesion and spreading

Biobrick containing HepG2 cells at 37 ℃ 5% CO₂H-DMEM medium containing 10% FBS (fetal bovine serum) for 5 days to allow cells to spread, proliferate, and establish connections (i.e., adhesion) between cells within the bio-brick. As described above, biobricks were double stained with calcein (green fluorescence) and propidium iodide (red fluorescence) and observed using a laser confocal microscope. The observation results are shown in FIGS. 10A to 10B.

Proliferation of cells

Biobrick containing HepG2 cells (100 cells/biobrick) at 37 ℃ 5% CO₂And cultured in H-DMEM medium containing 10% FBS (fetal bovine serum) for 5 days to allow the cells to proliferate. Subsequently, the cells were double stained using DAPI (blue fluorescence) and EdU (red fluorescence), and observed using a laser confocal microscope. The observation results are shown in fig. 11.

Comparison of BioTile with cellular microspheres

In this experiment, the proliferation/ligation of cells in the bio-brick of the present invention was compared with the proliferation/ligation of cells in cell microspheres prepared by conventional methods.

The cell microspheres were prepared by the following conventional method: directly wrapping the cells with sodium alginate by using a pelleting machine to form cell liquid drops; subsequently, the cell droplets were placed in CaCl₂In the solution, the sodium alginate forms calcium alginate under the action of calcium ions, thereby crosslinking and solidifying the cell drops into fine particlesA cytomicrosphere.

In addition, a bio-brick was prepared by the method of example 1, wherein the used cells were HepG2 cells, the main component of the shell layer was calcium alginate, and the main component of the core layer was sodium alginate + type I collagen.

The cell microspheres and the biological bricks prepared above are placed at 37 ℃ and 5% CO₂The culture was carried out for 7 days in the environment. Also, before and after 7 days of culture, the cell microspheres and bio-brick were stained with calcein (green fluorescence). The staining results are shown in FIGS. 12A-12E.

FIGS. 12A-12B show the cell proliferation (500 μm on a scale) of cell microspheres prepared by a conventional method during culture. The results show that cell proliferation was not evident in the cell microspheres after 7 days of culture (fig. 12B), cells were rounded, scattered and no connections were established between cells compared to before culture (fig. 12A).

FIGS. 12C-12D show the cell proliferation (500 μm on a scale) during culture of the bio-brick prepared by the method of example 1. The results show that after 7 days of culture (fig. 12D) cell proliferation was evident in the bio-brick compared to before culture (fig. 12C), and the cells stretched, adhered, and linked together in the bio-brick.

FIG. 12E shows a micrograph (100 μm on a scale) of a biobrick prepared using the method of example 1 after 7 days of culture. The results show that HepG2 cells in the bio-brick are interconnected to form an organic whole.

The results of fig. 12A-12E show that the bio-brick of the present invention can better promote the proliferation of cells and the establishment of connections between cells, compared to the cell microspheres prepared by the conventional method. This is of great significance for subsequent tissue formation.

Establishment of intercellular junctions-1

In this experiment, confocal microscopy was used to observe the establishment of intercellular junctions inside the bio-brick.

The bio-brick was prepared by the method of example 1, wherein the cells used were HepG2 labeled with cell tracker Green CMFDA (Green fluorescent), and human HUVEC cells labeled with cell tracker Green CMFDA (Green fluorescent)Marker with tracker CM-Dil (red fluorescence); the main components of the shell layer are calcium alginate, and the main components of the core layer are sodium alginate and I type collagen. The prepared biological brick is processed at 37 ℃ and 5% CO₂The culture was incubated for 7 days under the environment, followed by observation with a confocal microscope. The observation results are shown in fig. 13.

FIG. 13 shows the results of observation of the bio-brick (scale 100 μm in the figure) after 7 days of culture using a confocal microscope, wherein the bio-brick used contains both HepG2 cells labeled with green fluorescence and HUVEC cells labeled with red fluorescence, and the yellow region in the figure is due to superposition of red fluorescence and green fluorescence, indicating that a link was established between HepG2 cells and HUVEC cells. The results show that intercellular connections are established between HepG2 cells, between HUVEC cells and between HepG2 cells and HUVEC cells in the biological brick.

Establishment of intercellular junctions-2

In this experiment, a confocal microscope was used to observe the establishment of cell connections between biological tiles.

The bio-brick was prepared by the method of example 1, in which the main component of the shell layer was calcium alginate and the main component of the core layer was sodium alginate + type I collagen. The biological brick is prepared at 37 ℃ and 5% CO₂After culturing for 7 days in the environment, observation was performed by a confocal microscope. The results are shown in FIGS. 14A-14C.

The results of this example show that cells have high viability (viability of 98% or more) within the bio-brick of the invention and are capable of normal growth, proliferation, expansion and differentiation within the bio-brick. In addition, the results of this example also show that intercellular connections can be established between cells within a bio-brick and between cells of different bio-bricks. This shows that the bio-brick and the preparation method thereof of the present invention can effectively maintain the viability of cells, and can promote the proliferation of cells in the bio-brick and the establishment of connection between cells, thereby being advantageously used in various downstream applications, such as bioprinting.

Example 10 preparation of Biobrick comprising endothelial cells and mesenchymal Stem cells

Materials and cells used in the method of this example:

Nuclear material: 4mg/ml type I collagen, neutralized with sterile 1M NaOH;

shell material: 1 wt% polylysine

Seed cell: HUVEC and MSC were mixed at 1:10 to a total cell concentration of 3.7x10⁶/ml

The steps of the method of this embodiment are as follows:

1. preparing a U-shaped bottom super-hydrophobic pore plate: cleaning the U-shaped bottom hole plate with alcohol in an ultraclean room, and placing the U-shaped bottom hole plate into a hydrogen peroxide/concentrated sulfuric acid solution (30% (v/v), H)₂O₂:H₂SO₄1:3) at 80 ℃ for 1 hour, to obtainAnd carrying out hydroxylation treatment. The hydroxylated U-shaped bottom well plate was placed in a 1% 1H,1H,2H, 2H-perfluorodecyltriethoxysilane (Sigma) solution for 12 hours, and then heated in an oven at 100 ℃ for 4 hours to conduct silicification. And finally, cleaning the U-shaped bottom hole plate and air-drying.

2. Preparing a collagen solution containing seed cells: mu.l NaOH solution (1mol/L) was mixed with 750. mu. L I type collagen (4mg/mL), and then 130. mu.l of a mixed suspension of HUVEC mixed at 1:10 and rat MSC cells labeled with Tracker CM-Dil (total cell concentration 3.7X 10)⁶/ml, suspended in PBS), a collagen solution mixed with the seed cell cells was obtained.

3. Preparation of polylysine-FITC solution: poly-lysine (Sigma, number average molecular weight Mn 150,000-300,000) labeled with FITC (green fluorescence) was dissolved in DMEM high-sugar medium at pH7.2 to obtain a poly-lysine solution at a concentration of 1 wt%.

4. Collagen drop wise (formation of nuclear layer structure): an Electronic suction device capable of sucking and discharging nanoliter liquid is adopted (for example, Eppendorf Xplorer 0.5-10uL or transfer Electronic 0.5-10uL, the minimum liquid volume per minute can reach 0.1 mul by virtue of the liquid separation function of Eppendorf Xplorer, or an SGE automatic sample injector 1 mul or 0.5 mul can respectively realize 0.1 mul liquid titration for 10 times and 5 times, and particularly, a conical special needle can be used for titration to improve the precision.) 0.1 mul of the type I collagen solution prepared in the step 2 is precisely sucked and dripped into the U-shaped bottom super-hydrophobic pore plate prepared in the step 1 to form liquid drops, and the liquid drops are kept at the constant temperature of 37 ℃ for 30min to be molded.

5. Adding polylysine-FITC solution (shell structure): and (3) precisely sucking 0.5 mu l of the polylysine-FITC solution prepared in the step (3) after the suction head is replaced, dripping the polylysine-FITC solution on the surface of the nuclear layer formed in the step (4) at the central position of the super-hydrophobic pore plate, and reacting for 10min to form the biological brick containing HUVEC and MSC.

Example 11 bioprinting of three-dimensional constructs

This example illustrates the use of a bioink comprising a bio-brick prepared according to the method described in example 1, using which a three-dimensional construct (e.g. a blood vessel) was constructed by bioprinting.

Fig. 15 schematically depicts a flow chart for bioprinting blood vessels using the bio-brick/bio-ink of the present invention. Specifically, the method comprises the following steps:

(1) endothelial cells, smooth muscle cells and fibroblasts of the blood vessels were stained with DIO (green), michacker (red) and hoechst (blue), and then biological information of the rat blood vessels was collected and a digital model of the vascular structure was constructed. According to this model, blood vessels are divided into three layers, i.e., vascular endothelial cells located at the innermost layer, vascular smooth muscle cells located at the middle layer, and fibroblasts located at the outermost layer.

(2) Using the method described in example 1, bio-bricks comprising vascular endothelial cells, bio-bricks comprising vascular smooth muscle cells, and bio-bricks comprising fibroblasts were constructed. Wherein, the used vascular endothelial cells, vascular smooth muscle cells and fibroblasts are primary cultured cells derived from rats respectively; the core layer material and shell layer material used are as described in example 1. In addition, in order to promote cell proliferation and differentiation, Vascular Endothelial Growth Factor (VEGF) is added to the bio-brick nucleus layer containing vascular endothelial cells; adding Platelet Derived Growth Factor (PDGF) to the layer of the biological brick nucleus comprising vascular smooth muscle cells; fibroblast Growth Factor (FGF) is added to the layer of biological brick nuclei containing fibroblasts.

The size of the prepared biological brick containing the vascular endothelial cells is about 30 mu m, and the biological brick contains 2-3 vascular endothelial cells; the biological brick containing the vascular smooth muscle cells has the size of about 200 mu m and contains about 50 vascular smooth muscle cells; the bio-brick containing fibroblasts is about 100 μm in size and contains about 10 fibroblasts.

(3) And respectively mixing the biological adhesive with the 3 biological bricks obtained in the previous step to prepare three biological inks. The biological adhesive is sodium alginate and gelatin; the dosage ratio of the biological adhesive to the biological brick is 1:4 (by weight).

It should be noted that step (1) may be performed before, simultaneously with, or after steps (2) and (3).

(4) And (3) printing in a rotary printing mode by using a 3D bioprinter. In the printing process, the digital model of the blood vessel structure is used as a template, and corresponding biological ink is used for biological printing, wherein as shown in fig. 2, the innermost structure of the blood vessel is printed by using biological ink containing biological bricks containing blood vessel endothelial cells, the middle structure is printed by using biological ink containing biological bricks containing blood vessel smooth muscle cells, and the outermost structure is printed by using biological ink containing biological bricks containing fibroblasts. The bio-brick is cured by the bio-adhesive to form the blood vessel precursor.

(5) The vessel precursors were placed in a three-dimensional incubator at 37 ℃ with 5% CO₂The angio-precursors were cultured using a conventional cell culture medium (H-DMEM medium + 10% fetal bovine serum). During the culturing process, a physical stimulus, such as shear force, may be applied to the vascular precursor. Culturing for 7-10 days to make blood vessel precursor form blood vessel.

Example 12 preparation of Biobrick comprising endothelial cells and Primary rat liver cells and bioprinting thereof

The method described in example 10 was used to prepare a bio-brick, wherein a mixture of adipose-derived Mesenchymal Stem Cells (MSC) and primary cultured liver cells (Hepatocyte) mixed in a ratio of 10:1 was used as seed cells; using type I collagen as a core material; and, polylysine was used as the shell material. Using a 3D bioprinter to perform bioprinting on the prepared biological brick, and placing the biological brick at 37 ℃ and 5% CO₂And cultured in an H-DMEM environment containing 10% fetal calf serum for 7 days to prepare an artificial liver tissue. Subsequently, HE staining and immunohistochemical staining for albumin were performed on the obtained artificial liver tissue, and the results are shown in fig. 16. The HE staining results of fig. 16 show that in the artificial liver tissue obtained using biobrick printing, the cells are arranged in a cord-like arrangement, and the artificial tissue produces a structure similar to a liver lobule, similar to normal liver tissue. In addition, the immunohistochemical staining results of FIG. 16 show that liver cells located inside the artificial liver tissue were able to normally secrete the liver-specific protein Albumin (Albumin), whereas marginally located non-albumins The liver cells do not express albumin. The experimental results show that the biological brick can be used for biologically printing artificial liver tissues.

Example 13 bioprinting of constructs comprising microvessels

The bio-brick prepared in example 10 was printed in a ring-like structure using a 3D bio-printer and placed at 37 ℃ with 5% CO₂And culturing in H-DMEM environment containing 10% fetal calf serum for 9 days. The cultured artificial tissue was sectioned, and the section was stained with CD31(RD, US). The staining results are shown in FIG. 17. The results showed that a large number of microvessels appeared in the artificial tissue obtained using the bio-brick printing (fig. 17). The results of these experiments indicate that the prepared bio-brick can be used for bioprinting a construct containing microvessels.

EXAMPLE 14 Effect of different species and ratios of seed cells on microvascular formation

Biobricks were prepared using the cell combinations described in the following table using the method described in example 10, and then the prepared biobricks were printed, cultured, sliced and stained using the method described in example 11, and the microvascular structures in the obtained artificial tissues were observed, and the results are shown in fig. 18A-I, respectively.

TABLE 4

Note: BMSC: bone marrow-derived mesenchymal stem cells;

HUMSC is human umbilical cord mesenchymal stem cells;

SMC vascular smooth muscle cells.

It can be seen that when the seed cells were HUVEC and BMSC, microvessel formation was seen with the combination of HUVEC and BMSC at various ratios between 1:1.5 and 1:20, and especially when the ratio of HUVEC and BMSC was 1:10, a large number of microvessels were able to be formed (fig. 18A-F). While microvessel formation was also seen when rat liver cells were present in seed cells in addition to HUVEC and BMSC (data not shown); in particular, when HUVEC: when BMSC was 1:1:10, a large number of microvessels were visible (fig. 18G). In addition, when SMC (vascular smooth muscle cells) was present in the seed cells in addition to HUVEC and BMSC, microvascular formation was also observed (fig. 18H). While microvessel formation was also seen with combinations of HUVEC and HUMSC at different ratios between 1:1.5 and 1:20 when the seed cells were HUVEC and HUMSC (data not shown). For example, microvessel formation was seen when the ratio of HUVEC to HUMSC was 1:3 (fig. 18I).

Example 15: various applications of biological bricks

Studies of Stem cell differentiation

A plurality of isolated bio-bricks each comprising mesenchymal stem cells derived from bone marrow are prepared. An agent or combination of agents that induces differentiation of stem cells towards osteoblasts, adipocytes, chondrocytes or myocytes is added to each isolated bio-brick. The plurality of isolated bio-bricks are cultured in the same culture system, for example, in the same container (e.g., petri dish or flask). Cells in each of the isolated bio-bricks were observed, expression of stem cell markers in the cells was analyzed, and the effect of different microenvironments on stem cell differentiation was evaluated.

Tissue regeneration

This example provides an exemplary method of tissue regeneration for repairing large wounds in the skin, avoiding large scars that may result from the natural healing process of the large wound.

First, a wound is scanned using medical imaging methods to obtain structural information of the skin and the wound site.

Secondly, based on medical imaging data, a digital repair model is constructed according to structural information of the wound and cell distribution information of skin tissues. Further, based on the digital repair model, corresponding types of biological bricks are prepared, including biological bricks containing fibroblasts and biological bricks containing endothelial cells. These bio-bricks are then used for bioprinting directly on the wound according to a digital repair model.

In some cases, the cells in the bio-brick are derived from autologous stem cells obtained from the same subject. After bioprinting, the cells in the bio-brick proliferate and differentiate in different layers and microenvironments of the wound site, forming corresponding tissue layers and structures, thereby repairing the wound of the skin.

Example 16: various applications of constructs

In vitro study of tissue development Using constructs

A plurality of bio-bricks are prepared, each comprising different types of stem cells. Bioprinting was performed using the prepared bio-brick according to the cell distribution pattern of the tissue of interest to obtain the corresponding construct (i.e., tissue precursor). The obtained tissue precursor is cultured in vitro under suitable conditions to develop it into the tissue of interest. Exposing cells in a biological brick to a candidate agent or combination of agents that may affect tissue development. Then, the cell change in the bio-brick and the tissue development process change were observed throughout the development process.

In vivo study of graft immunology

A bio-brick is prepared comprising cells derived from a subject (experimental animal) to be subjected to tissue transplantation. Bioprinting is performed using the prepared bio-brick to obtain a tissue precursor or an artificial tissue. Subsequently, the tissue precursor or artificial tissue is implanted into the subject and the subject is observed for an immunological response to the tissue precursor or artificial tissue, including biocompatibility and immunological rejection.

Drug discovery

Suitable bio-bricks are prepared and printed as artificial tissue associated with the pharmaceutical function. Such artificial tissue may be healthy tissue or diseased tissue depending on the conditions used in the manufacturing process, such as the source of the cells in the bio-brick, the reagents or stimuli contained in the nuclear layer of the bio-brick, or the culture conditions. Exposing the obtained artificial tissue to a set of compounds and, optionally, comparing the effect of each compound on diseased artificial tissue with the effect of the same compound on corresponding healthy artificial tissue, thereby determining the therapeutic effect of each compound on a disease associated with the tissue. Toxicity and side effects of various compounds are also determined based on their effect on healthy, engineered tissues. Subsequently, the compound with the best therapeutic effect and/or the lowest toxicity and side effects, or the compound that achieves the best balance between therapeutic effect and side effects, is identified as the lead compound for further drug development.

While specific embodiments of the invention have been described in detail, those skilled in the art will understand that: various modifications and changes in detail can be made in light of the overall teachings of the disclosure, and such changes are intended to be within the scope of the present invention. The full scope of the invention is given by the appended claims and any equivalents thereof.

Claims

1. A method of making a construct comprising a microvessel, comprising the step of bioprinting with a bio-brick or a composition comprising a bio-brick; wherein the bio-brick comprises: a cell, a core layer encapsulating the cell, and, a shell layer encapsulating the core layer; the core layer and the shell layer of the biological brick are respectively and independently made of biodegradable materials; wherein the cells encapsulated by the nuclear layer comprise endothelial cells;

the biological brick is a basic unit for biological printing, and has certain mechanical strength, so that three-dimensional stacking can be realized; the thickness of the shell layers is 2-50 μm respectively; the bio-brick has a hardness of 0.01-0.4GPa, and an elastic modulus of 0.01-10 MPa;

the biodegradable materials used to prepare the core and shell layers are each independently naturally occurring, synthetic, recombinantly produced, modified, or any combination thereof,

The naturally occurring biodegradable material is selected from the group consisting of collagen, elastin, fibrin, chitosan, alginate, starch, hyaluronic acid, laminin, agarose, gelatin, dextran, and any combination thereof,

the modified biodegradable material is oxidized alginate,

the synthetic biodegradable material is selected from polyphosphazenes, polyacrylic acid and derivatives thereof, polylactic acid, polyglycolic acid, polylactic acid-glycolic acid copolymers, polyorthoesters, polycaprolactone, polyhydroxybutyrate, polyamino acids, degradable polyurethanes, and any combination thereof.

2. The method of claim 1, wherein the construct is a three-dimensional construct, a tissue precursor, a tissue or an organ.

3. The method of claim 1, wherein said nuclear layer encapsulated cells further comprise undifferentiated cells.

4. The method of claim 3, wherein said undifferentiated cells are selected from stem cells, progenitor cells, or a combination thereof.

5. The method of claim 1, wherein the method produces a construct having a predetermined pattern.

6. The method of claim 5, wherein the subscription mode is any predefined setting.

7. The method of claim 5, wherein the construct is a three-dimensional construct, an artificial tissue, or a precursor thereof.

8. The method of claim 5, wherein the construct has a sheet-like structure, or a hollow three-dimensional structure, or a solid three-dimensional structure, or any combination thereof.

9. The method of claim 8, wherein the sheet-like structure is a rectangular, square, circular, oval, hexagonal, or irregularly shaped sheet-like structure.

10. The method of claim 8, wherein the hollow three-dimensional structure is a hollow tube, a hollow sphere, a hollow rectangular prism, a hollow cylinder, or a hollow irregularly shaped three-dimensional structure.

11. The method of claim 8, wherein the solid three-dimensional structure is a solid sphere, a solid rectangular prism, a solid cylinder, or a solid irregularly shaped three-dimensional structure.

12. The method of claim 5, wherein the construct mimics the shape of a natural tissue or organ.

13. The method of claim 1, wherein said method uses at least 1 of said compositions comprising bio-bricks.

14. The method of claim 13, wherein 2, 3, 4, 5, 6, 7, 8, 9, or 10 of said composition comprising bio-bricks are used in said method.

15. The method of claim 1, wherein the bioprinting step in the method is continuous and/or substantially continuous.

16. The method of claim 1, wherein the method comprises bioprinting a plurality of layers in series to obtain a three-dimensional construct having a predetermined pattern comprising a plurality of layers, wherein each layer is bioprinted with the composition and/or one or more additional compositions according to the predetermined pattern, the additional compositions comprising a second bio-brick comprising cells selected according to a desired construct type.

17. The method of claim 16, wherein the construct type is a tissue type.

18. The method of claim 1, wherein the method comprises bioprinting a plurality of segments in series to obtain a three-dimensional construct having a predetermined pattern comprising a plurality of segments, wherein each segment is bioprinted with the composition and/or one or more additional compositions according to the predetermined pattern, the additional compositions comprising a second bioprinting comprising cells selected according to the desired construct.

19. The method of claim 18, wherein the construct type is a tissue type.

20. The method of claim 1, wherein the method further comprises the step of preparing the composition using a bio-brick.

21. The method of claim 1, wherein the method further comprises the step of preparing the composition using the bio-brick and a carrier.

22. The method of claim 21, wherein the carrier is a bioadhesive.

23. The method of claim 1, further comprising the step of modeling the structure of the construct based on the shape and/or cellular arrangement pattern of the native tissue or organ.

24. The method of claim 23, wherein the construct is a three-dimensional construct.

25. The method of claim 1 which does not mechanically damage cells in the composition or within the bio-brick.

26. The method of claim 25, wherein 80% -85%, 85% -87.5%, 87.5% -90%, 90% -92.5%, 92.5% -95%, 95% -98%, or at least 98% of the cells in the composition or within the bio-brick are capable of surviving, proliferating, differentiating, secreting, migrating, and/or having normal metabolism after bioprinting.

27. The method of claim 1, wherein the method further comprises culturing the obtained construct under conditions that allow proliferation, differentiation, migration, secretion and/or metabolism of cells within the bio-brick.

28. The method of claim 27, wherein the obtained construct is cultured for 0-1, 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, 11-12, 12-13, 13-14, 14-15, 15-16, 16-17, 17-18, 18-19, 19-20, 20-21, 21-25, 25-30, or at least 30 days.

29. The method of claim 27, wherein the obtained construct is cultured in a 3D incubator or bioreactor.

30. The method of claim 27, wherein the construct is subjected to a physical and/or chemical stimulus during the culturing.

31. The method of claim 30, wherein the physical stimulus is selected from the group consisting of pressure, shear force, light, and heat.

32. The method of claim 30, wherein the chemical stimulus comprises a hormone.

33. The method of claim 30, wherein the chemical stimulus comprises a cytokine.

34. The method of claim 30, wherein the chemical stimulus comprises a chemical agent.

35. The method of claim 27, wherein the biodegradable material in the core layer and/or the shell layer and/or the carrier of the bio-brick is at least partially degraded during the culturing.

36. The method of claim 27, wherein the cells within a bio-brick and/or between bio-bricks are attached to each other during the culturing process.

37. The method of claim 1, wherein the method produces constructs having a size of 30-50 μm, 50-100 μm, 100-200 μm, 200-500 μm, 500 μm-1mm, 1-2mm, 2-5mm, 5mm-1cm, 1-2cm, 2-5cm, 5-10cm, 10-20cm, 20-50cm, or at least 50 cm.

38. The method of claim 1, 13, 14, 16, 18, 20, 21, 25, or 26, wherein the composition is a bioinoch.

39. The method of claim 1, wherein the nuclear layer-encapsulated endothelial cells are obtained from an animal; the endothelial cells include venous endothelial cells or arterial endothelial cells.

40. The method of claim 39, wherein the nuclear layer-encapsulating endothelial cells are obtained from a mammal.

41. The method of claim 40, wherein said mammal is selected from the group consisting of a human, an ape, a gorilla, a cow, a pig, a dog, a sheep, and a goat.

42. The method of claim 39, wherein said venous endothelial cells are umbilical vein endothelial cells.

43. The method of claim 39, wherein said venous endothelial cells are human umbilical vein endothelial cells.

44. The method of claim 4, wherein the nuclear layer encapsulated stem cells are pluripotent stem cells.

45. The method of claim 44, wherein said pluripotent stem cell is an induced pluripotent stem cell.

46. The method of claim 4, wherein the nuclear layer encapsulated stem cells comprise mesenchymal stem cells.

47. The method of claim 46, wherein said mesenchymal stem cells are bone marrow, adipose, umbilical cord blood, and/or placenta-derived mesenchymal stem cells.

48. The method of claim 46, wherein said mesenchymal stem cells are bone marrow-derived mesenchymal stem cells.

49. The method of claim 46, wherein the mesenchymal stem cells are obtained from an animal.

50. The method of claim 49, wherein the animal is a mammal.

51. The method of claim 50, wherein said mammal is selected from the group consisting of a human, an ape, a gorilla, a cow, a pig, a dog, a sheep, and a goat.

52. The method of claim 3, wherein the cells encapsulated by the nuclear layer comprise additional cells derived from a tissue selected from the group consisting of: connective tissue, muscle tissue, urogenital tissue, gastrointestinal tissue, lung tissue, bone tissue, neural tissue, and epithelial tissue.

53. The method of claim 3, wherein the cells encapsulated by the nuclear layer comprise additional cells derived from a tissue selected from the group consisting of: tissue derived from endoderm, tissue derived from mesoderm and tissue derived from ectoderm.

54. The method of claim 52, wherein the connective tissue is selected from the group consisting of loose connective tissue, dense connective tissue, elastic tissue, reticulated connective tissue, and adipose tissue.

55. The method of claim 52, wherein said muscle tissue is selected from the group consisting of skeletal muscle, smooth muscle, and cardiac muscle.

56. The method of claim 52, wherein the epithelial tissue is selected from the group consisting of a single epithelium and a stratified epithelium.

57. The method of claim 52, wherein the additional cells are selected from muscle cells, connective tissue cells, bone marrow cells, epithelial cells, or any combination thereof.

58. The method of claim 52, wherein said additional cells are selected from the group consisting of skin cells, breast cells, vascular cells, blood cells, lymphocytes, nerve cells, Schwann cells, gastrointestinal cells, liver cells, pancreatic cells, lung cells, tracheal cells, corneal cells, urogenital cells, kidney cells, or any combination thereof.

59. The method of claim 52, wherein the additional cells are adipocytes.

60. The method of claim 52, wherein the additional cells are parenchymal cells.

61. The method of claim 52, wherein said additional cells are pericytes.

62. The method of claim 52, wherein said additional cells are mesothelial cells.

63. The method of claim 52, wherein the additional cells are stromal cells.

64. The method of claim 53, wherein the additional cells are selected from endodermal-derived cells, mesodermal-derived cells, ectodermal-derived cells, or any combination thereof.

65. The method of claim 52, wherein the additional cells are cancer-derived cells.

66. The method of claim 52, wherein the additional cell is a cell line.

67. The method of claim 57, wherein said muscle cell is selected from the group consisting of a skeletal muscle cell, a cardiac muscle cell, a smooth muscle cell, and a myoblast.

68. The method of claim 57, wherein the connective tissue cells are selected from the group consisting of osteocytes, chondrocytes, fibroblasts, and cells that differentiate into osteoblasts, chondrocytes, or lymphoid tissue.

69. The method of claim 58, wherein said additional cells are hepatocytes.

70. The method of claim 3, wherein said endothelial cells and said undifferentiated cells are encapsulated in the same nuclear layer or different nuclear layers.

71. The method of claim 70, wherein said endothelial cells are in a first nuclear layer and said undifferentiated cells are in a second nuclear layer, or vice versa.

72. The method of claim 52 or 53, wherein said endothelial cells, said undifferentiated cells and said additional cells are encapsulated in the same nuclear layer or different nuclear layers.

73. The method of claim 72, wherein two of said endothelial cells, said undifferentiated cells and said additional cells are in the same nuclear layer and a third is in another nuclear layer.

74. The method of claim 73, wherein two of said endothelial cells, said undifferentiated cells and said additional cells are in a first nuclear layer and a third is in a second nuclear layer.

75. The method of claim 1, wherein said endothelial cells comprise between 1% and 100% of the total number of cells.

76. The method of claim 75, wherein said endothelial cells comprise between 2% and 90% of the total number of cells.

77. The method of claim 75, wherein said endothelial cells comprise between 3% and 80% of the total number of cells.

78. The method of claim 75, wherein said endothelial cells comprise between 4% and 70% of the total number of cells.

79. The method of claim 75, wherein said endothelial cells comprise 5% to 60% of the total number of cells.

80. The method of claim 75, wherein said endothelial cells comprise 5.5% to 50% of the total number of cells.

81. The method of claim 75, wherein said endothelial cells comprise between 6% and 40% of the total number of cells.

82. The method of claim 75, wherein said endothelial cells comprise between 6.5% and 30% of the total number of cells.

83. The method of claim 75, wherein said endothelial cells comprise between 7% and 20% of the total number of cells.

84. The method of claim 75, wherein said endothelial cells comprise between 7.5% and 19% of the total number of cells.

85. The method of claim 75, wherein said endothelial cells comprise 8% to 18% of the total number of cells.

86. The method of claim 75, wherein said endothelial cells comprise 8.5% to 17% of the total number of cells.

87. The method of claim 75, wherein said endothelial cells comprise between 9% and 16% of the total number of cells.

88. The method of claim 75, wherein said endothelial cells comprise between 9.1% and 15% of the total number of cells.

89. The method of claim 75, wherein said endothelial cells comprise between 9.2% and 14% of the total number of cells.

90. The method of claim 75, wherein said endothelial cells comprise between 9.3% and 13% of the total number of cells.

91. The method of claim 75, wherein said endothelial cells comprise between 9.4% and 12% of the total number of cells.

92. The method of claim 75, wherein said endothelial cells comprise between 9.5% and 11.5% of the total number of cells.

93. The method of claim 75, wherein said endothelial cells comprise between 9.6% and 11% of the total number of cells.

94. The method of claim 75, wherein said endothelial cells comprise between 9.7% and 10.9% of the total number of cells.

95. The method of claim 75, wherein said endothelial cells comprise between 9.8% and 10.8% of the total number of cells.

96. The method of claim 75, wherein said endothelial cells comprise between 9.9% and 10.7% of the total number of cells.

97. The method of claim 75, wherein said endothelial cells comprise between 9.9% and 10.6% of the total number of cells.

98. The method of claim 75, wherein said endothelial cells comprise between 9.9% and 10.5% of the total number of cells.

99. The method of claim 75, wherein said endothelial cells comprise between 9.9% and 10.4% of the total number of cells.

100. The method of claim 75, wherein said endothelial cells comprise between 9.9% and 10.3% of the total number of cells.

101. The method of claim 75, wherein said endothelial cells comprise between 9.9% and 10.2% of the total number of cells.

102. The method of claim 75, wherein said endothelial cells comprise between 9.9% and 10.1% of the total number of cells.

103. The method of claim 75, wherein said endothelial cells comprise 10.0% of the total number of cells.

104. The method of claim 3, wherein said undifferentiated cells comprise between 0% and 99% of the total number of cells.

105. The method of claim 104, wherein said undifferentiated cells comprise between 1% and 90% of the total number of cells.

106. The method of claim 104, wherein said undifferentiated cells comprise between 5% and 80% of the total number of cells.

107. The method of claim 104, wherein said undifferentiated cells comprise between 10% and 70% of the total number of cells.

108. The method of claim 104, wherein said undifferentiated cells comprise between 15% and 65% of the total number of cells.

109. The method of claim 104, wherein said undifferentiated cells comprise between 20% and 60% of the total number of cells.

110. The method of claim 104, wherein said undifferentiated cells comprise between 25% and 55% of the total number of cells.

111. The method of claim 104, wherein said undifferentiated cells comprise between 30% and 50% of the total number of cells.

112. The method of claim 104, wherein said undifferentiated cells comprise between 35% and 45% of the total number of cells.

113. The method of claim 104, wherein said undifferentiated cells comprise between 36% and 44% of the total number of cells.

114. The method of claim 104, wherein said undifferentiated cells comprise between 37% and 43% of the total number of cells.

115. The method of claim 104, wherein said undifferentiated cells comprise between 38% and 42% of the total number of cells.

116. The method of claim 104, wherein said undifferentiated cells comprise between 39% and 41% of the total number of cells.

117. The method of claim 104, wherein said undifferentiated cells comprise 39.1%, 39.2%, 39.3%, 39.4%, 39.5%, 39.6%, 39.7%, 39.8%, 39.9%, 40.0%, 40.1%, 40.2%, 40.3%, 40.4%, 40.5%, 40.6%, 40.7%, 40.8%, or 40.9% of the total number of cells.

118. The method of claim 1, wherein the bio-brick comprises one or more cells.

119. The method of claim 118, wherein the bio-brick comprises 1 to 10⁶And (4) cells.

120. The method of claim 119, wherein the bio-brick comprises 10-900 cells.

121. The method of claim 119, wherein the bio-brick comprises 20-800 cells.

122. The method of claim 119, wherein the bio-brick comprises 30-700 cells.

123. The method of claim 119, wherein the bio-brick comprises 40-600 cells.

124. The method of claim 119, wherein the bio-brick comprises 50-500 cells.

125. The method of claim 119, wherein said bio-brick comprises 60-400 cells.

126. The method of claim 119, wherein said bio-brick comprises 70-300 cells.

127. The method of claim 119, wherein the bio-brick comprises 80-200 cells.

128. The method of claim 119, wherein the bio-brick comprises 10-100 cells.

129. The method of claim 119, wherein the bio-brick comprises 10 "10³And (4) cells.

130. The method of claim 119, wherein the bio-brick comprises 10 "10 ⁴And (4) cells.

131. The method of claim 119, wherein the bio-brick comprises 10 "10⁵And (4) cells.

132. The method of claim 119, wherein the bio-brick comprises 10 "10⁶And (4) cells.

133. The method of claim 1, wherein the bio-brick has a size of 20 to 2000 μm.

134. The method of claim 133, wherein the bio-brick has a size of 30 to 1900 μ ι η.

135. The method of claim 133, wherein the bio-brick has a size of 40 to 1800 μ ι η.

136. The method of claim 133, wherein the bio-brick has a size of 50 to 1700 μ ι η.

137. The method of claim 133, wherein the bio-brick has a size of 60 to 1600 μm.

138. The method of claim 133, wherein the bio-brick has a size of 70 to 1500 μ ι η.

139. The method of claim 133, wherein the bio-brick has a size of 80 to 1400 μ ι η.

140. The method of claim 133, wherein the bio-brick has a size of 90 to 1300 μ ι η.

141. The method of claim 133 wherein the size of the biological brick is 100-.

142. The method of claim 133, wherein the dimensions of the bio-brick are 200-1000 μm.

143. The method of claim 133, wherein the dimensions of the bio-brick are 300-800 μm.

144. The method of claim 133, wherein the dimensions of the biological brick are 400-600 μm.

145. The method of claim 133 wherein the dimensions of the bio-brick are 100-500 μm.

146. The method of claim 1, wherein the bio-brick is spherical, rectangular prism, hexagonal prism, cylindrical, or irregular in shape.

147. The method of claim 1, wherein the bio-brick is solid or semi-solid.

148. The method of claim 1, wherein the bio-brick is in a gel state.

149. The method of claim 1, wherein the bio-brick is present in a mixture.

150. The method of claim 1, wherein the bio-brick is an isolated bio-brick.

151. The method of claim 1, wherein the bio-brick is provided in a container.

152. The method of claim 3, wherein the ratio of endothelial cells to undifferentiated cells is from 1:20 to 1:1.

153. The method of claim 152, wherein the ratio of endothelial cells to undifferentiated cells is 1:19, 1:18, 1:17, 1:16, 1:15, 1:14, 1:13, 1:12, 1:11, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, or 1: 1.5.

154. The method of claim 152, wherein the ratio of endothelial cells to undifferentiated cells is 1:11.5, 1:10.5, 1:9.5, or 1: 8.5.

155. The method of claim 152, wherein said endothelial cells are human umbilical vein endothelial cells, said undifferentiated cells are bone marrow-derived mesenchymal stem cells, and the ratio of said human umbilical vein endothelial cells to said bone marrow-derived mesenchymal stem cells is 1: 10.

156. The method of claim 152, wherein the bio-brick further comprises additional cells, wherein the ratio of the number of additional cells to the number of endothelial cells is 1: 1.

157. The method of claim 156, wherein the additional cells are hepatocytes.

158. The method of claim 157, wherein the endothelial cells are human umbilical vein endothelial cells, the undifferentiated cells are bone marrow-derived mesenchymal stem cells, and the ratio of human umbilical vein endothelial cells, hepatocytes, and bone marrow-derived mesenchymal stem cells is 1:1: 10.

159. The method of claim 1, wherein the shell layer of the bio-brick comprises no cells.

160. The method of claim 1, wherein the bio-brick comprises 1, 2, 3, 4, 5 or more nuclear layers.

161. The method of claim 1, wherein the bio-brick comprises at least 2 core layers and each core layer is independently made of a biodegradable material and/or each core layer independently encapsulates the same or different cells or combination of cells.

162. The method of claim 1, wherein the bio-brick comprises 1, 2, 3, 4, 5 or more shells.

163. The method of claim 1, wherein the bio-brick comprises at least 2 shells and each shell is independently made of a biodegradable material.

164. The method of claim 1, wherein the outermost side of the bio-brick comprises at least one shell layer.

165. The method of claim 1, wherein the bio-brick comprises: a core layer and a shell layer; alternatively, one core layer and 2 or more shell layers; or, 2 or more core layers and one shell layer; alternatively, at least 2 core layers and at least 2 shell layers.

166. The method of claim 1, wherein the bio-brick comprises, in order from the inside out: a core layer and a shell layer; or, a core layer, a first shell layer, and a second shell layer; alternatively, a first core layer, a second core layer, and a shell layer; or, a first core layer, a second core layer, a first shell layer, and a second shell layer; alternatively, the first core layer, the first shell layer, the second core layer, and the second shell layer.

167. The method of claim 1, wherein the bio-brick has a hardness of 0.01 to 0.02, 0.02 to 0.03, 0.03 to 0.04, 0.04 to 0.05, 0.05 to 0.06, 0.06 to 0.07, 0.07 to 0.08, 0.08 to 0.09, 0.09 to 0.1, 0.1 to 0.15, 0.15 to 0.2, 0.2 to 0.3, or 0.3 to 0.4 GPa.

168. The method of claim 1, wherein the bio-brick has a hardness of 0.01 to 0.05, 0.05 to 0.1, 0.1 to 0.2, or 0.2 to 0.4 GPa.

169. The method of claim 1, wherein the bio-brick has a hardness of 0.05-0.15 GPa.

170. The method of claim 1, wherein the bio-brick has a hardness of 0.06-0.1 GPa.

171. The method of claim 1, wherein the bio-brick has an elastic modulus of 0.01 to 0.05, 0.05 to 0.1, 0.1 to 0.5, 0.5 to 0.8, 0.8 to 1, 1 to 1.2, 1.2 to 1.4, 1.4 to 1.6, 1.6 to 1.8, 1.8 to 2, 2 to 2.4, 2.4 to 2.8, 2.8 to 3.2, 3.2 to 4, or 4 to 10 MPa.

172. The method of claim 1, wherein the bio-brick has an elastic modulus of 0.5 to 4 MPa.

173. The method of claim 1, wherein the bio-brick has an elastic modulus of 0.5 to 1, 1 to 1.5, 1.5 to 2, or 2 to 3 MPa.

174. The method of claim 1, wherein the bio-brick has an elastic modulus of 0.8 to 1.6 MPa.

175. The method of claim 1, wherein the bio-brick has an elastic modulus of 1.4 to 2.4 MPa.

176. The method of claim 1, wherein the bio-brick has an elastic modulus of 0.8 to 3.2 MPa.

177. The method of claim 1, wherein the core layer of the bio-brick is capable of providing a microenvironment for the vital activity of the cells.

178. The method of claim 177, wherein the microenvironment is a physical, biological, or chemical factor that promotes vital activities of the cell.

179. The method of claim 1, wherein said alginate is sodium alginate.

180. The method of claim 1, wherein said oxidized alginate is oxidized sodium alginate.

181. The method of claim 1, wherein the polyacrylic acid and derivatives thereof are selected from polymethacrylic acid, or copolymers of acrylic acid and methacrylic acid.

182. The method of claim 1, wherein the polyamino acid is polylysine.

183. The method of claim 1, wherein the biodegradable material used to prepare the core layer is degradable by an enzyme.

184. The method of claim 183, wherein said enzyme is a cell secreted enzyme.

185. The method of claim 183, wherein degradation of said nuclear layer is capable of providing nutrients that maintain or promote vital functions of said cell.

186. The method of claim 1 wherein the collagen is selected from the group consisting of type I, type II and type III collagen.

187. The method of claim 1, wherein the nuclear layer comprises type I collagen and/or alginate.

188. The method of claim 187 wherein the nuclear layer comprises type I collagen and sodium alginate.

189. The method of claim 1, wherein the nuclear layer comprises laminin.

190. The method of claim 1, wherein the core layer comprises starch.

191. The method of claim 1, wherein the core layer comprises a degradable polyurethane.

192. The method of claim 1, wherein said core layer comprises alginate and oxidized alginate.

193. The method of claim 192, wherein said alginate is sodium alginate.

194. The method of claim 192, wherein said oxidized alginate is oxidized sodium alginate.

195. The method of claim 1, wherein the core layer is gel-like.

196. The method of claim 1, wherein the shell of the bio-brick provides mechanical protection to the encapsulated cells.

197. The method of claim 1, wherein the shell materials each independently have a hardness of 0.01-0.4GPa and an elastic modulus of 0.01-10 MPa.

198. The method of claim 197, wherein the shell materials each independently have a hardness of 0.01-0.02, 0.02-0.03, 0.03-0.04, 0.04-0.05, 0.05-0.06, 0.06-0.07, 0.07-0.08, 0.08-0.09, 0.09-0.1, 0.1-0.15, 0.15-0.2, 0.2-0.3, or 0.3-0.4 GPa.

199. The method of claim 197, wherein the shell materials each independently have a hardness of 0.01 to 0.05, 0.05 to 0.1, 0.1 to 0.2, or 0.2 to 0.4 GPa.

200. The method of claim 197, wherein the shell materials each independently have a hardness of 0.05-0.15 GPa.

201. The method of claim 197, wherein the shell materials each independently have a hardness of 0.06-0.1 GPa.

202. The method of claim 197, wherein the shell materials each independently have an elastic modulus of 0.01 to 0.05, 0.05 to 0.1, 0.1 to 0.5, 0.5 to 0.8, 0.8 to 1, 1 to 1.2, 1.2 to 1.4, 1.4 to 1.6, 1.6 to 1.8, 1.8 to 2, 2 to 2.4, 2.4 to 2.8, 2.8 to 3.2, 3.2 to 4, or 4 to 10 MPa.

203. The method of claim 197, wherein the shell materials each independently have an elastic modulus of 0.5 to 4 MPa.

204. The method of claim 197, wherein the shell materials each independently have an elastic modulus of 0.5-1, 1-1.5, 1.5-2, or 2-3 MPa.

205. The method of claim 197, wherein the shell materials each independently have an elastic modulus of 0.8 to 1.6 MPa.

206. The method of claim 197, wherein the shell materials each independently have an elastic modulus of 1.4-2.4 MPa.

207. The method of claim 197, wherein the shell materials each independently have an elastic modulus of 0.8-3.2 MPa.

208. The method of claim 1, wherein the shell material is capable of providing a microenvironment for the vital movements of the cells.

209. The method of claim 208, wherein the microenvironment is a physical, biological or chemical factor that promotes vital activity of the cell.

210. The method of claim 1, wherein the different shell materials differ in composition.

211. The method of claim 1, wherein said alginate is sodium alginate or calcium alginate.

212. The method of claim 1, wherein said biodegradable material used to prepare the shell material is capable of being degraded by an enzyme.

213. The method of claim 212, wherein the enzyme is a cell secreted enzyme.

214. The method of claim 212, wherein degradation of the shell material is capable of providing nutrients that maintain or promote vital functions of the cell.

215. The method of claim 1, wherein said shell material comprises alginate.

216. The method of claim 215, wherein said alginate is selected from sodium alginate or calcium alginate.

217. The method of claim 215, wherein said shell material comprises calcium alginate and gelatin.

218. The method of claim 215, wherein the shell material further comprises elastin.

219. The method of claim 1, wherein said shell material comprises an oxidized alginate.

220. The method of claim 219, wherein said oxidized alginate is oxidized sodium alginate.

221. The method of claim 1, wherein said shell material comprises alginate and oxidized alginate.

222. The method of claim 221, wherein said alginate is selected from sodium alginate or calcium alginate.

223. The method of claim 221, wherein said oxidized alginate is oxidized sodium alginate.

224. The method of claim 1, wherein the shell material comprises alginate and agarose.

225. The method of claim 224, wherein said alginate is selected from sodium alginate or calcium alginate.

226. The method of claim 1, wherein each of said shell layers is optionally treated.

227. The method of claim 226, wherein the treating is performed using a shell fixative.

228. The method of claim 1, wherein the outermost shell of the bio-brick is treated.

229. The method of claim 228, wherein the outermost shell of the bio-brick is treated with a shell fixative.

230. The method of claim 1, wherein each of said shell layers is independently permeable.

231. The method of claim 230, wherein the shell is permeable to water, oxygen, and nutrients.

232. The method of claim 231, wherein the nutrients are selected from the group consisting of sugars, fats, proteins, amino acids, minerals, vitamins, and nucleotides.

233. The method of claim 232, wherein the saccharide is glucose.

234. The method of claim 231, wherein the nutrient comprises a short peptide.

235. The method of claim 231, wherein the nutrients comprise cytokines.

236. The method of claim 1, wherein the shell layers each independently have channels or pores for the exchange of substances inside and outside the bio-brick.

237. The method of claim 236, wherein the diameter of the channel is 10-20nm, 20-50nm, 50-100nm, 100-150nm, 150-200nm, 200-250nm, 250-300nm, 300-350nm, 350-400nm, 400-500nm or at least 500 nm.

238. The method as set forth in claim 236, wherein the diameter of the pore is 100-200nm, 200-400nm, 400-600nm, 600-800nm, 800-1000nm, 1000-1500nm, 1500-2000nm, 2000-4000nm, 4000-5000nm or at least 5000 nm.

239. The method of claim 1, wherein the shell layers each independently have a thickness of 2-5, 5-10, 10-15, 15-20, 20-25, 25-30, or 30-50 μ ι η.

240. The method of claim 1, wherein the shell layers each independently have a thickness of 10 to 20 μm.

241. The method of claim 1, wherein the shell layers each independently have a thickness of 10 to 30 μm.

242. The method of claim 1, wherein the shell layers each independently have a thickness of 5 to 20 μm.

243. The method of claim 1, wherein the core layer and/or the shell layer of the bio-brick each independently further comprises an additional agent.

244. The method of claim 243, wherein the additional agent comprises a nutrient.

245. The method of claim 243, wherein said additional agent comprises an extracellular matrix.

246. The method of claim 243, wherein said additional agent comprises a cytokine.

247. The method of claim 243, wherein the additional agent comprises a pharmaceutically active ingredient.

248. The method of claim 243, wherein said additional agent is capable of modulating proliferation, differentiation, migration, secretion and/or metabolism of the cell.

249. The method of claim 243, wherein said additional agent is capable of promoting proliferation, differentiation, migration, secretion and/or metabolism of the cell.

250. The method of claim 244, wherein the nutrients are selected from the group consisting of nucleotides, amino acids, polypeptides, carbohydrates, lipids, and vitamins.

251. The method of claim 250, wherein said carbohydrate is selected from the group consisting of monosaccharides, oligosaccharides, and polysaccharides.

252. The method of claim 245, wherein the extracellular matrix is selected from the group consisting of a polysaccharide, a structural protein, and an adhesion protein.

253. The method of claim 252, wherein the polysaccharide is selected from the group consisting of glycosaminoglycans and proteoglycans.

254. The method of claim 252, wherein the structural protein is selected from the group consisting of collagen and elastin.

255. The method of claim 252, wherein the adhesion protein is selected from the group consisting of fibronectin and laminin.

256. The method of claim 246, wherein the cytokine is a cytokine for regulating proliferation, differentiation, migration, secretion, and/or metabolism of a cell selected from the group consisting of:

-a cytokine associated with cell growth;

-cytokines associated with cell differentiation;

-cytokines associated with cell migration; and/or

-cytokines associated with cellular metabolism.

257. The method of claim 256, wherein said cytokine associated with cell growth is selected from the group consisting of insulin, insulin-like growth factor, transforming growth factor, vascular endothelial growth factor, epidermal growth factor, fibroblast growth factor, platelet-derived growth factor, osteosarcoma-derived growth factor, growth hormone release inhibitory factor, nerve growth factor, interleukin, erythropoiesis factor, colony stimulating factor, cortisol, thyroxine, or any combination thereof.

258. The method of claim 257, wherein said insulin-like growth factor is selected from the group consisting of IGF-i and IGF-ii.

259. The method of claim 257, wherein said transforming growth factor is selected from TGF α and TGF β.

260. The method of claim 257, wherein the interleukin is selected from the group consisting of IL-1, IL-11, and IL-3.

261. The method of claim 256, wherein the cytokine associated with cell differentiation is selected from Oct3/4, Sox2, Klf4, C-Myc, GATA4, TSP1, sodium beta-glycerophosphate, dexamethasone, vitamin C, insulin, IBMX, indomethazinc, platelet-derived growth factor BB, 5-azacytidine, or any combination thereof.

262. The method of claim 256, wherein said cytokine associated with cell migration is selected from the group consisting of cyclic adenosine monophosphate, phosphatidylinositol triphosphate, stromal cell derived factor-1, N-cadherin, nuclear factor kb, osteonectin, thromboxane a2, Ras, or any combination thereof.

263. The method of claim 256, wherein the cytokine associated with cellular metabolism is selected from the group consisting of insulin growth factor 1, TRIP-Br2, DKK-1, sRANKL, OPG, TRACP-5b, ALP, SIRT1(2-7), PGC-1 α, PGC-1 β, OPG, IL-3, IL-4, IL-6, TGF- β, PGE2, G-CSF, TNF- α, or any combination thereof.

264. The method of claim 247, wherein said pharmaceutically active ingredient is an agent capable of modulating proliferation, differentiation, migration, secretion and/or metabolism of a cell.

265. The method of claim 247, wherein the pharmaceutically active ingredient is an agent capable of promoting proliferation, differentiation, migration, secretion and/or metabolism of the cell.

266. The method of claim 247, wherein said pharmaceutically active ingredient is selected from the group consisting of rhIL-2, rhIL-11, rhEPO, IFN- α, IFN- β, IFN- γ, G-CSF, GM-CSF, rHuEPO, sTNF-R1, and rhTNF- α.

267. The method of claim 1, wherein the method comprises the step of bioprinting with a composition comprising a bio-brick, the composition comprising a bio-brick as defined in any one of claims 39 to 266.

268. The method of claim 267, wherein the composition is a bioinoch.

269. The method of claim 267, wherein the composition comprises a bio-brick and a carrier.

270. The method of claim 269, wherein the carrier comprises a bioadhesive.

271. The method of claim 269, wherein the carrier and its degradation products are non-toxic to the cell.

272. The method of claim 269, wherein the vector and its degradation products are non-immunogenic to the host.

273. The method of claim 269, wherein the carrier comprises a biodegradable material.

274. The method of claim 273, wherein the biodegradable material in the carrier is biocompatible.

275. The method of claim 273, wherein degradation of the biodegradable material in the carrier is capable of providing nutrients that maintain or promote vital activities of cells within the bio-brick.

276. The method of claim 273, wherein the biodegradable material in the carrier is naturally occurring, synthetic, recombinantly produced, modified, or any combination thereof.

277. The method of claim 276, wherein the biodegradable material in the carrier is a naturally occurring biodegradable material derived from an animal or plant.

278. The method of claim 273, wherein the biodegradable material in the carrier comprises a naturally occurring degradable polymer.

279. The method of claim 278, wherein the naturally occurring degradable polymer is selected from the group consisting of collagen, fibrin, chitosan, alginate, starch, hyaluronic acid, laminin, gelatin, dextran, elastin, and any combination thereof.

280. The method of claim 273, wherein the biodegradable material in the carrier comprises a modified degradable polymer.

281. The method of claim 280, wherein the modified degradable polymer is a modified alginate.

282. The method of claim 281, wherein the modified alginate is an oxidized alginate.

283. The method of claim 282, wherein said oxidized alginate is oxidized sodium alginate.

284. The method of claim 273, wherein the biodegradable material in the carrier comprises a synthetic degradable polymer.

285. The method of claim 284, wherein said synthetic degradable polymer is selected from polyphosphazenes, polyacrylic acid and derivatives thereof, polylactic acid, polyglycolic acid, polylactic-glycolic acid copolymers, polyorthoesters, polycaprolactones, polyhydroxybutyrates, polyaminoacids, degradable polyurethanes, and any combination thereof.

286. The method of claim 285, wherein the polyacrylic acid and derivatives thereof are selected from polymethacrylic acid, or copolymers of acrylic acid and methacrylic acid.

287. A method according to claim 285, wherein the polyamino acid is polylysine.

288. The method of claim 273, wherein the biodegradable material in the carrier is selected from agarose, methylcellulose, polyvinyl alcohol, polyacrylamide, poly-N-substituted acrylamide, or any combination thereof.

289. The method of claim 288, wherein said alginate is sodium alginate or calcium alginate.

290. The method of claim 269, wherein the carrier comprises sodium alginate.

291. The method of claim 269, wherein the carrier comprises alginate and oxidized alginate.

292. The method of claim 291, wherein said alginate is sodium alginate or calcium alginate.

293. The method of claim 291, wherein the oxidized alginate is oxidized sodium alginate.

294. The method of claim 269, wherein the carrier further comprises water, an inorganic salt, or any combination thereof.

295. The method of claim 269, wherein the carrier further comprises a pH buffer, a stabilizer, a preservative, or any combination thereof.

296. The method of claim 269, wherein the carrier is a liquid or semi-liquid.

297. The method of claim 269, wherein the carrier is a gel.

298. The method of claim 269, wherein the viscosity of the carrier is between 1 and 1000 Pas.

299. The method of claim 298 wherein the carrier has a viscosity of 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-12, 12-14, 14-16, 16-18, 18-20, 20-25, 25-30, 30-50, 50-80, 80-100, 100-.

300. The method of claim 298, wherein the carrier has a viscosity of 1-3, 3-8, 8-16, or 30-160 Pas.

301. The method of claim 298, wherein the carrier has a viscosity of 3 to 10, 10 to 20, 20 to 50, or 50 to 160 Pas.

302. The method of claim 269, wherein the carrier comprises additional reagents.

303. The method of claim 302, wherein the carrier comprises additional agents comprising nutrients.

304. The method of claim 302, wherein the vector comprises an additional agent comprising an extracellular matrix.

305. The method of claim 302, wherein the vector comprises an additional agent comprising a cytokine.

306. The method of claim 302, wherein the carrier comprises an additional agent comprising a pharmaceutically active ingredient.

307. The method of claim 302, wherein the additional agent is capable of modulating proliferation, differentiation, migration, secretion and/or metabolism of the cell.

308. The method of claim 302, wherein the additional agent is capable of promoting proliferation, differentiation, migration, secretion and/or metabolism of the cell.

309. The method of claim 302, wherein the additional agent comprises, nutrients that maintain or promote vital activities of the cell; and/or, a substance that improves or regulates a cell's vital activity.

310. The method of claim 309, wherein the nutrients that maintain or promote the vital activity of the cell are selected from the group consisting of nucleotides, amino acids, polypeptides, carbohydrates, lipids, and vitamins.

311. The method of claim 309, wherein the nutrients that maintain or promote vital activity of the cell comprise cell culture media.

312. The method of claim 310, wherein said carbohydrate is selected from the group consisting of monosaccharides, oligosaccharides, and polysaccharides.

313. The method of claim 309, wherein the substance that improves or modulates a vital activity of the cell comprises a cytokine.

314. The method of claim 309, wherein the substance that improves or modulates a living activity of a cell comprises an extracellular matrix.

315. The method of claim 309, wherein the substance that improves or modulates a vital activity of the cell comprises an anti-apoptotic agent.

316. The method of claim 309, wherein the substance that improves or modulates a vital activity of the cell comprises an antioxidant.

317. The method of claim 309, wherein the substance that improves or modulates a vital activity of the cell comprises a pharmaceutically active ingredient.

318. The method of claim 314, wherein said extracellular matrix is selected from the group consisting of polysaccharides, structural proteins, and adhesion proteins.

319. The method of claim 318, wherein said polysaccharide is selected from the group consisting of glycosaminoglycans and proteoglycans.

320. The method of claim 318, wherein said structural protein is selected from the group consisting of collagen and elastin.

321. The method of claim 318, wherein the adhesion protein is selected from the group consisting of fibronectin and laminin.

322. The method of claim 313, wherein the cytokine is a cytokine for regulating proliferation, differentiation, migration, secretion and/or metabolism of a cell selected from the group consisting of:

-a cytokine associated with cell growth;

-cytokines associated with cell differentiation;

-cytokines associated with cell migration; and/or

-cytokines associated with cellular metabolism.

323. The method of claim 322, wherein said cytokine associated with cell growth is selected from the group consisting of insulin, insulin-like growth factor, transforming growth factor, vascular endothelial growth factor, epidermal growth factor, fibroblast growth factor, platelet-derived growth factor, osteosarcoma-derived growth factor, growth hormone release inhibitory factor, nerve growth factor, interleukin, erythropoiesis factor, colony stimulating factor, cortisol, thyroxine, or any combination thereof.

324. The method of claim 323, wherein said insulin-like growth factor is selected from the group consisting of IGF-i and IGF-ii.

325. The method of claim 323, wherein said transforming growth factor is selected from the group consisting of TGF α and TGF β.

326. The method of claim 323, wherein said interleukin is selected from the group consisting of IL-1, IL-11, and IL-3.

327. The method of claim 322, wherein the cytokine associated with cell differentiation is selected from Oct3/4, Sox2, Klf4, C-Myc, GATA4, TSP1, sodium beta-glycerophosphate, dexamethasone, vitamin C, insulin, IBMX, indomethazinc, platelet-derived growth factor BB, 5-azacytidine, or any combination thereof.

328. The method of claim 322, wherein said cytokine associated with cell migration is selected from cyclic adenosine monophosphate, phosphatidylinositol triphosphate, stromal cell derived factor-1, N-cadherin, nuclear factor kb, osteonectin, thromboxane a2, Ras, or any combination thereof.

329. The method of claim 322, wherein said cytokine associated with cellular metabolism is selected from the group consisting of insulin growth factor 1, TRIP-Br2, DKK-1, sRANKL, OPG, TRACP-5b, ALP, SIRT1(2-7), PGC-1 α, PGC-1 β, OPG, IL-3, IL-4, IL-6, TGF- β, PGE2, G-CSF, TNF- α, or any combination thereof.

330. The method of claim 317, wherein said pharmaceutically active ingredient is an agent capable of modulating proliferation, differentiation, migration, secretion and/or metabolism of a cell.

331. The method of claim 317, wherein said pharmaceutically active ingredient is an agent capable of promoting proliferation, differentiation, migration, secretion and/or metabolism of a cell.

332. The method of claim 317, wherein said pharmaceutically active ingredient is selected from the group consisting of rhIL-2, rhIL-11, rhEPO, IFN- α, IFN- β, IFN- γ, G-CSF, GM-CSF, rHuEPO, sTNF-R1, and rhTNF- α.

333. The method of claim 267, wherein the composition comprises, by weight, 10% -20%, 20% -30%, 30% -40%, 40% -50%, 50% -60%, 60% -70%, 70% -80%, 80% -90%, or at least 90% of bio-bricks.

334. The method of claim 267, wherein the composition is a liquid, semi-solid, or solid composition.

335. The method of claim 334, wherein the composition is a solution, a suspension, a gel, or a concentrate.

336. The method of claim 267, wherein the composition is an extrudable composition.

337. The method of any one of claims 271-, 276, 278, 280, 284, 288, 290, 296, 298, or 3302 wherein the carrier is a bioadhesive.

338. The method of claim 333, 334, or 336, wherein the composition is a bioinock.

339. The method of claim 1, wherein the bio-brick is prepared by a method comprising the steps of:

(1) providing one or more core layer materials, each independently made of a biodegradable material, and each independently encapsulating the same or different cells or cell combinations; the cells comprise endothelial cells;

(5) optionally, repeating step (4) one or more times;

340. The method of claim 339, wherein said cells further comprise undifferentiated cells.

341. The method of claim 340, wherein said undifferentiated cells are selected from stem cells, progenitor cells, or a combination thereof.

342. The method of claim 339, wherein, in step (1), the cells, the biodegradable material for forming the core layer material are homogeneously mixed, thereby obtaining the core layer material.

343. The method of claim 339, wherein, in step (1), the cells, the biodegradable material for forming the nuclear layer material and the desired additional agent are homogeneously mixed, thereby obtaining the nuclear layer material.

344. The method of claim 343, wherein the additional agent comprises a nutrient.

345. The method of claim 343, wherein the additional agent comprises extracellular matrix.

346. The method of claim 343, wherein the additional agent comprises a cytokine.

347. The method of claim 343, wherein the additional agent comprises a pharmaceutically active ingredient.

348. The method of claim 339, wherein said shell material of step (2) does not comprise cells.

349. The method of claim 339, wherein, in steps (3) - (6), the granulating and coating are performed using an apparatus for preparing microspheres.

350. The method of claim 349, wherein the apparatus for preparing microspheres is a pelletizer.

351. The method of claim 339, wherein, after each performing step (4), if the outermost layer of the obtained product is coated as a shell material, optionally performing the steps of: the outermost coating is treated.

352. The method of claim 339, wherein, after step (6), the outermost shell layer of the obtained bio-brick is treated.

353. The method of claim 351 or 352, wherein the treatment is with a shell fixative.

354. The method of claim 339, wherein the method of preparing a bio-brick is performed under aseptic conditions.

355. The method of claim 339, wherein the method is performed in a GMP suite.

356. The method of claim 339, wherein, after step (6), the method of preparing a bio-brick stores the obtained bio-brick at 4 ℃.

357. The method of claim 356, wherein the obtained biobrick is stored for 3 hours, 6 hours, 12 hours, 1 day, 2 days, or 3 days.

358. The method of claim 1, wherein the composition is prepared by a process comprising the steps of: mixing the bio-brick as defined in any one of claims 39 to 266 with a carrier.

359. The method of claim 358 wherein the composition is as defined in any one of claims 268-336 and/or the carrier is as defined in any one of claims 270-332.

360. The method of claim 358 or 359, wherein the carrier is a bioadhesive.

361. The method of claim 359, wherein the composition is a bioinoch.

362. A construct comprising a microvessel, made by the method of any one of claims 1-361.

363. The construct of claim 362, wherein the construct is a three-dimensional construct, a tissue precursor, a tissue, or an organ.

364. The construct of claim 362, wherein the construct is a living construct.

365. The construct of claim 362, wherein the construct comprises a plurality of bio-bricks.

366. The construct of claim 365, wherein the biological bricks are arranged in a predetermined pattern.

367. The construct of claim 362, wherein the construct has a size of 30-50 μm, 50-100 μm, 100-200 μm, 200-500 μm, 500 μm-1mm, 1-2mm, 2-5mm, 5mm-1cm, 1-2cm, 2-5cm, 5-10cm, 10-20cm, 20-50cm, or at least 50 cm.

368. The construct of claim 367, wherein the construct is a three-dimensional construct, a tissue precursor, a tissue, or an organ.

369. The construct of claim 362, wherein the construct has a predetermined structure.

370. The construct of claim 362, wherein the construct has one or more layers of structure.

371. The construct of claim 370, wherein each layer structure is constructed from one or more layers of bio-bricks.

372. The construct of claim 362, wherein the construct is a microtissue block.

373. The construct of claim 372, wherein the pieces of microtissue are on the order of microns to centimeters in size.

374. The construct of claim 373, wherein the size of the microtissue block is between 30 μm and 50 cm.

375. The construct of claim 373, wherein the size of the microtissue block is between 30 μm and 10 cm.

376. The construct of claim 373, wherein the size of the microtissue block is between 50 μm and 1 cm.

377. The construct of claim 373, wherein the size of the microtissue blocks is between 100 μm and 800 μm.

378. The construct of claim 373, wherein the size of the microtissue blocks is between 300 μm and 600 μm.

379. The construct of claim 362, wherein the construct is further cultured.

380. The construct of claim 379, wherein the construct is cultured for 0-1, 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, 11-12, 12-13, 13-14, 14-15, 15-16, 16-17, 17-18, 18-19, 19-20, 20-21, 21-25, 25-30, or at least 30 days.

381. The construct of claim 362, wherein the cells in the bio-brick of the construct are capable of growth, proliferation, differentiation, secretion and/or migration.

382. The construct of claim 362, wherein the construct has a sheet-like structure, or a hollow three-dimensional structure, or a solid three-dimensional structure, or any combination thereof.

383. The construct of claim 382, wherein the sheet-like structure is selected from a rectangular, square, circular, oval, hexagonal, or irregularly shaped sheet-like structure.

384. The construct of claim 382, wherein the hollow three-dimensional structure is selected from a hollow tube, a hollow sphere, a hollow rectangular prism, a hollow cylinder, or a hollow irregularly shaped three-dimensional structure.

385. The construct of claim 382, wherein the solid three-dimensional structure is selected from a solid sphere, a solid rectangular prism, a solid cylinder, or a solid irregularly shaped three-dimensional structure.

386. The construct of claim 362, wherein the construct mimics the shape of a natural tissue or organ.

387. The construct of claim 362, wherein the construct comprises a three-layered structure, an endothelial cell layer, a smooth muscle cell layer, and a fibroblast cell layer.

388. A microvessel-containing construct comprising a biological brick as defined in any one of claims 39 to 266 or a composition as defined in any one of claims 267 and 338.

389. Use of a microvessel-containing construct of claim 362 or 388 for studying stem cell differentiation, for non-diagnostic or therapeutic purposes.

390. Use of a microvessel-containing construct of claim 362 or 388 for drug discovery, for non-diagnostic or therapeutic purposes.

391. Use of a microvessel-containing construct of claim 362 or 388 for drug screening, for non-diagnostic or therapeutic purposes.

392. Use of a microvessel-containing construct of claim 362 or 388 for in vitro assays, for non-diagnostic or therapeutic purposes.

393. Use of a microvessel-containing construct of claim 362 or 388 for assessing the effect of a factor on a tissue or cells in a tissue in vitro for non-diagnostic or therapeutic purposes.

394. Use of a microvessel-containing construct of claim 362 or 388 for in vitro three-dimensional tissue culture for non-diagnostic or therapeutic purposes.

395. Use of a microvessel-containing construct of claim 362 or 388 for the preparation of a kit for studying stem cell differentiation.

396. Use of a microvessel-containing construct of claim 362 or 388 for the preparation of a kit for use in drug discovery.

397. Use of a microvessel-containing construct of claim 362 or 388 for the preparation of a kit for use in drug screening.

398. Use of a microvessel-containing construct of claim 362 or 388 for the preparation of a kit for in vivo or in vitro assays.

399. Use of a microvessel-containing construct of claim 362 or 388 to prepare a kit for implantation into a host.

400. Use of a microvessel-containing construct of claim 362 or 388 for the preparation of a kit for use in tissue engineering.

401. Use of a microvessel-containing construct of claim 362 or 388 for the preparation of a kit for tissue regeneration.

402. Use of a microvessel-containing construct of claim 362 or 388 to prepare a kit for assaying a cell for a change in response to a stimulus or agent in vivo.

403. Use of a microvessel-containing construct of claim 362 or 388 to prepare a kit for studying the effects of the microenvironment in vivo.

404. Use of a microvessel-containing construct of claim 362 or 388 for the preparation of a kit for treating a subject in need thereof.

405. Use of a microvessel-containing construct of claim 362 or 388 to prepare a kit for assessing the effect of a factor on a tissue or cells in a tissue.

406. Use of a microvessel-containing construct of claim 362 or 388 for the preparation of a kit for three-dimensional tissue culture.

407. Use of a microvessel-containing construct of claim 362 or 388 for the preparation of a kit for repairing damaged tissue in a subject.

408. The use of claim 402, wherein the change is a morphological change or a functional change.

409. The use of claim 393 or 405, wherein the agent is selected from the group consisting of a chemical agent and a physical stimulus.

410. The use of claim 409, wherein the chemical agent is a compound.

411. The use of claim 409, wherein the physical stimulus is radiation or heat.

412. A kit comprising the microvessel-containing construct of claim 362 or 388.

413. The kit of claim 412, wherein the construct is a three-dimensional construct, a tissue precursor, a tissue, or an organ.

414. A method of assessing the effect of a factor on a tissue or cells in a tissue in vitro comprising exposing a construct of claim 362 or 388 to the factor and assessing changes in the cells in the construct in response to the factor to determine the effect of the factor on the tissue or cells in the tissue, the method being for non-diagnostic or therapeutic purposes.

415. The method of claim 414, wherein the agent is selected from the group consisting of a chemical agent and a physical stimulus.

416. The method of claim 415, wherein the chemical agent is a chemical compound.

417. The method of claim 415, wherein the physical stimulus is radiation or heat.

418. The method of claim 414, wherein the construct is a three-dimensional construct, a tissue precursor, a tissue, or an organ.

419. The method of claim 414, wherein the change is a morphological change or a functional change.